Veradigm (MDRX) 10-K 26 Feb 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 22, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-35547
Entity Incorporation, State or Country Code	DE
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Tax Identification Number	36-4392754
Entity Central Index Key	0001124804
Entity Address, Address Line One	222 Merchandise Mart Plaza
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		140,032,248
Entity Public Float			$ 1,078,860,200
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement related to its 2021 annual meeting of stockholders (the “2021 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2021 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 531,104	$ 129,668
Restricted cash	6,361	7,871
Accounts receivable, net of allowance of $31,596 and $22,005 as of December 31, 2020 and December 31, 2019, respectively	347,355	424,415
Contract assets, net of allowance of $1,068 and $0 as of December 31, 2020 and December 31, 2019, respectively	106,717	93,292
Income tax receivable	25,421	0
Prepaid expenses and other current assets	136,264	144,145
Current assets attributable to discontinued operations	0	41,871
Total current assets	1,153,222	841,262
Fixed assets, net	72,162	87,953
Software development costs, net	193,202	222,692
Intangible assets, net	286,602	367,128
Goodwill	974,729	974,110
Deferred taxes, net	5,790	5,704
Contract assets - long-term, net of allowance of $4,273 and $0 as of December 31, 2020 and December 31, 2019, respectively	43,682	63,525
Right-of-use assets - operating leases	96,601	95,757
Other assets	91,628	119,587
Long-term assets attributable to discontinued operations	0	428,021
Total assets	2,917,618	3,205,739
Current liabilities:
Accounts payable	35,905	102,823
Accrued expenses	100,262	270,281
Accrued compensation and benefits	118,771	65,782
Deferred revenue	334,764	335,619
Current maturities of long-term debt	0	364,465
Current operating lease liabilities	22,264	22,328
Current liabilities attributable to discontinued operations	322,811	49,392
Total current liabilities	934,777	1,210,690
Long-term debt	167,587	551,004
Deferred revenue	3,471	11,068
Deferred taxes, net	18,186	21,038
Long-term operating lease liabilities	93,463	93,588
Other liabilities	33,891	30,320
Long-term liabilities attributable to discontinued operations	0	2,843
Total liabilities	1,251,375	1,920,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of December 31, 2020 and December 31, 2019	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of December 31, 2020 and December 31, 2019; 274,558 and 139,942 shares issued and outstanding as of December 31, 2020, respectively; 272,609 and 162,475 shares issued and outstanding as of December 31, 2019, respectively	2,745	2,725
Treasury stock: at cost, 134,616 and 110,134 shares as of December 31, 2020 and December 31, 2019, respectively	(870,558)	(571,157)
Additional paid-in capital	1,902,776	1,907,348
Retained earnings (accumulated deficit)	633,118	(49,336)
Accumulated other comprehensive loss	(1,838)	(4,392)
Total stockholders’ equity	1,666,243	1,285,188
Total liabilities and stockholders’ equity	$ 2,917,618	$ 3,205,739

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 31,596	$ 22,005
Contract assets, allowance	1,068	0
Contract assets - long-term, allowance	$ 4,273	$ 0
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	274,558,000	272,609,000
Common stock, shares outstanding	139,942,000	162,475,000
Treasury stock at cost, shares	134,616,000	110,134,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Revenue from contract with customers	$ 1,502,700	$ 1,632,611	$ 1,617,841
Cost of revenue:
Amortization of software development and acquisition-related assets	118,399	107,874	96,682
Total cost of revenue	937,005	1,022,324	996,450
Gross profit	565,695	610,287	621,391
Selling, general and administrative expenses	389,941	400,808	432,849
Research and development	206,061	245,443	258,736
Asset impairment charges	74,969	10,837	58,166
Goodwill impairment charge	0	25,700	13,466
Amortization of intangible and acquisition-related assets	25,604	27,188	26,558
Loss from operations	(130,880)	(99,689)	(168,384)
Interest expense	(34,104)	(43,172)	(50,914)
Other income (loss), net	54	(138,904)	69
Gain on sale of businesses, net	0	0	172,258
Impairment of long-term investments	(1,575)	(651)	(15,487)
Equity in net income of unconsolidated investments	17,194	665	259
Loss before income taxes	(149,311)	(281,751)	(62,199)
Income tax benefit	16,692	43,340	18,983
Loss from continuing operations, net of tax	(132,619)	(238,411)	(43,216)
Income from discontinued operations	71,448	75,235	2,501
Gain on sale of discontinued operations	1,156,504	0	500,471
Income tax effect on discontinued operations	(394,926)	(19,426)	(51,949)
Income from discontinued operations, net of tax	833,026	55,809	451,023
Net income (loss)	700,407	(182,602)	407,807
Net loss attributable to non-controlling interests	0	424	4,527
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0	0	(48,594)
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 700,407	$ (182,178)	$ 363,740
Basic
Continuing operations	$ (0.83)	$ (1.43)	$ (0.22)
Discontinued operations	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	4.40	(1.10)	2.07
Diluted
Continuing operations	(0.83)	(1.43)	(0.22)
Discontinued operations	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ 4.40	$ (1.10)	$ 2.07
Software delivery, Support and Maintenance [Member]
Revenue:
Revenue from contract with customers	$ 914,662	$ 1,004,195	$ 1,011,624
Cost of revenue:
Total cost of revenue	287,954	319,140	315,102
Client services [Member]
Revenue:
Revenue from contract with customers	588,038	628,416	606,217
Cost of revenue:
Total cost of revenue	$ 530,652	$ 595,310	$ 584,666

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 700,407	$ (182,602)	$ 407,807
Other comprehensive income (loss):
Foreign currency translation adjustments	1,435	1,192	(2,908)
Change in fair value of derivatives qualifying as cash flow hedges	1,509	(262)	(873)
Other comprehensive income (loss) before income tax (expense) benefit	2,944	930	(3,781)
Income tax (expense) benefit related to items in other comprehensive income (loss)	(390)	67	377
Total other comprehensive income (loss)	2,554	997	(3,404)
Comprehensive income (loss)	702,961	(181,605)	404,403
Comprehensive loss attributable to non-controlling interests	0	424	4,527
Comprehensive income (loss), net	$ 702,961	$ (181,181)	$ 408,930

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Retained earnings (accumulated deficit) [Member]	Retained earnings (accumulated deficit) [Member]Cumulative Effect Period Of Adoption Adjustment [Member]Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Accumulated Other Comprehensive Loss [Member]	Non-controlling Interest [Member]
Beginning Balance, Shares at Dec. 31, 2017		269,335	(88,504)
Beginning Balance at Dec. 31, 2017	$ 1,160,072	$ 2,693	$ (322,735)	$ 1,781,059	$ (338,150)		$ (1,985)	$ 39,190
Beginning Balance (ASU 2016-13 [Member]) at Dec. 31, 2017						$ 0
Beginning Balance (ASC 606 [Member]) at Dec. 31, 2017						58,658
Stock-based compensation				34,638
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,620
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 16		(8,197)
Issuance of 0.875% Convertible Senior Notes				0
Capped call transactions				0
Allocation of discounts and debt issuance costs for issuance of 0.875%Convertible Senior Notes				0
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	(48,594)			72,386
Subsidiary issuance of common stock				0
Issuance of treasury stock, Shares			76
Issuance of treasury stock	1,121		$ 1,121	(61)
Purchase of treasury stock, Shares			(11,303)
Purchase of treasury stock			$ (138,929)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				2,729
Acquisition of non-controlling interest				(1,060)				(5,349)
Net income (loss) less net loss attributable to non-controlling interests					412,334
Foreign currency translation adjustments, net	(2,908)						(2,908)
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							(496)
Unrecognized gain on available for sale securities, net of tax							0
Net loss attributable to non-controlling interests	(4,527)							(4,527)
Ending Balance, Shares at Dec. 31, 2018		270,955	(99,731)
Ending Balance at Dec. 31, 2018	1,580,427	$ 2,709	$ (460,543)	1,881,494	132,842		(5,389)	29,314
Ending Balance (ASU 2016-13 [Member]) at Dec. 31, 2018						0
Ending Balance (ASC 606 [Member]) at Dec. 31, 2018						0
Stock-based compensation				38,713
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,654
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 16		(7,227)
Issuance of 0.875% Convertible Senior Notes				40,058
Capped call transactions				(17,222)
Allocation of discounts and debt issuance costs for issuance of 0.875%Convertible Senior Notes				(1,140)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0			0
Subsidiary issuance of common stock				0
Issuance of treasury stock, Shares			61
Issuance of treasury stock	701		$ 846	(144)
Purchase of treasury stock, Shares			(10,464)
Purchase of treasury stock			$ (111,460)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				2,729
Acquisition of non-controlling interest				(29,913)				(28,890)
Net income (loss) less net loss attributable to non-controlling interests					(182,178)
Foreign currency translation adjustments, net	1,192						1,192
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							(195)
Unrecognized gain on available for sale securities, net of tax							0
Net loss attributable to non-controlling interests	$ (424)							(424)
Ending Balance, Shares at Dec. 31, 2019	272,609	272,609	(110,134)
Ending Balance at Dec. 31, 2019	$ 1,285,188	$ 2,725	$ (571,157)	1,907,348	(49,336)		(4,392)	0
Ending Balance (ASU 2016-13 [Member]) at Dec. 31, 2019						(17,953)
Ending Balance (ASC 606 [Member]) at Dec. 31, 2019						$ 0
Stock-based compensation				34,036
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,949
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 20		(6,059)
Issuance of 0.875% Convertible Senior Notes				0
Capped call transactions				797
Allocation of discounts and debt issuance costs for issuance of 0.875%Convertible Senior Notes				0
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0			0
Subsidiary issuance of common stock				0
Issuance of treasury stock, Shares			198
Issuance of treasury stock	752		$ 1,193	(440)
Purchase of treasury stock, Shares			(12,984)
Purchase of treasury stock			$ (134,863)
Accelerated share repurchase program, Shares			(11,696)
Accelerated share repurchase program			$ (165,731)	(34,269)
Warrants issued				1,363
Acquisition of non-controlling interest				0				0
Net income (loss) less net loss attributable to non-controlling interests					700,407
Foreign currency translation adjustments, net	1,435						1,435
Unrecognized gain (loss) on derivatives qualifying as cash flow hedges, net of tax							1,119
Unrecognized gain on available for sale securities, net of tax							0
Net loss attributable to non-controlling interests	$ 0							0
Ending Balance, Shares at Dec. 31, 2020	274,558	274,558	(134,616)
Ending Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	$ 1,902,776	$ 633,118		$ (1,838)	$ 0

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Dec. 09, 2019
0.875% Convertible Senior Notes [Member]
Debt instrument interest rate	0.875%	0.875%	0.875%	0.875%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ 700,407	$ (182,602)	$ 407,807
Less: Income from discontinued operations	833,026	55,809	451,023
Loss from continuing operations	(132,619)	(238,411)	(43,216)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	192,269	198,226	184,357
Operating right-of-use asset amortization	20,720	21,882	0
Stock-based compensation expense	34,036	38,982	34,638
Deferred taxes	(3,275)	(37,970)	4,144
Asset impairment charges	74,969	10,837	58,166
Goodwill impairment charge	0	25,700	13,466
Impairment of long-term investments	1,575	651	15,487
Equity in net income of unconsolidated investments	(17,194)	(665)	(259)
Gain on sale of businesses, net	0	0	(172,258)
Other (income) loss, net	(5,900)	10,042	(9,079)
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	35,163	(9,430)	(120,522)
Prepaid expenses and other assets	(34,418)	(16,251)	(96,701)
Accounts payable	(66,987)	27,552	(10,809)
Accrued expenses	(3,064)	(3,894)	43,424
Accrued compensation and benefits	49,492	(32,764)	20,441
Deferred revenue	28,667	(92,067)	65,029
Other liabilities	5,334	(7,555)	11,900
Operating leases	(19,266)	(24,470)	0
Accrued DOJ settlement	(147,169)	145,000	0
Net cash provided by (used in) operating activities - continuing operations	12,333	15,395	(1,792)
Net cash (used in) provided by operating activities - discontinued operations	(119,048)	30,859	69,683
Net cash (used in) provided by operating activities	(106,715)	46,254	67,891
Cash flows from investing activities:
Capital expenditures	(17,025)	(16,450)	(30,345)
Capitalized software	(87,993)	(103,317)	(103,454)
Cash paid for business acquisitions, net of cash acquired	0	(23,443)	(177,233)
Cash received from sale of businesses, net of cash divested	1,710,000	0	807,764
Purchases of equity securities, other investments and related intangible assets, net	(7,097)	(8,235)	(16,934)
Sale of other investments	24,967	1,044	0
Other proceeds from investing activities	0	14	54
Net cash provided by (used in) investing activities - continuing operations	1,622,852	(150,387)	479,852
Net cash used in investing activities - discontinued operations	(7,664)	(10,669)	(231,839)
Net cash provided by (used in) investing activities	1,615,188	(161,056)	248,013
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	0	0	1,283
Taxes paid related to net share settlement of equity awards	(6,033)	(7,286)	(9,466)
Proceeds from issuance of 0.875% Convertible Senior Notes	0	218,000	0
Payments for issuance costs on 0.875% Convertible Senior Notes	(758)	(5,445)	0
Payments for capped call transaction on 0.875% Convertible Senior Notes	0	(17,222)	0
Repayment of Convertible Senior Notes	(352,361)	0	0
Credit facility payments	(1,315,000)	(220,000)	(713,751)
Credit facility borrowings, net of issuance costs	903,625	279,241	430,843
Repurchase of common stock	(134,863)	(111,460)	(138,928)
Payment of acquisition and other financing obligations	(4,369)	(14,685)	(5,198)
Purchases of subsidiary shares owned by non-controlling interest	0	(53,800)	(7,198)
Net cash (used in) provided by financing activities - continuing operations	(1,109,759)	67,343	(442,415)
Net cash provided by financing activities - discontinued operations	0	0	149,432
Net cash (used in) provided by financing activities	(1,109,759)	67,343	(292,983)
Effect of exchange rate changes on cash and cash equivalents	1,212	203	(624)
Net increase (decrease) in cash and cash equivalents	399,926	(47,256)	22,297
Cash, cash equivalents and restricted cash, beginning of period	137,539	184,795	162,498
Cash, cash equivalents and restricted cash, end of period	537,465	137,539	184,795
Accelerated Share Repurchase Program [Member]
Cash flows from financing activities:
Repurchase of common stock	$ (200,000)	$ 0	$ 0

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 19 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results. Cash and Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values. Other Financial Assets and Liabilities We have investments in equity instruments for which it is not practicable to estimate fair value primarily because of their illiquidity and restricted marketability. Such investments are recorded initially at cost, less impairment and changes resulting from observable price changes and equity methods of accounting. Refer to Note 6, “Fair Value Measurements and Other Investments” for additional information about these investments. Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. As of December 31, 2019, the carrying amount of the 1.25% Notes (as defined in Note 10, “Debt”) approximated fair value since the effective interest rate on the 1.25% Notes approximated current market rates. On July 1, 2020, the 1.25% Notes matured and were paid in full. See Note 10, “Debt” for further information regarding our long-term financial liabilities. Derivative Financial Instruments Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation. See Note 16, “Derivative Financial Instruments” for information regarding gains and losses from derivative instruments during the years ended December 31, 2020, 2019 and 2018. Trade Accounts Receivable Accounts receivable are recorded at the invoiced amounts and do not bear interest. Contingent Liabilities A liability is contingent if the amount is not presently known but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments. Fixed Assets Fixed assets are stated at cost. Depreciation and amortization are computed under the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred. Business Combinations Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated statements of operations. Goodwill and Intangible Assets Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than the carrying value, an impairment loss equal to the excess will be recorded not to exceed the carrying amount of goodwill assigned to the reporting unit. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of an asset to its estimated fair value. If we determine that the carrying value of an asset exceeds its estimated fair value, an impairment loss equal to the excess will be recorded. The determination of the fair value of our reporting units is based on a combination of a market approach, which considers benchmark company market multiples, and an income approach, which utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the combined fair values estimated for our reporting units. In accordance with GAAP, definite-lived intangible assets are required to be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize their value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time. Long-Lived Assets and Long-Lived Assets to Be Disposed Of We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Software Development Costs We capitalize purchased software upon acquisition if it is accounted for as internal-use software or if it meets the future alternative use criteria. For software to be sold, we capitalize incurred labor costs for software development from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal-use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is determined to be shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years. At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value is recorded as a charge to earnings. The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2020 2019 Software development costs $ 327,519 $ 393,728 Less: accumulated amortization (134,317 ) (171,036 ) Software development costs, net $ 193,202 $ 222,692 Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue are illustrated in the following table: Year Ended December 31, (In thousands) 2020 2019 2018 Capitalized software development costs $ 87,993 $ 103,317 $ 103,454 Write-offs and divestitures of capitalized software development costs $ 31,214 $ 0 $ 34,083 Amortization of capitalized software development costs $ 86,269 $ 72,840 $ 59,653 Income Taxes We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors. In addition, we are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements. The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing authorities. To the extent we prevail in matters for which liabilities have been established or are required to pay amounts in excess of our liabilities, our effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution. We report interest and penalties related to uncertain income tax positions in the income tax (provision) benefit line of our consolidated statements of operations. We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United States. Stock-Based Compensation We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation cost at the grant date based on the fair value of the award and recognize the expense over the requisite service period typically on a straight-line basis, net of estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We settle employee stock option exercises and stock awards with newly issued common shares. Refer to Note 12, “Stock Award Plan” for detailed discussion about our stock-based incentive plan. Employee Benefit Plans We provide employees with defined contribution savings plans. We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans: Year Ended December 31, (In thousands) 2020 2019 2018 Company contributions to employee benefit plans $ 21,143 $ 23,998 $ 28,803 Foreign Currency The determination of the functional currency of our foreign subsidiaries is made based on the appropriate economic and management indicators. Our foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our operating subsidiaries in India and Israel which use the United States dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into United States dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. We periodically enter into non-deliverable forward foreign currency exchange contracts in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. See Note 16, “Derivative Financial Instruments,” for information regarding these foreign currency exchange contracts. Concentrations of Credit Risk Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally. We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In general, we do not require collateral from our clients, but we do enter into advance deposit agreements, if appropriate. The majority of our revenue is derived from clients located in the United States. The majority of long-lived assets are also located in the United States. For the year ended December 31, 2020, we had one client that accounted for 12% of our revenue. Other than this one client, no single client accounted for more than 10% of our revenue in the years ended December 31, 2020, 2019 and 2018. No client represented more than 10% of accounts receivable as of December 31, 2020 and 2019. Recently Adopted Accounting Pronouncements We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020, and the adoption had no impact on our consolidated financial statements. Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	2. Revenue from Contracts with Customers Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery, support and maintenance revenue consists of all of our proprietary software sales (either under a perpetual or term license delivery model), subscription-based software sales, transaction-related revenue, the resale of hardware and third-party software and revenue from post-contract client support and maintenance services, which include telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services and project-based revenue from implementation, training and consulting services. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. Costs to Obtain or Fulfill a Contract Capitalized costs to obtain or fulfill a contract are amortized over periods ranging from two to six years which represent the initial contract term or a longer period, if renewals are expected and the renewal commission, if any, is not commensurate with the initial commission. We classify such capitalized costs as current or non-current based on the expected timing of expense recognition. The current and non-current portions are included in Prepaid expenses and other current assets, and Other assets, respectively, in our consolidated balance sheets. At December 31, 2020 and 2019, we had capitalized costs to obtain or fulfill a contract of $16.8 million and $18.4 million, respectively, in Prepaid and other current assets and $27.9 million and $28.9 million, respectively, in Other assets. During the year ended December 31, 2020 and 2019, we recognized $23.6 million and $30.5 million, respectively, of amortization expense related to such capitalized costs, which is included in selling, general and administrative expenses. Contract Balances The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. In general, with the exception of fixed fee project-based client service offerings (such as implementation services), we sell our software solutions on date-based milestone events where control transfers and use of the software occurs on the delivery date but the associated payments for the software license occur on future milestone dates. In such instances, unbilled amounts are included in contract assets since our right to receive payment is conditional upon the continued functionality of the software and the provision of ongoing support and maintenance. Our fixed fee project-based client service offerings typically require us to provide the services with either a significant portion or all amounts due prior to service completion. Since our right to payment is not unconditional, amounts associated with work prior to the completion date are also deemed to be contract assets. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under the FASB Accounting Standards Codification 606, Revenue from Contracts with Customers (“ASC 606”). A performance obligation is considered distinct when both (i) a customer can benefit from the product or service either on its own or together with other resources that are readily available to the customer and (ii) the promised product or service is separately identifiable from other promises in the contract. Activities related to the fulfillment of a contract that do not transfer products or services to a customer, such as contract preparation or legal review of contract terms, are not deemed to be performance obligations. We generally sell our solutions through contracts with multiple performance obligations where we provide the customer with (1) software licenses, (2) support and maintenance, (3) embedded content such as third-party software and (4) client services. Incremental solutions, such as hardware and managed services are also provided based upon a customer’s preferences and requirements. We deem that a customer is typically able to benefit from a product or service on its own or together with readily available resources when we sell such product or service on a standalone basis. We have historically sold the majority of our performance obligations, with the exception of software licenses, on a standalone basis. Incremental solutions, such as hardware, client services and managed services, are often negotiated and fulfilled on an independent sales order basis as customer needs and requirements change over the course of a relationship period. In addition, support and maintenance and embedded content are provided on a stand-alone basis through the renewal process. One of the product offerings under our CareInMotion TM Our support and maintenance obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall support and maintenance obligations can be viewed as a single performance obligation since both the unspecified product upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently. The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Three Months Ended June 30, 2020 Three Months Ended September 30, 2020 Three Months Ended December 31, 2020 Revenue related to deferred revenue balance at beginning of period $ 105,366 $ 119,545 $ 118,300 $ 138,279 Revenue related to new performance obligations satisfied during the period 216,580 195,308 192,658 182,690 Revenue recognized under "right-to-invoice" expedient 58,059 54,082 54,313 65,108 Reimbursed travel expenses, shipping and other revenue 1,359 369 347 337 Total revenue $ 381,364 $ 369,304 $ 365,618 $ 386,414 (In thousands) Three Months Ended March 31, 2019 Three Months Ended June 30, 2019 Three Months Ended September 30, 2019 Three Months Ended December 31, 2019 Revenue related to deferred revenue balance at beginning of period $ 93,602 $ 113,288 $ 116,812 $ 136,460 Revenue related to new performance obligations satisfied during the period 248,126 233,293 227,954 214,952 Revenue recognized under "right-to-invoice" expedient 55,923 62,245 61,814 60,826 Reimbursed travel expenses, shipping and other revenue 1,467 2,057 1,700 2,092 Total revenue $ 399,118 $ 410,883 $ 408,280 $ 414,330 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.1 billion as of December 31, 2020, of which we expect to recognize approximately 35% over the next 12 months, and the remaining 65% thereafter. Transaction price and allocation Our contracts with customers often include multiple distinct performance obligations such as software licenses, software support and maintenance, hardware, client services, private cloud hosting and Software-as-a-Service. We adjust the transaction price on a contract-by-contract basis for (i) the effect of the time value of money when a contract has a significant financing component and/or (ii) customer discounts and incentives deemed to be variable consideration. We then allocate the contract transaction price to the distinct performance obligations in the contract. Such allocation is based on the stand-alone selling price (“SSP”) of each distinct performance obligation. The transaction price allocated to each distinct performance obligation is adjusted for discounts offered to customers that are outside of the Company’s established sufficiently narrow ranges for distinct performance obligations’ SSPs on a relative SSP basis. We use observable stand-alone pricing to determine the SSP for each distinct performance obligation. Such observable SSPs are based upon our listed sales prices and consider discounts offered to customers. In instances where SSP is not directly observable because we do not sell the product or service separately, we determine the SSP through the residual approach or cost-plus margin models using information that includes market conditions and other observable inputs. Such instances primarily relate to sales of new products and service offerings and our acute suite of software licenses. Our acute suite of software licenses is sold to a diverse set of customers for a broad range of amounts and, therefore, SSP is not discernible from past transactions due to the high variability of selling prices. Our products and services are generally not sold with a right of return, except for certain hardware sales, which are not material to our consolidated revenue. We may provide credits or incentives on a contract-by-contract basis which are accounted for either as a material right or as variable consideration, respectively, when allocating the transaction price. Such credits and incentives have historically not been significant. We do not provide additional warranties to clients above and beyond warranties that the solutions purchased will perform in accordance with the agreed-upon specifications. On rare occasions, when additional warranties are granted, we evaluate on a case-by-case basis whether the additional warranty granted represents a separate performance obligation. Accounting Policy Elections and Practical Expedients We have elected to exclude from the measurement of the transaction price all taxes (e.g., sales, use, value-added) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes. We contract with customers to deliver and ship tangible products within the normal course of business, such as computer hardware. The control of the products transfers to the customer when the product reaches the shipper based on free on board (FOB) shipping clauses in these situations. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. We record as revenue any amounts billed to customers for shipping and handling costs and record as cost of revenue the actual shipping costs incurred. Our standard contract terms allow for the reimbursement by a customer for certain travel expenses necessary to provide on-site services to the customer, such as implementation and training. Such reimbursed travel expenses are reported on a gross basis. Since such reimbursed travel expenses do not represent a distinct good or service nor incremental value provided to a customer, a performance obligation is deemed not to exist. In certain situations, however, when the allowable reimbursable expenses amount is capped, we believe that such cap represents the most likely amount of variable consideration and the capped amount is included in the total contract transaction price. In accordance with ASC 606, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice (“right-to-invoice” practical expedient). We have elected to utilize this expedient as it relates to transaction-based services (such as revenue cycle management) and electronic data interchange transactions. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. The following table summarizes the pattern of revenue recognition for our most significant performance obligations: Performance Obligation Revenue Type Recurring or Non-recurring Nature Revenue Recognition Pattern Measure of progress Support and maintenance ("SMA") Software delivery, support and maintenance Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Software as a service ("SaaS") Software delivery, support and maintenance Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Private cloud hosting Client services Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Client/Education services Client services Non-recurring Over time Input method (cost to cost) – revenue is recognized proportionally over the service implementation based on hours Outsourcing services Client services Recurring Over time Input method (cost to cost) – revenue is recognized proportionally over the outsourcing period Payerpath (transaction volume) Software delivery, support and maintenance Recurring Over time Output method ("right-to-invoice" practical expedient) – value transferred to the customer is reflected on invoicing. Software licenses Software delivery, support and maintenance Non-recurring Point in time Upon electronic delivery Hardware Software delivery, support and maintenance Non-recurring Point in time Upon shipment Recurring software delivery, support and maintenance revenue consists of recurring subscription-based software sales, support and maintenance revenue, and recurring transaction-related revenue. Non-recurring software delivery, support and maintenance revenue consists of perpetual software licenses sales, resale of hardware and non-recurring transaction-related revenue. Recurring client services revenue consists of revenue from managed services solutions, such as outsourcing, private cloud hosting and revenue cycle management. Non-recurring client services revenue consists of project-based client services revenue. SMA, SaaS and private cloud hosting performance obligations are deemed to be performance obligations satisfied evenly over time as these are fulfilled as stand-ready obligations to perform. Client services, such as those relating to implementation, consulting, training or education, are generally not fulfilled evenly over the contract period, but rather over a shorter timeline where work effort can increase, or decline based upon stages of the project work effort. These client services are typically quoted to a customer as a fixed fee amount that covers the implementation effort. Delivery progress for these services is measured by establishing an approved cost budget with labor hour inputs utilized to gauge percentage of completion of the work effort. Therefore, revenue for our client, education and outsourcing services is recognized proportionally with the progress of the implementation work effort. Payerpath transaction volume and other transaction-based service obligations, such as revenue cycle management services, are fulfilled over time but are not provided evenly over the contract period and reliable inputs are not available to track progress of completion. We determined that value is provided to the customer throughout the contract period and the pricing charged to the customer varies on a monthly basis, based upon the volume of the customer’s transactions processed in that respective period. The invoiced amount to the customer represents this value and, accordingly, the practical expedient to recognize revenue based upon invoicing is most appropriate. We considered the specific implementation guidance for accounting for licenses of intellectual property (“IP”) to determine if point in time or over time recognition was more appropriate. The first step in the licensing framework is to determine whether the license is distinct or combined with other goods and services. For most of our software licensing products, the licenses are distinct, with the exception of one of our product offerings under our CareInMotion TM Disaggregation of Revenue We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Year Ended December 31, (In thousands) 2020 2019 2018 Revenue: Recurring revenue $ 1,222,731 $ 1,278,456 $ 1,313,281 Non-recurring revenue 279,969 354,155 304,560 Total revenue $ 1,502,700 $ 1,632,611 $ 1,617,841 Year Ended December 31, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 676,655 $ 250,877 $ (12,870 ) $ 914,662 Client services 577,594 10,444 0 588,038 Total revenue $ 1,254,249 $ 261,321 $ (12,870 ) $ 1,502,700 Year Ended December 31, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 761,836 $ 249,561 $ (7,202 ) $ 1,004,195 Client services 615,311 13,103 2 628,416 Total revenue $ 1,377,147 $ 262,664 $ (7,200 ) $ 1,632,611 Year Ended December 31, 2018 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 791,417 $ 237,320 $ (17,113 ) $ 1,011,624 Client services 588,082 9,398 8,737 606,217 Total revenue $ 1,379,499 $ 246,718 $ (8,376 ) $ 1,617,841 Contract Assets – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of ASU 2016-13 for contract assets was recorded as a debit to retained earnings of $5.3 million as of January 1, 2020. At adoption, we segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools were aligned with management’s review of financial performance. In the fourth quarter of 2020, we used each customer’s primary business unit in our pooling determination. This assessment provides additional information of the customer including size, segment and industry. Using this perspective, we added one new pool. We reallocated pools and loss rates accordingly and noted slight shifts in each pool. The new pools are aligned with management’s review of financial performance. As of December 31, 2020, no other adjustments to the pools were necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twenty-four-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The December 31, 2020 analysis resulted in no change in the ending estimate of credit losses. Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at December 31, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273

Accounts Receivables

Accounts Receivables	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Accounts Receivables	3. Accounts Receivable Trade Accounts Receivable – Estimate of Credit Losses We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. The new guidance required the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of ASU 2016-13 for trade accounts receivable was recorded as a debit to retained earnings of $12.6 million as of January 1, 2020. At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment, and business size. The pools were aligned with management’s review of financial performance. In the fourth quarter of 2020, we used each customer’s primary business unit in our pooling determination. This assessment provides additional information of the customer including size, segment and industry. Using this perspective, we added one new pool. We reallocated pools and loss rates accordingly and noted slight shifts in each pool. The new pools are aligned with management’s review of financial performance. As of December 31, 2020, no other adjustments to the pools were necessary. We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a twelve-month lookback period of credit memos and adjustments divided by the average accounts receivable balance for each pool during that period. We considered current economic conditions, including how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 33,256 Current period provision 8,726 Write-offs (10,484 ) Recoveries 98 Balance at December 31, 2020 $ 31,596

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Lessee Disclosure [Abstract]
Leases	4. Leases We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases, and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. We have elected the group of practical expedients under ASU 2016-02 to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate and vehicle leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically comprise of executory costs, which under the practical expedient allows for executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities . Our operating leases mainly include office leases and our finance leases include office and computer equipment leases. Our finance leases are not significant. Our leases have remaining lease terms up to 8 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Operating costs associated with leased assets are as follows: (In thousands) Year Ended December 31, 2020 2019 Operating lease cost (1) $ 25,394 $ 27,235 Less: Sublease income (1,121 ) (3,265 ) Total operating lease costs $ 24,273 $ 23,970 (1) Supplemental information for operating leases is as follows: (In thousands) Year Ended December 31, 2020 2019 Operating cash flows from operating leases $ 26,638 $ 29,348 Right-of-use assets obtained in exchange for operating lease obligations $ 21,770 $ 141,787 The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) December 31, 2020 December 31, 2019 Right-of-use assets - operating leases $ 96,601 $ 95,757 Current operating lease liabilities $ 22,264 $ 22,328 Long-term operating lease liabilities $ 93,463 $ 93,588 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 % The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of December 31, 2020. December 31, 2020 (In thousands) Operating Leases 2021 $ 26,090 2022 24,501 2023 22,752 2024 17,388 2025 14,927 Thereafter 22,069 Total lease liabilities 127,727 Less: Amount representing interest (12,000 ) Less: Short-term lease liabilities (22,264 ) Total long-term lease liabilities $ 93,463

Business Combinations and Dives

Business Combinations and Divestitures	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Business Combinations and Divestitures	5. Business Combinations and Divestitures 2020 Divestitures On December 31, 2020, we completed the sale of our CarePort business to a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to a purchase agreement (the “CarePort Purchase Agreement”) by which WellSky purchased substantially all of the assets of the CarePort business. The total consideration for CarePort was $1.35 billion, which is subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. We realized a pre-tax gain upon the sale of $933.9 million, which is included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. The divestiture is being treated as a discontinued operation as of December 31, 2020. Refer to Note 18, “Discontinued Operations” for further details regarding the historical assets, liabilities and results of operations of CarePort. On December 31, 2020, we repaid $161.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below). On October 15, 2020, we completed the sale of our EPSi business to Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation pursuant to a purchase agreement (the “EPSi Purchase Agreement”) by which Strata purchased substantially all of assets of the . Refer to Note 18, “Discontinued Operations” for further details regarding the historical assets, liabilities and results of operations of EPSi. On October 29, 2020, we repaid $19.0 million of the Term Loan as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement. 2019 Business Combinations We acquired the Pinnacle and Diabetes Collaborative Registries from the American College of Cardiology (“ACC”) as part of our broader strategic partnership with the ACC on July 2, 2019. The total purchase price was $19.7 million, consisting of an initial payment of $11.7 million plus up to an aggregate of $8.0 million pending the attainment certain milestones over the next 18 months. The contingent consideration of up to $8.0 million was valued at $5.0 million at the time of closing. We acquired the assets of a business engaged in the development, implementation, customization, marketing, licensing and sale of a specialty prescription drug platform including software that collects, saves and transmits information required to fill a prescription on June 10, 2019. The drug platform and software will enable healthcare providers, pharmacists and payors to digitally interact with one another to fill a prescription. The business is included in our Data, Analytics and Care Coordination business segment. We acquired all of the outstanding minority interest in Pulse8, Inc. on March 1, 2019 for $53.8 million (subject to adjustments for net working capital and a contingency holdback), plus up to a $5.0 million earnout based upon revenue targets through 2019. Pulse8, Inc. is a healthcare analytics and technology company that provides business intelligence software solutions for health plans and at-risk providers to enable them to analyze their risk adjustment and quality management programs. We initially acquired a controlling stake in Pulse 8, Inc. on September 8, 2016. This transaction was treated as an equity transaction, and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the year ended December 31, 2019. 2018 Business Combinations and Divestitures Acquisition of Health Grid On May 18, 2018, we acquired all the capital stock of Health Grid Holding Company, a Delaware corporation (“Health Grid”), for a total price of $110.0 million, consisting of an initial payment of $60.0 million plus up to an aggregate of $50.0 million in future earnout payments based on Health Grid achieving certain revenue targets over the three years following the acquisition. At the time of closing, we pre-paid $10.0 million of the earnout payments and the remaining contingent consideration of up to $40.0 million was valued at $23.9 million. Health Grid is a patient engagement solutions provider that assists independent providers, hospitals and health systems to improve patient interactions and satisfaction. We have integrated the capabilities of Health Grid into our FollowMyHealth ® (In thousands) Aggregate purchase price $ 60,000 First earnout payment paid by Allscripts 10,000 Fair value of contingent consideration payment 23,915 Closing purchase price adjustments 2,009 Total consideration paid for Health Grid $ 95,924 The allocation of the fair value of the consideration transferred as of the acquisition date of May 18, 2018 is shown in the table below. The allocation of purchase price was finalized in the fourth quarter of 2018. The goodwill is not deductible for tax purposes. (In thousands) Cash and cash equivalents $ 1,783 Accounts receivable, net 3,968 Prepaid expenses and other assets 185 Fixed assets 200 Intangible assets 41,000 Goodwill 53,953 Accounts payable and accrued expenses (478 ) Deferred revenue (700 ) Long-term deferred tax liability (3,987 ) Net assets acquired $ 95,924 The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 15 $ 28,000 Technology 8 13,000 $ 41,000 We incurred $0.5 million of acquisition costs which are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2018. The results of operations of Health Grid were not material to our consolidated results of operations for the year ended December 31, 2018. Acquisition of Practice Fusion, Inc. On February 13, 2018, we completed the acquisition of Practice Fusion, Inc., a Delaware corporation (“Practice Fusion”), for aggregate consideration of $113.6 million paid in cash. Practice Fusion offers an affordable certified cloud-based electronic health record (“EHR”) for traditionally hard-to-reach small, independent physician practices. The consideration paid for Practice Fusion is shown below: (In thousands) Aggregate purchase price $ 100,000 Add: Net working capital surplus 373 Add: Closing cash 14,951 Less: Adjustment to assumed indebtedness (1,684 ) Total consideration paid for Practice Fusion $ 113,640 The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. (In thousands) Cash and cash equivalents $ 14,951 Accounts receivable, net 13,328 Prepaid expenses and other current assets 809 Fixed assets 1,764 Intangible assets 67,100 Goodwill 35,092 Other assets 42 Accounts payable and accrued expenses (7,378 ) Deferred revenue (2,400 ) Long-term deferred tax liability (8,853 ) Other liabilities (815 ) Net assets acquired $ 113,640 The following table summarizes the fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships - Physician Practices 15 $ 29,000 Customer Relationships - Pharmaceutical Partners 20 19,400 Technology 8 14,800 Tradenames 10 3,900 $ 67,100 We incurred $1.2 million of acquisition costs which are included in selling, general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2018. The results of operations of Practice Fusion were not material to our consolidated results of operations for the year ended December 31, 2018. Netsmart LLC Divestiture On December 31, 2018, we sold all of the Class A Common Units of Netsmart LLC, a Delaware limited liability company (“Netsmart”), owned by the Company in exchange for $566.6 million, plus a final settlement as determined following the closing pursuant to the terms of the sales agreement. Netsmart was originally acquired in April 2016, and we realized a pre-tax gain on sale of $500.5 million, which is included on the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2018. The divestiture of Netsmart is being treated as a discontinued operation as of December 31, 2018. Refer to Note 18, “Discontinued Operations” for further details regarding the historical assets, liabilities and results of operations of Netsmart. Other Acquisitions and Divestitures On June 15, 2018, we acquired all the outstanding minority interests in a third party for $6.9 million. We initially acquired a controlling interest in the third party in April 2015. Therefore, this transaction was treated as an equity transaction, and the cash payment is reported as part of cash flow from financing activities in the consolidated statement of cash flows for the year ended December 31, 2018. On April 2, 2018, we sold substantially all of the assets of the Allscripts’ business providing hospitals and health systems document and other content management software and services generally known as “OneContent” to Hyland Software, Inc., an Ohio corporation (“Hyland”). Allscripts acquired the OneContent business during the fourth quarter of 2017 through the acquisition of the EIS Business (as defined below). Certain assets of Allscripts relating to the OneContent business were excluded from the transaction and retained by Allscripts. In addition, Hyland assumed certain liabilities related to the OneContent business. The total consideration for the OneContent business was $260 million, which was subject to certain adjustments for liabilities assumed by Hyland and net working capital. We realized a pre-tax gain upon sale of $177.9 million which is included in the Gain on sales of businesses, net line in our consolidated statements of operations for the year ended December 31, 2018. On March 15, 2018, we contributed certain assets and liabilities of our Strategic Sourcing business unit, acquired as part of the acquisition of the EIS Business in 2017, into a new entity together with $2.7 million of cash as additional consideration. In exchange for our contributions, we obtained a 35.7% interest in the new entity, which was valued at $4.0 million and is included in Other assets in our consolidated balance sheet as of December 31, 2018. This investment is accounted for under the equity method of accounting. As a result of this transaction, we recognized an initial pre-tax loss of $0.9 million and $4.7 million in additional losses due to measurement period adjustments upon the finalization of carve-out balances, mainly related to accounts receivable. These losses are included on the “Gain on sale of businesses, net” line in our consolidated statements of operations for the year ended December 31, 2018. On February 6, 2018, we acquired all of the common stock of a cloud-based analytics software platform provider for a purchase price of $8.0 million in cash. The allocation of the consideration is as follows: $1.1 million of intangible assets related to technology; $0.6 million to customer relationships; $6.6 million of goodwill; $0.8 million to accounts receivable; deferred revenue of $0.6 million and $0.5 million of long-term deferred income tax liabilities. The allocation was finalized in the fourth quarter of 2018. The acquired intangible asset related to technology will be amortized over 8 years using a method that approximates the pattern of economic benefits to be gained from the intangible asset. The customer relationship was amortized over one year. The goodwill is not deductible for tax purposes. The results of operations of this acquisition were not material to our consolidated financial statements.

Fair Value Measurements and Oth

Fair Value Measurements and Other Investments	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements and Other Investments	6. Fair Value Measurements and Other Investments Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at December 31, 2020 or 2019. Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 16, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet December 31, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange derivative assets Prepaid expenses and other current assets $ 0 $ 1,509 $ 0 $ 1,509 $ 0 $ 0 $ 0 $ 0 1.25% Call Option Other assets 0 0 0 0 0 0 84 84 Total assets $ 0 $ 1,509 $ 0 $ 1,509 $ 0 $ 0 $ 84 $ 84 Contingent consideration - current Accrued expenses $ 0 $ 0 $ 1,011 $ 1,011 $ 0 $ 0 $ 17,100 $ 17,100 Contingent consideration - long-term Other liabilities 0 0 0 0 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 0 0 0 0 185 185 Total liabilities $ 0 $ 0 $ 1,011 $ 1,011 $ 0 $ 0 $ 19,700 $ 19,700 The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2018 $ 25,624 $ (870 ) Additions 12,073 0 Payments/write-downs (1) (18,624 ) 0 Fair value adjustments 442 769 Balance at December 31, 2019 $ 19,515 $ (101 ) Additions 770 0 Payments/write-downs (2) (19,274 ) 0 Fair value adjustments 0 101 Balance at December 31, 2020 $ 1,011 $ 0 (1) Payments and write-downs for the year ended December 31, 2019 primarily consisted of $10.0 million in payments for the Health Grid earnout and a $5.0 million write-down related to the Pulse8 earnout. (2) The following table summarizes the quantitative information about our Level 3 fair value measurements at December 31, 2020: December 31, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 1,011 Probability Weighted Discounted cash flow Discount rate 5.3% to 5.5% 5.4 % Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 1,011 (1) The weighted average is calculated based upon the absolute fair value of the instruments. Long-term Investments The following table summarizes our other equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at December 31, 2020 Cost December 31, 2020 December 31, 2019 Equity method investments (1) 3 $ 7,099 $ 10,744 $ 11,332 Cost less impairment 8 37,568 25,059 32,462 Total long-term equity investments 11 $ 44,667 $ 35,803 $ 43,794 (1) During 2020, we recorded a $16.8 million gain from the sale of a third-party equity-method investment. The gain is recognized in the Equity in net income (loss) of unconsolidated investments line in the consolidated statements of operations. During 2018, w e acquired certain non-marketable equity securities of two third parties and entered into a commercial agreement with one of the third parties for total consideration of $11.7 million. During 2018, we also acquired a $1.8 million non-marketable convertible note of a third party. These investments are recorded in the Other asset caption within the consolidated balance sheets. It is not practicable to estimate the fair value of our equity investments primarily because of their illiquidity and restricted marketability as of December 31, 2020. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions. Impairment and Recovery of Long-Term Investments Management performs a quarterly assessment of each of our investments on an individual basis to determine if there are any declines in fair value. Based on our review in the third quarter of 2020, we recognized a $1.0 million non-cash impairment charge related to one of our cost-method investments, which equaled the cost basis of our initial investment. In the second quarter of 2020, we reached a settlement agreement with one of our third-party equity-method investments, which resulted in the recognition of a $0.6 million non-cash impairment charge. W e recognized non-cash impairment charges of $1.7 million during 2019 related to one of our long-term investments. We also recovered $1.0 million from a third-party cost-method investment that we had previously impaired. The non-cash impairment charges and the amount recovered are recognized in the Impairment (recovery) of long-term investments line in the consolidated statements of operations for the year ended December 31, 2020 and 2019.

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Fixed Assets	7. Fixed Assets Fixed assets consist of the following: Estimated December 31, December 31, (Dollar amounts in thousands) Useful Life 2020 2019 Computer equipment and software 3 to 10 years $ 329,564 $ 343,756 Facility furniture, fixtures and equipment 5 to 7 years 25,932 24,282 Leasehold improvements Shorter of 7 years or life of lease 40,115 38,948 Assets under finance leases 1 to 3 years 524 524 Fixed assets, gross 396,135 407,510 Less: Accumulated depreciation and amortization (323,973 ) (319,557 ) Fixed assets, net $ 72,162 $ 87,953 Accumulated amortization for assets under finance leases totaled $0.5 million and $0.4 million as of December 31, 2020 and 2019, respectively. Year Ended December 31, (In thousands) 2020 2019 2018 Fixed assets depreciation and amortization expense, including finance leases $ 32,324 $ 46,705 $ 46,951

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: December 31, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 535,092 $ (465,292 ) $ 69,800 $ 534,873 $ (433,017 ) $ 101,856 Customer contracts and relationships 674,336 (509,534 ) 164,802 701,805 (488,533 ) 213,272 Total $ 1,209,428 $ (974,826 ) $ 234,602 $ 1,236,678 $ (921,550 ) $ 315,128 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 974,729 974,110 Total $ 1,026,729 $ 1,026,110 During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. As a result of this change, our reporting units became Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and EPSi. Refer to Note 19, “Business Segments,” for further discussion on the impact of the change to our reportable segments. During the second quarter of 2020, we made two changes in our reporting units. We transferred the Follow My Health business, previously included in the Data, Analytics and Care Coordination reporting unit, to the Core Clinical and Financial Solutions reporting unit. We also transferred Payerpath, a portion of the Ambulatory business that was previously included in the Clinical and Financial Solutions reporting unit, to the Data, Analytics and Care Coordination reporting unit. During 2020, as a result of these organizational changes, we performed interim goodwill impairment tests as of January 1, 2020 and April 1, 2020. The fair value of each reporting unit substantially exceeded its carrying value, and no indicators of impairment were identified. We performed our annual 2020 goodwill impairment test as of October 1, 2020. The fair value of each reporting unit substantially exceeded its carrying value, and no indicators of impairment were identified. We performed our 2019 goodwill impairment test as of October 1, 2019. As a result of this test, we concluded that the carrying value of the historical Hospitals and Health Systems (“HHS”) reporting unit exceeded its fair value. As a result, we recognized a goodwill impairment charge of $25.7 million. This goodwill impairment charge is reflected on the Goodwill impairment charge line in our consolidated statements of operations. The historical HHS reporting unit is now reported within the Core Clinical and Financial Solutions reporting unit. The fair values of all other reporting units substantially exceeded their carrying values. As of December 31, 2019, the goodwill allocated to the historical HHS reporting unit was $485.5 million. We performed our 2018 goodwill impairment test as of October 1, 2018. We concluded that the carrying value of the historical NantHealth reporting unit exceeded its fair value as a result of this test. Our latest available financial forecasts at the time of the annual goodwill impairment test reflected that projected future operating costs exceeded projected revenues resulting in negative operating margins for the historical NantHealth reporting unit. We recognized a goodwill impairment charge of $13.5 million as a result, representing the entire goodwill balance assigned to the historical NantHealth reporting unit. This goodwill impairment charge is reflected on the Goodwill impairment charge line in our consolidated statements of operations for the year ended December 31, 2018. T he determination of the fair value of our reporting units is based on a combination of a market approach, which considers benchmark company market multiples, and an income approach, which utilizes discounted cash flows for each reporting unit and other Level 3 inputs. We determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate under the income approach. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change given the inherent uncertainty in predicting future results. The discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. We also consider our market capitalization in assessing the reasonableness of the combined fair values estimated for our reporting units as part of goodwill impairment testing. We recognized an intangible asset impairment charge of $23.1 million relating to Health Grid’s remaining customer relationship intangible balance during 2020. We also recognized an intangible asset impairment charge of $8.1 million relating to NantHealth’s remaining customer relationship intangible balance during 2019. In addition, we recognized an intangible asset impairment charge of $ 2.2 million during 2018 relating to NantHealth’s acquired proprietary technology because the carrying value of this definite-lived intangible assets no longer appeared recoverable based on latest available financial forecasts at the time of the annual goodwill impairment test. These impairment charges are included in the Asset impairment charges line in our consolidated statements of operations for the years ended December 31, 2020, 2019 and 2018. As of December 31, 2020, there were no accumulated impairment losses associated with goodwill. Accumulated impairment losses associated with goodwill totaled $39.2 million and $13.5 million as of December 31, 2019 and 2018, respectively. Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2020 and 2019 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Total Balance as of December 31, 2018 $ 760,294 $ 225,543 $ 985,837 Additions 0 13,684 13,684 Goodwill impairment charge (25,700 ) 0 (25,700 ) Foreign exchange translation 289 0 289 Balance as of December 31, 2019 734,883 239,227 974,110 Goodwill impairment charge 0 0 0 Foreign exchange translation 619 0 619 Balance as of December 31, 2020 $ 735,502 $ 239,227 $ 974,729 Additions to goodwill in 2019 resulted from the purchase of the Pinnacle and Diabetes Collaborative Registries and a prescription drug software company. Refer to Note 5, “Business Combinations and Divestitures” for additional information regarding these transactions. As stated above, we also recognized a goodwill impairment charge in 2019 for $25.7 million related to the HHS reporting unit. Intangible assets are being amortized over their estimated useful lives, and amortization expense related to intangible assets was as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Proprietary technology amortization included in cost of revenue $ 32,130 $ 35,034 $ 37,029 Intangible amortization included in operating expenses 25,604 27,188 26,558 Total intangible amortization expense $ 57,734 $ 62,222 $ 63,587 Future amortization expense for the intangible assets as of December 31, 2020, based on foreign currency exchange rates in effect as of such date, is as follows: Year Ended December 31, (In thousands) 2021 $ 50,556 2022 44,155 2023 27,943 2024 23,799 2025 20,180 Thereafter 67,969 Total $ 234,602

Asset Impairment Charges

Asset Impairment Charges	12 Months Ended
	Dec. 31, 2020
Asset Impairment Charges [Abstract]
Asset Impairment Charges	9. Asset Impairment Charges During the year ended December 31, 2020, we recorded several non-cash asset impairment charges. We recorded a non-cash asset impairment charge of $23.1 million related to the write-off of the remaining Health Grid acquired customer relationship intangible balance . This was partially offset by the write-off of $13.9 million related to the Health Grid contingent consideration accrual. The write-off was primarily related to one product in which we determined it would no longer be placed into service. The write-off was driven by the expectation of improved efficiencies in the utilization of our contract compared with historical deferred costs, which was identified through our broader cost reduction initiatives. Asset impairment charges incurred during the year ended December 31, 2019 were primarily the result of impairing the remaining NantHealth acquired customer relationship intangible balance of $8.1 million. We also recognized non-cash impairment charges of $2.7 million on the retirement of certain hosting assets due to data center migrations. Impairment of long-term investments during the year ended December 31, 2019 consisted of an impairment of $1.7 million associated with one of our long-term equity investments. We also recovered $1.0 million from one of our long-term equity investments that we had previously impaired. We also recorded a goodwill impairment charge of $25.7 million related to our HHS reporting unit. Refer to Note 8, “Goodwill and Intangible Assets” for further information regarding this impairment. We incurred several non-cash asset impairment charges during the year ended December 31, 2018. We recorded non-cash asset impairment charges of $33.2 million related to the write-off of capitalized software as a result of our decision to discontinue several software development projects. We also recorded $22.9 million of non-cash asset impairment charges related to our acquisition of the patient/provider engagement solutions business from NantHealth in 2017, which included the write-downs of $2.2 million of acquired technology and $20.7 million, representing the unamortized value assigned to the modification of our existing commercial agreement with NantHealth, as we no longer expected to recover the value assigned to these assets. The remaining $2.1 million of non-cash asset impairment charges recorded during the year ended December 31, 2018 relate to the disposal of fixed assets as a result of relocating and consolidating business functions and locations from recent acquisitions. We recorded a goodwill impairment charge of $13.5 million related to NantHealth during the year ended December 31, 2018. Refer to Note 8, “Goodwill and Intangible Assets” for further information regarding this impairment. We recognized non-cash impairment charges of $15.5 million in 2018 related to two of our cost-method equity investments and a related note receivable. These charges equaled the cost bases of the investments and the related note receivable prior to the impairment. The following table summarizes the non-cash asset impairment charges recorded during the periods indicated and where they appear in the corresponding consolidated statements of operations: Year Ended December 31, (In thousands) 2020 2019 2018 Asset impairment charges $ 74,969 $ 10,837 $ 58,166 Goodwill impairment charge $ 0 $ 25,700 $ 13,466 Impairment of long-term investments $ 1,575 $ 651 $ 15,487

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	10. Debt Debt outstanding, excluding lease obligations, consisted of the following: December 31, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 167,853 $ (3,166 ) $ 171,019 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 0 0 0 345,000 7,552 337,448 Senior Secured Credit Facility 0 3,432 (3,432 ) 410,000 5,224 404,776 Total debt $ 167,853 $ 266 $ 167,587 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 0 0 0 364,653 188 364,465 Total long-term debt, less current maturities $ 167,853 $ 266 $ 167,587 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital. Interest expense consisted of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Interest expense $ 18,113 $ 26,648 $ 35,366 Amortization of discounts and debt issuance costs 15,991 16,524 15,548 Total interest expense $ 34,104 $ 43,172 $ 50,914 Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, which is included in total interest expense above, consisted of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Coupon interest $ 4,016 $ 4,429 $ 4,312 Amortization of discounts and debt issuance costs 13,484 14,926 13,867 Total interest expense related to the convertible notes $ 17,500 $ 19,355 $ 18,179 Allscripts 0.875% Convertible Senior Notes On December 9, 2019, we issued $200.0 million aggregate principal amount of Allscripts’ 0.875% Convertible Senior Notes due 2027 (the “0.875% Notes”) in a private offering. The 0.875% Notes are Allscripts’ senior, unsecured obligations that bear interest at a rate of 0.875% per year, payable semiannually in arrears on January 1 and July 1 of each year, commencing on July 1, 2020. The 0.875% Notes will mature on January 1, 2027, unless earlier repurchased by us or converted in accordance with their terms prior to such date. The 0.875% Notes are convertible at the option of the holders (in whole or in part) at any time prior to the close of business on the business day immediately preceding July 1, 2026 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2019 (and only during such calendar quarter), if the last reported sale price of Allscripts’ common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on and including the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per principal amount of 0.875% Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Allscripts’ common stock and the conversion rate on each such trading day; or (3) upon the occurrence of certain corporate events as specified in the indenture governing the 0.875% Notes (the “0.875% Notes Indenture”). On or after July 1, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 0.875% Notes at any time, regardless of the foregoing conditions. Upon conversion, Allscripts will pay or deliver, as the case may be, cash, shares of Allscripts’ common stock, or a combination of cash and shares of Allscripts’ common stock, at Allscripts’ election, in amounts determined in the manner set forth in the 0.875% Notes Indenture. The initial conversion rate for the 0.875% Notes will be 75.0962 shares of Allscripts’ common stock per $1,000 principal amount of the 0.875% Notes, which is equivalent to an initial conversion price of approximately $13.32 per share of Allscripts’ common stock. The initial conversion price of the 0.875% Notes represents a premium of approximately 32.5% to $10.05 per share last reported sale price of Allscripts’ common stock on December 4, 2019. The conversion rate will be subject to adjustment upon the occurrence of certain specified events, but will not be adjusted for any accrued and unpaid interest. In addition, upon the occurrence of a “make-whole fundamental change” (as defined in Section 1.01 of the 0.875% Notes Indenture), Allscripts’ will, in certain circumstances, increase the conversion rate by a number of additional shares of Allscripts’ common stock for a holder that elects to convert its 0.875% Notes in connection with such make-whole fundamental change. We may not redeem the 0.875% Notes prior to the maturity date, and no sinking fund is provided for the 0.875% Notes. Upon the occurrence of a “fundamental change” (as defined in Section 1.01 of the 0.875% Notes Indenture), holders of the 0.875% Notes may require us to repurchase all or any portion of their 0.875% Notes in principal amounts of $1,000 or an integral multiple thereof at a fundamental change repurchase price in cash equal to 100% of the principal amount of the 0.875% Notes to be repurchased, plus any accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. The 0.875% Notes Indenture contains customary terms and covenants, including that upon certain events of default, including cross acceleration to certain other indebtedness of Allscripts and its subsidiaries, either the trustee under the 0.875% Notes Indenture or the holders of not less than 25% in aggregate principal amount of the 0.875% Notes then outstanding may declare the unpaid principal of the 0.875% Notes and accrued and unpaid interest, if any, thereon immediately due and payable. In December 2019, in connection with the 0.875% Notes offering, we entered into privately negotiated capped call transactions with JPMorgan Chase Bank, National Association, New York Branch, Wells Fargo Bank, National Association, Bank of America, N.A. and Deutsche Bank AG, London Branch (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to Allscripts’ common stock upon any conversion of 0.875% Notes and/or offset any cash payments Allscripts is required to make in excess of the principal amount of the converted 0.875% Notes upon conversion of the 0.875% Notes, as the case may be, in the event that the market price of Allscripts’ common stock is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the 0.875% Notes of approximately $13.32 per share of Allscripts’ common stock and is subject to certain adjustments under the terms of the capped call transactions), with such reduction and/or offset subject to a cap based on the cap price of the capped call transactions. The cap price of the capped call transactions is initially $17.5875 per share, representing a premium of 75% above the last reported sale price of $10.05 per share of Allscripts’ common stock on December 4, 2019, and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the 0.875% Notes, the number of shares of Allscripts’ common stock that underlie the 0.875% Notes. The capped call transactions are not part of the terms of the 0.875% Notes and will not affect any holder’s rights under the 0.875% Notes. Holders of the 0.875% Notes will not have any rights with respect to the capped call transactions. The aggregate net proceeds of the 0.875% Notes were $195.0 million after deducting $5.0 million for the initial purchasers’ discount but before deducting other estimated expenses. On December 9, 2019, we used $15.8 million of the net proceeds to pay the cost of the capped call transactions and the remainder of $179.2 million to repay outstanding borrowings under our senior secured revolving credit facility. On December 18, 2019, the initial purchasers notified us of the partial exercise of their option to purchase additional 0.875% Notes. On December 20, 2019 we issued an additional $18.0 million in aggregate principal amount of the 0.875% Notes (the “Option Notes”) pursuant to a partial exercise of the initial purchasers’ option to purchase additional 0.875% Notes. The Option Notes have the same terms as the 0.875% Notes previously described and are issued pursuant to the same 0.875% Notes Indenture. The net proceeds from the sale of the Option Notes totaled $17.5 million after deducting $0.5 million in debt issuance costs. In connection with the initial purchasers’ exercise of their option to purchase the Option Notes, we entered into additional privately negotiated capped call transactions (the “additional capped call transactions”) with each of the option counterparties. On December 20, 2019, we used $1.4 million of the net proceeds to pay the cost of additional capped call transactions and the remainder to repay additional outstanding borrowings under our senior secured revolving credit facility. The issuance in December 2019 of the combined $218.0 million aggregate purchase amount of the 0.875% Notes and the Option Notes (collectively, the “0.875% Convertible Senior Notes”) incurred $0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes including any discounts and issuance costs by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95% was used to compute the initial fair value of the liability component, which totaled $177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $40.1 million at the time of issuance before deducting any paid capped call fees. The equity component of $40.1 million, the $17.2 million in paid capped call fees and an allocation of $1.1 million in combined discounts and issuance costs were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount that will be accreted into interest expense through January 1, 2027 using the interest method. In June 2020, we paid $7.7 million to repurchase $10.1 million of the aggregate principal amount of the 0.875% Convertible Senior Notes, which resulted in a $0.5 million gain. In connection with the repurchase, the capped call transaction was partially terminated, and we received $0.3 million, which resulted in a recognition of $0.8 million in equity to offset the capped call fees and a $0.5 million loss. The remaining principal amount of the 0.875% Convertible Senior Notes at December 31, 2020 totaled $207.9 million. The carrying value of the combined equity component, net of capped call fees, issuance costs and accretion, at December 31, 2020 totaled $16.1 million. Allscripts Senior Secured Credit Facility On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 $900 a five-year The Term Loan is repayable in quarterly installments, which commenced on June 30, 2018. to $50 $10 $100 million On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provides the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 22, “Contingencies” while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $ 0.8 On July 20, 2020, we entered into a Second Amendment to the Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $ 1.4 The proceeds of the Revolving Facility can be used to finance Allscripts’ working capital needs and for general corporate purposes, including, without limitation, for financing permitted acquisitions, and for share repurchases. Allscripts is also permitted to add one or more incremental revolving and/or term loan facilities in an aggregate amount of up to $600 million, subject to certain conditions. The initial applicable interest rate margin for Base Rate borrowings is 1.00 %, and for Eurocurrency Rate borrowings is 2.00 %. On and after December 31, 20 20 , the interest rate margins will be determined from a pricing table and will depend upon Allscripts’ total leverage ratio. The applicable margins for Base Rate borrowings under the Second Amended Credit Agreement range from 0.50 % to 1.25 % depending on Allscripts’ total leverage ratio range. The applicable margins for Eurocurrency Rate loans range from 1.50 % to 2.25 %, depending on Allscripts’ total leverage ratio. Subject to certain agreed upon exceptions, all obligations under the Senior Secured Credit Facility remain guaranteed by each of our existing and future direct and indirect material domestic subsidiaries other than Coniston Exchange LLC and certain domestic subsidiaries owned by our foreign subsidiaries (the “Guarantors”) pursuant to a related Guarantee and Collateral Agreement among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, certain of our other subsidiaries, and JPMorgan Chase Bank, N.A., as administrative agent. Our obligations under the Senior Secured Credit Facility, any swap agreements and any cash management arrangements provided by any lender, remain secured, subject to permitted liens and other agreed upon exceptions, by a perfected first priority security interest in all of the tangible and intangible assets (including, without limitation, intellectual property, material owned real property and all of the capital stock of each Guarantor and, in the case of foreign subsidiaries, up to 65% of the capital stock of first tier material foreign subsidiaries) of Allscripts Healthcare Solutions, Inc. and certain of our subsidiary guarantors. The Second Amended Credit Agreement requires us to maintain a minimum interest coverage ratio of 3.5 to 1.0 and a maximum total net leverage ratio of 4.25 to 1.0. The minimum interest coverage ratio is calculated by dividing earnings before interest expense, income tax expense, depreciation and amortization expense by cash interest expense, subject to various agreed upon adjustments. The total net leverage ratio is calculated by dividing total indebtedness reduced by a portion of domestic unrestricted cash, by earnings before interest expense, income tax expense, depreciation and amortization expense, subject to various agreed upon adjustments. The Second Amended Credit Agreement also provides that during the four-quarter period following permitted acquisitions that are financed in whole or in part with indebtedness and the consideration paid by us is $100 million or more, we are required to maintain a maximum total leverage ratio of 4.5 to 1.0. In addition, the Second Amended Credit Agreement requires mandatory prepayments of the debt outstanding under the Senior Secured Credit Facility in certain specific circumstances, and contains a number of covenants which, among other things, restrict our ability to incur additional indebtedness, engage in mergers, or declare dividends or other payments in respect of our capital stock. The Second Amended Credit Agreement also contains certain customary events of default, including relating to non-payment, breach of covenants, cross-default, bankruptcy and change of control. As of December 31, 2020, $1.1 million in letters of credit were outstanding under the Second Amended Credit Agreement. No amounts under the Term Loan or the Revolving Facility were outstanding under the Second Amended Credit Agreement. As of December 31, 2020, the interest rate on the Senior Secured Credit Facility was LIBOR plus 2.00%, which totaled 2.15%. We were in compliance with all financial covenants under the Second Amended Credit Agreement as of December 31, 2020. As of December 31, 2020, we had $898.9 million available borrowing capacity, net of outstanding letters of credit, under the Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. In connection with the sale of our EPSi business on October 15, 2020, which is further discussed in Note 5, “Business Combinations and Divestitures”, the terms of our Second Amended and Restated Credit Agreement required us to make a mandatory prepayment of our Term Loan in the amount of $19.0 million on October 29, 2020. In connection with the sale of our CarePort business on December 31, 2020, which is further discussed in Note 5, “Business Combinations and Divestitures”, the terms of our Second Amended and Restated Credit Agreement required us to make a mandatory prepayment of our Term Loan in the amount of $161.0 million on December 31, 2020. Allscripts 1.25% Cash Convertible Senior Notes On June 18, 2013, we issued $345.0 million aggregate principal amount of Allscripts' 1.25% Cash Convertible Senior Notes due 2020 (the “1.25% Notes”). The aggregate net proceeds of the 1.25% Notes were $305.1 million, after payment of the net cost of the 1.25% Notes Call Spread Overlay (as described below) and transaction costs. Interest on the 1.25% Notes was payable semiannually in arrears on January 1 st st The 1.25% Notes were convertible only into cash, and not into shares of our common stock or any other securities. Holders could have converted their 1.25% Notes solely into cash at their option at any time prior to the close of business on the business day immediately preceding January 1, 2020 only under the following circumstances: (1) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period immediately after any five consecutive trading day period in which the trading price per $1,000 principal amount of the 1.25% Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after January 1, 2020 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders could have converted their 1.25% Notes solely into cash at any time, regardless of the foregoing circumstances. Upon conversion, in lieu of receiving shares of our common stock, a holder would have received an amount in cash, per $1,000 principal amount of the 1.25% Notes, equal to the settlement amount, determined in the manner set forth in the indenture governing the 1.25% Notes (the “1.25% Notes Indenture”). The initial conversion rate was 58.1869 shares of our common stock per $1,000 principal amount of the 1.25% Notes (equivalent to an initial conversion price of approximately $17.19 per share of common stock). The conversion rate was subject to adjustment in some events but was not adjusted for any accrued and unpaid interest. In addition, in the event that certain corporate events had occurred prior to the maturity date, we would have paid a cash make-whole premium by increasing the conversion rate for a holder who elected to convert such holder’s 1.25% Notes in connection with such a corporate event in certain circumstances. We did not redeem the 1.25% Notes prior to the maturity date, and no sinking fund was provided for the 1.25% Notes. If we would have undergone a fundamental change (as defined in the 1.25% Notes Indenture), holders could have required us to repurchase for cash all or part of their 1.25% Notes at a repurchase price equal to 100% of the principal amount of the 1.25% Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The 1.25% Notes Indenture provided for customary events of default, including cross acceleration to certain other indebtedness of ours, and our subsidiaries. The 1.25% Notes were senior unsecured obligations, and ranked senior in right of payment to any of our indebtedness that was expressly subordinated in right of payment to the 1.25% Notes; equal in right of payment to any of our unsecured indebtedness that was not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. The 1.25% Notes contained an embedded cash conversion option. We determined that the embedded cash conversion option was a derivative financial instrument, required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option transaction settled or expired. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the 1.25% Notes, refer to Note 16, “Derivative Financial Instruments.” The reduced carrying value of the 1.25% Notes resulted in a debt discount that was amortized to the 1.25% Notes’ principal amount through the recognition of non-cash interest expense over the expected term of the 1.25% Notes, which extended through their maturity date of July 1, 2020. This has resulted in our recognition of interest expense on the 1.25% Notes at an effective rate approximating what we would have incurred had nonconvertible debt with otherwise similar terms been issued. The effective interest rate of the 1.25% Notes at issuance was 5.4%, which was imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the 1.25% Notes. We recorded interest expense until the 1.25% Notes matured on July 1, 2020. In connection with the settlement of the 1.25% Notes, we paid $8.4 million in transaction costs. Such costs were allocated to the 1.25% Notes, the 1.25% Call Option (as defined below) and the 1.25% Warrants (as defined below). The amount allocated to the 1.25% Notes, or $8.3 million, was capitalized and was amortized over the expected term of the 1.25% Notes. 1.25% Notes Call Spread Overlay In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions (collectively, the “1.25% Call Option”) and warrant transactions (collectively, the “1.25% Warrants”), with certain of the initial purchasers of the 1.25% Notes (collectively, the “Call Spread Overlay”). Assuming full performance by the counterparties, the 1.25% Call Option was intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. We used $82.8 million from the initial proceeds of the 1.25% Notes to pay for the 1.25% Call Option, and simultaneously received $51.2 million from the sale of the 1.25% Warrants, for a net cash outlay of $31.6 million for the Call Spread Overlay. The 1.25% Call Option was a derivative financial instrument and is discussed further in Note 16, “Derivative Financial Instruments.” The 1.25% Warrants were equity instruments and are further discussed in Note 13, “Stockholders’ Equity.” Future Debt Payments The following table summarizes future debt payments as of December 31, 2020: (In thousands) Total 2021 2022 2023 2024 2025 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Total debt $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The following is a geographic breakdown of loss from continuing operations before income tax benefits: Year Ended December 31, (In thousands) 2020 2019 2018 United States $ (148,174 ) $ (287,088 ) $ (61,292 ) Foreign (1,137 ) 5,337 (907 ) Loss from continuing operations before income taxes $ (149,311 ) $ (281,751 ) $ (62,199 ) The following is a summary of the components of the benefit for income taxes: Year Ended December 31, (In thousands) 2020 2019 2018 Current tax provision Federal $ (19,346 ) $ (8,232 ) $ (14,018 ) State (219 ) (1,809 ) (3,859 ) Foreign 3,803 5,054 5,015 (15,762 ) (4,987 ) (12,862 ) Deferred tax provision Federal 2,931 (28,732 ) (5,781 ) State (2,981 ) (8,763 ) 236 Foreign (880 ) (858 ) (576 ) (930 ) (38,353 ) (6,121 ) Income tax benefit $ (16,692 ) $ (43,340 ) $ (18,983 ) Taxes computed at the statutory federal income tax rate of 21% for the years ended December 31, 2020, 2019 and 2018 are reconciled to the provision for income taxes as follows: Year Ended December 31, (In thousands) 2020 2019 2018 United States federal tax at statutory rate $ (31,355 ) $ (59,170 ) $ (13,062 ) Items affecting federal income tax rate Non-deductible acquisition and reorganization expenses 0 31 291 Non-deductible portion of Department of Justice Settlement 0 18,546 0 Research credits (6,500 ) (6,126 ) (6,185 ) Change in unrecognized tax benefits 3,204 1,046 3 State income taxes, net of federal benefit (2,940 ) (7,411 ) (2,916 ) Compensation 5,314 4,664 3,213 Meals and entertainment 118 549 616 Impact of foreign operations 1,443 3,079 3,627 Provision-to-Return adjustments (2,362 ) (383 ) (2,140 ) Deemed Dividends 352 473 373 Federal, state and local rate changes 0 (630 ) 0 US Tax reform impact 0 (2,972 ) 0 Goodwill impairment 0 5,397 0 Non-deductible items 28 43 34 Noncontrolling interest 0 0 951 True-up of prior year income of Consolidated Investment 0 0 913 Valuation allowance 16,949 922 (5,208 ) Other (943 ) (1,398 ) 507 Income tax benefit $ (16,692 ) $ (43,340 ) $ (18,983 ) Significant components of our deferred tax assets and liabilities consist of the following: December 31, (In thousands) 2020 2019 Deferred tax assets Accruals and reserves, net $ 18,260 $ 29,627 Allowance for doubtful accounts 9,571 11,507 Stock-based compensation, net 8,428 10,382 Deferred revenue 35,016 21,786 Operating and finance lease liabilities 22,902 22,085 Net operating loss carryforwards 35,695 37,717 Research and development tax credit 251 899 Other 4,519 7,488 Less: Valuation Allowance (35,491 ) (19,219 ) Total deferred tax assets 99,151 122,272 Deferred tax liabilities Prepaid expense (4,329 ) (5,372 ) Property and equipment, net (2,062 ) (3,695 ) Acquired intangibles, net (86,841 ) (111,284 ) Operating and finance right-of-use assets (18,315 ) (17,255 ) Total deferred tax liabilities (111,547 ) (137,606 ) Net deferred tax liabilities $ (12,396 ) $ (15,334 ) The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows: December 31, (In thousands) 2020 2019 Non-current deferred tax assets, net $ 5,790 $ 5,704 Non-current deferred tax liabilities, net (18,186 ) (21,038 ) Non-current deferred tax liabilities, net $ (12,396 ) $ (15,334 ) We had federal net operating loss (“NOL”) carryforwards of $164 million and $174 million as of December 31, 2020, and 2019, respectively. The federal NOL carryforward includes U.S. NOL carryovers of $4.3 million and Israeli NOL carryovers of $49 million that do not expire. We also had state NOL carryforwards of $2.5 million for the years ended December 31, 2020 and 2019. The NOL carryforwards expire in various amounts starting in 2021 for both federal and state tax purposes. The utilization of the federal NOL carryforwards is subject to limitation under the rules regarding changes in stock ownership as determined by the Internal Revenue Code. For federal purposes, 2017 to 2020 tax years remain subject to income tax examination by federal authorities. For our state tax jurisdictions, 2017 to 2020 tax years remain open to income tax examination by state tax authorities. Tax years remain open in various foreign jurisdictions beginning in 2015. We have a subsidiary in India that is entitled to a tax holiday that allows for tax-free operations during such tax holiday. This tax holiday for the subsidiary began to partially expire in 2012 and fully expired in 2017. Tax savings realized from this holiday totaled $0.4 million for the year ended December 31, 2017, which reduced our loss per share by less than $0.01 through 2017. There is a potential for a partial tax holiday for 5 years beginning on April 1, 2017, which is contingent upon a certain level of capital expenditure spending, among other conditions. Tax savings impact of $0.2 million has been recorded for this potential tax holiday for the year ended December 31, 2020, which impacted our diluted earnings per share by less than $0.01 in this year. GAAP principles prescribe a threshold of more-likely-than-not to be sustained upon examination for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These principles also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Changes in the amounts of unrecognized tax benefits were as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Beginning balance as of January 1 $ 20,604 $ 19,821 $ 10,939 Increases for tax positions related to the current year 8,053 1,240 8,977 Increases for tax positions related to prior years 427 95 367 Increases acquired in business acquisitions 0 0 540 Foreign currency translation 2 3 (5 ) Reductions due to lapsed statute of limitations (201 ) (555 ) (997 ) Ending balance as of December 31 $ 28,885 $ 20,604 $ 19,821 We had gross unrecognized tax benefits of $28.9 million and $20.6 million as of December 31, 2020 and 2019, respectively. The main driver of the increase in the unrecognized tax benefits as of December 31, 2020 is $6.4 million related to the uncertain positions taken on the state tax treatment of the gains on the sales of our EPSi and CarePort businesses. If the current gross unrecognized tax benefits were recognized, the result would be an increase in our income tax benefit of $30.8 million and $20.7 million, for 2020 and 2019, respectively. These amounts are net of accrued interest and penalties relating to unrecognized tax benefits of $2.0 million and $0.4 million, respectively. We believe that it is reasonably possible that $0.2 million of our currently remaining unrecognized tax benefits may be recognized by the end of 2021, as a result of a lapse of the applicable statute of limitations. We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Interest and penalties included in the provision for income taxes $ 1,620 $ 229 $ 543 The amount of interest and penalties included in our consolidated balance sheets is as follows: December 31, (In thousands) 2020 2019 Interest and penalties included in the liability for uncertain tax positions $ 2,048 $ 427 During the year ended December 31, 2020, we reversed valuation allowance of $1.0 million related to the We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United States. We are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements. We intend to indefinitely reinvest the undistributed earnings of our foreign subsidiaries as a general rule, as most of our foreign subsidiaries have third party customers, as well as formal sales proposals that could require significant resources. Specifically, our subsidiary in India may repatriate all current 2020 earnings at the discretion of management. As of December 31, 2020, we have no other plans to repatriate any other funds at this time. A Netherlands holding company currently holds all of our foreign subsidiaries. Our holding company makes it more efficient for us to share resources between the respective foreign subsidiaries. As we have determined that the earnings of these subsidiaries are not required as a source of funding for our U.S. operations, such earnings are not planned to be distributed to the United States in the foreseeable future. Determination of the amount of unrecognized income tax liability related to these undistributed foreign subsidiary earnings, if repatriated, is currently not practicable.

Stock Award Plan

Stock Award Plan	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plan	12. Stock Award Plan Total recognized stock-based compensation expense is included in our consolidated statements of operations as shown in the table below. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. Year Ended December 31, (In thousands) 2020 2019 2018 Cost of revenue: Software delivery, support and maintenance $ 1,640 $ 2,075 $ 2,184 Client services 4,421 4,067 3,997 Total cost of revenue 6,061 6,142 6,181 Selling, general and administrative expenses 25,002 27,348 24,213 Research and development 7,827 9,200 8,937 Total stock-based compensation expense $ 38,890 $ 42,690 $ 39,331 The estimated income tax benefit of stock-based compensation expense included in the provision for income taxes for the year ended December 31, 2020 is approximately $4.8 million. No stock-based compensation costs were capitalized during the years ended December 31, 2020, 2019 and 2018. The calculation of stock-based compensation expenses includes an estimate for forfeitures at the time of grant. This estimate can be revised in subsequent periods if actual forfeitures differ from those estimates, which are based on historical trends. Total unrecognized stock-based compensation expense related to non-vested awards and options was $51.3 million as of December 31, 2020, and this expense is expected to be recognized over a weighted-average period of 2.3 years. Allscripts Long-Term Incentive Plan Allscripts adopted the 2019 Stock Incentive Plan (the “Plan”), which became effective May 23, 2019. The Plan provides for the granting of stock options, service-based awards, performance-based share awards and market-based share awards, among other awards. The maximum number of shares available for awards under the Plan is 5.5 million, plus the number of available shares of common stock under the Amended and Restated 2011 Stock Incentive plan as of the effective date of the Plan. There were 8.2 million shares as of December 31, 2020 of common stock reserved for issuance under future share-based awards to be granted to any of Allscripts employees, officers, directors or independent consultants at terms and prices to be determined by our Board, and subject to the terms of the Plan. We issue service-based, performance-based and market-based awards in the form of restricted stock units or stock options. A description of each category of awards is presented below. Service-based Share Awards Service-based share awards include stock options and restricted stock units, and typically vest over a four-year There was $42.6 million of total estimated unrecognized stock-based compensation expense related to the service-based share awards as of December 31, 2020, which is expected to be recognized over a weighted-average period of 2.4 years. Performance-based Share Awards Performance-based share awards include restricted stock units. The purpose of such awards is to align management’s compensation with our financial performance and other operational objectives and, in certain cases, to retain key employees over a specified performance period. Awards granted under this category are based on the achievement of various targeted financial measures as defined by the Plan. The awards are earned based on actual results achieved compared to targeted amounts. Stock-based compensation expense related to these awards is recognized over a three-year There was $2.4 million of total estimated unrecognized stock-based compensation expense as of December 31, 2020, assuming various target attainments related to the performance-based share awards, which is expected to be recognized over a weighted-average period of 2.2 years. Market-based Share Awards Market-based share awards include restricted stock units. The purpose of such awards is to align management’s compensation with the performance of our common stock relative to the market. Awards granted under this category are dependent on our total shareholder returns relative to a specified peer group of companies over three-year There was $6.3 million of total estimated unrecognized stock-based compensation expense as of December 31, 2020, which is expected to be recognized over a weighted-average period of 1.7 years. Restricted Stock Units The following table summarizes the activity for restricted stock units during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock units as of December 31, 2017 7,259 $ 12.57 Awarded 4,024 13.25 Vested (2,222 ) 13.03 Forfeited (1,111 ) 12.43 Unvested restricted stock units as of December 31, 2018 7,950 12.81 Awarded 4,777 10.15 Vested (2,360 ) 12.62 Forfeited (1,453 ) 12.20 Unvested restricted stock units as of December 31, 2019 8,914 11.53 Awarded 5,607 6.88 Vested (2,756 ) 11.69 Forfeited (2,097 ) 10.79 Unvested restricted stock units as of December 31, 2020 9,668 $ 8.95 Net Share-settlements Upon vesting, restricted stock units are generally net share-settled upon vesting to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units that vested during the years ended December 31, 2020, 2019 and 2018 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory tax obligations for the applicable income and other employment taxes and remitted the equivalent amount of cash to the appropriate taxing authorities. Total payments for the employees’ minimum statutory tax obligations are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld during the years ended December 31, 2020, 2019 and 2018 were 808 thousand, 705 thousand and 695 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued at the vesting date. Stock Options The following table summarizes the status of stock options outstanding and the changes during the periods presented: Options Weighted-Average Options Weighted-Average (In thousands, except per share amounts) Outstanding Exercise Price Exercisable Exercise Price Balance as of December 31, 2017 1,635 $ 13.85 1,635 $ 13.85 Options granted 0 0.00 Options exercised (92 ) 14.01 Options forfeited (211 ) 14.74 Balance as of December 31, 2018 1,332 13.69 1,332 13.69 Options granted 0 0 Options exercised 0 0 Options forfeited (98 ) 14.01 Balance as of December 31, 2019 1,234 13.67 1,234 13.67 Options granted 0 0 Options exercised 0 0 Options forfeited (1,234 ) 13.67 Balance as of December 31, 2020 0 $ 0.00 0 $ 0.00 We estimated the fair value of our service-based stock option awards on the date of grant using the Black-Scholes-Merton option-pricing model. Option valuation models, including the Black-Scholes-Merton option-pricing model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense. Our stock options had a contractual term of 7 years. The aggregate intrinsic value of stock options outstanding or exercisable as of December 31, 2020 was zero, as all outstanding stock options were forfeited as of December 31, 2020. The intrinsic value of stock options outstanding represents the amount that would have been received by the option holders had all option holders exercised their stock options as of that date. The following activity occurred under the Plan: Year Ended December 31, (In thousands) 2020 2019 2018 Total intrinsic value of stock options exercised $ 0 $ 0 $ 69 Total fair value of share awards vested $ 32,218 $ 29,793 $ 28,954 Allscripts Employee Stock Purchase Plan Our Employee Stock Purchase Plan (the “ESPP”) allows eligible employees to authorize payroll deductions of up to 20% of their base salary to be applied toward the purchase of full shares of common stock on the last business day of each offering period. Offering periods under the ESPP are three months in duration and begin on each March 1 st st st st We treat the ESPP as a compensatory plan in accordance with GAAP. For each of the years ended December 31, 2020 and 2019, there were 2.0 million shares purchased under the ESPP.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	13. Stockholders’ Equity Stock Repurchases On August 2, 2018, we announced that our Board approved a stock purchase program (the “2018 Program”) under which we could repurchase up to $250 million of our common stock through December 31, 2020. During 2020, we repurchased 10.6 million shares of our common stock under the 2018 Program for a total of $102.0 million. During 2019, we repurchased 10.5 million shares of our common stock under the 2018 Program for a total of $111.5 million. On November 18, 2020, we announced that our Board approved a new stock purchase program (the “2020 Program”) under which we may repurchase up to $ 300 million of our common stock through December 31, 2021. The 2020 Program replaced the 2018 Program. During the fourth quarter of 2020, we repurchased million of our common stock under the 2020 Program. This is inclusive of shares repurchased through the a ccelerated s hare r epurchase a greement s noted below. On November 30, 2020, we entered into separate Master Confirmations (each, a “Master Confirmation”) and Supplemental Confirmations (each, together with the related Master Confirmation, an “ASR Agreement”), with JPMorgan Chase Bank, National Association and Wells Fargo Bank, National Association (each, an “ASR Counterparty”, or collectively, “ASR Counterparties”), to purchase shares of our common stock for a total payment of $200.0 million (the “Prepayment Amount”). Under the terms of the ASR Agreements, on November 30, 2020, we paid the Prepayment Amount to the ASR Counterparties and received on December 2, 2020 an initial delivery of 11.7 million shares of our common stock, which is approximately 80% of the total number of shares that could be repurchased under the ASR Agreements if the final purchase price per share equaled the closing price of our common stock on November 30, 2020. These repurchased shares became treasury shares and were recorded as a $165.7 million reduction to shareholder’s equity. The remaining $34.3 million of the Prepayment Amount was recorded as a reduction to shareholders’ equity as an unsettled forward contract indexed to our common stock. We excluded the potential share impact of any remaining shares subject to repurchase from the computation of diluted earnings per share as these shares would be anti-dilutive for the year ended December 31, 2020. The approximate dollar value of shares of our common stock that may yet be purchased under the 2020 Program following the ASR Agreements is $67.2 million as of December 31, 2020. At final settlement, depending on the final purchase price per share, the ASR Counterparties may be required to deliver additional shares of our common stock to the Company, or, under certain circumstances, we may be required to make a cash payment to each ASR Counterparty or may elect to deliver the equivalent value in shares of our common stock. The final purchase price per share under each ASR Agreement will generally be based on the average of daily volume-weighted average prices of shares of our common stock during a term set forth in the such ASR Agreement. The ASR Agreements contain provisions customary for agreements of this type, including provisions for adjustments to the transaction terms, the circumstances generally under which the ASR Agreements may be accelerated, extended or terminated early by the ASR Counterparties and various acknowledgments, representations and warranties made by the parties to one another. Final settlement of the ASR Agreements is expected to be completed during the second quarter of 2021, although the settlement may be accelerated at the ASR Counterparties’ option. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. Issuance of Common Stock and Warrants On December 31, 2020, we completed the issuance of a warrant to a commercial partner, as part of a new and expanded commercial relationship, pursuant to which the warrant holder has the right to purchase 1.5 million shares of our common stock at an exercise price of $9.82 per share, (the closing price of the Company’s common stock on the date definitive agreements with respect to the new and expanded commercial relationship were executed), three-year On June 30, 2016, we issued to a commercial partner, as part of an overall commercial relationship, unregistered warrants to purchase (i) 900,000 shares of our common stock, par value $0.01 per share, at a price per share of $12.47, (ii) 1,000,000 shares of our common stock at a price per share of $14.34 and (iii) 1,100,000 shares of our common stock at a price per share of $15.59, in each case subject to customary anti-dilution adjustments. The warrants vested in four equal annual installments of 750 thousand shares beginning in June 2017 and expire in June 2026. Our issuance of the warrants was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act. These warrants are not actively traded and were valued based on an option pricing model that used observable and unobservable market data for inputs. The warrants were valued at $11 million and were amortized into earnings over the four-year In June 2013, in connection with the issuance of the 1.25% Notes, we issued the 1.25% Warrants exercisable for 20.1 million shares of our common stock (subject to anti-dilution adjustments under certain circumstances) with an initial exercise price of $ 23.135 per share, subject to customary adjustments. The net proceeds from the sale of the 1.25% Warrants of $ 51.2 million are included as additional paid in capital in the accompanying consolidated balance sheets as of December 31, 20 20 and 201 9 . The 1.25% Warrants began to expire as of October 1, 2020 , with expiration continuing to expire over the next 70 trading days . The 1.25% Warrants are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap. For each 1.25% Warrant that is exercised, we will deliver to the option counterparties a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of fractional shares. We will not receive any additional proceeds if the 1.25% Warrants are exercised. The number of warrants and the strike price are subject to adjustment under certain circumstances. The 1.25% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock (as measured under the terms of the warrant transactions) exceeds the applicable strike price of the 1.25% Warrants. As of December 31, 2020, none of the 1.25% Warrants have been exercised. Issuance of 0.875% Convertible Senior Notes In December 2019, we issued the 0.875% Convertible Senior Notes that, at the option of the holders, may be converted into cash, Allscripts’ common stock or a combination of cash and Allscripts’ common stock. The issuance of the 0.875% Convertible Senior Notes generated a $40.1 million equity component for the embedded conversion option, which was recorded as Additional paid-in capital within the consolidated balance sheets as a discount that will be accreted into interest expense through January 1, 2027 using the interest method. The carrying value of the embedded conversion option was $16.1 million as of December 31, 2020. Refer to Note 10, “Debt” for further information regarding the 0.875% Convertible Senior Notes and embedded conversion option.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	14. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Year Ended December 31, (In thousands, except per share amounts) 2020 2019 2018 Basic income (loss) per Common Share: Loss from continuing operations, net of tax $ (132,619 ) $ (238,411 ) $ (43,216 ) Net loss attributable to non-controlling interests 0 424 4,527 Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (132,619 ) $ (237,987 ) $ (38,689 ) Income from discontinued operations, net of tax 833,026 55,809 451,023 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations 0 0 (48,594 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 833,026 55,809 402,429 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 700,407 $ (182,178 ) $ 363,740 Weighted-average common shares outstanding 159,281 166,306 176,038 Basic loss from continuing operations per Common Share $ (0.83 ) $ (1.43 ) $ (0.22 ) Basic income from discontinued operations per Common Share $ 5.23 $ 0.33 $ 2.29 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 4.40 $ (1.10 ) $ 2.07 Diluted income (loss) per Common Share: Loss from continuing operations, net of tax $ (132,619 ) $ (238,411 ) $ (43,216 ) Net loss attributable to non-controlling interests 0 424 4,527 Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (132,619 ) $ (237,987 ) $ (38,689 ) Income from discontinued operations, net of tax $ 833,026 $ 55,809 $ 451,023 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations 0 0 (48,594 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 833,026 55,809 402,429 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 700,407 $ (182,178 ) $ 363,740 Weighted-average common shares outstanding 159,281 166,306 176,038 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 Weighted-average common shares outstanding assuming dilution 159,281 166,306 176,038 Diluted (loss) income from continuing operations per Common Share $ (0.83 ) $ (1.43 ) $ (0.22 ) Diluted income from discontinued operations per Common Share $ 5.23 $ 0.33 $ 2.29 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 4.40 $ (1.10 ) $ 2.07 As a result of the loss from continuing operations, net of tax for the years ended December 31, 2020, 2019 and 2018, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Year Ended December 31, (In thousands) 2020 2019 2018 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 42,845 27,945 26,175

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss	15. Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss Changes in the balances of each component included in accumulated other comprehensive loss (“AOCI”) are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2017 (1) (2,676 ) 691 (1,985 ) Other comprehensive (loss) income before reclassifications (2,908 ) (264 ) (3,172 ) Net (gains) losses reclassified from accumulated other comprehensive loss 0 (232 ) (232 ) Net other comprehensive (loss) income (2,908 ) (496 ) (3,404 ) Balance as of December 31, 2018 (2) (5,584 ) 195 (5,389 ) Other comprehensive income (loss) before reclassifications 1,192 61 1,253 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (256 ) (256 ) Net other comprehensive income (loss) 1,192 (195 ) 997 Balance as of December 31, 2019 (2) (4,392 ) 0 (4,392 ) Other comprehensive income (loss) before reclassifications 1,435 1,587 3,022 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (468 ) (468 ) Net other comprehensive income (loss) 1,435 1,119 2,554 Balance as of December 31, 2020 (3) $ (2,957 ) $ 1,119 $ (1,838 ) (1) (2) Tax effects for the years ended December 31, 2019 and 2018 include $149 (3) Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives. Income Tax Effects Related to Components of Other Comprehensive Loss The following tables reflect the tax effects allocated to each component of other comprehensive loss (“OCI”) Year Ended December 31, 2020 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,435 $ 0 $ 1,435 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,139 (552 ) 1,587 Net (gains) losses reclassified into income (630 ) 162 (468 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,509 (390 ) 1,119 Other comprehensive income (loss) $ 2,944 $ (390 ) $ 2,554 Year Ended December 31, 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,192 $ 0 $ 1,192 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 82 (21 ) 61 Net (gains) losses reclassified into income (344 ) 88 (256 ) Net change in unrealized (losses) gains on foreign exchange contracts (262 ) 67 (195 ) Other comprehensive income $ 930 $ 67 $ 997 Year Ended December 31, 2018 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,908 ) $ 0 $ (2,908 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period (357 ) 93 (264 ) Net (gains) losses reclassified into income (1) (516 ) 284 (232 ) Net change in unrealized (losses) gains on foreign exchange contracts (873 ) 377 (496 ) Other comprehensive (loss) income $ (3,781 ) $ 377 $ (3,404 ) (1) Net of taxes of $68 thousand for unrealized net gains on foreign exchange contract derivatives

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	16. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: December 31, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,509 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 0 Total derivatives $ 1,509 $ 0 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future INR expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of December 31, 2020, there were six forward contracts outstanding that were staggered to mature monthly starting in January 2021 June 2021 The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized in OCI Location of Gain (Loss) Reclassified from AOCI into Income Amount of Gain (Loss) Reclassified from AOCI into Income Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 2018 2020 2019 2018 Foreign exchange contracts $ 2,139 $ 82 $ (357 ) Cost of Revenue $ 249 $ 124 $ 165 Selling, general and administrative expenses 122 83 138 Research and development 259 137 214 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into the 1.25% Call Option with certain of the initial purchasers of the 1.25% Notes (the “Option Counterparties”). Assuming full performance by the Option Counterparties, the 1.25% Call Option was intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. On July 1, 2020, the 1.25% Notes matured and were repaid in full (refer to Note 10, “Debt”), and the 1.25% Call Option expired. Aside from the initial payment of a premium to the Option Counterparties of $82.8 million for the 1.25% Call Option, we were not required to make any cash payments to the Option Counterparties under the 1.25% Call Option, and, subject to the terms and conditions thereof, would have been entitled to receive from the Option Counterparties an amount of cash, generally equal to the amount by which the market price per share of our common stock exceeded the strike price of the 1.25% Call Option during the relevant valuation period. The strike price under the 1.25% Call Option was equal to the conversion price of the 1.25% Notes of $17.19 per share of our common stock. The 1.25% Call Option, which was indexed to our common stock, was a derivative asset that required mark-to-market accounting treatment, due to the cash settlement features, until the 1.25% Call Option settled or expired. The 1.25% Call Option was measured and reported at fair value on a recurring basis within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 6, “ Fair Value Measurements and Other Investments The 1.25% Call Option did not qualify for hedge accounting treatment. Therefore, the change in fair value of this instrument was recognized immediately in our consolidated statements of operations in Other income (loss), net. Because the terms of the 1.25% Call Option were substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed next, we expected the net effect of those two derivative instruments on our results of operations to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes was required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value recognized immediately in our consolidated statements of operations in Other income (loss), net until the cash conversion option settled or expired. The cash conversion option expired without ever having required settlement prior to the maturity of the 1.25% Notes. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option was measured and reported at fair value on a recurring basis within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 6, “ Fair Value Measurements and Other Investments The following table shows the net impact of the changes in fair values of the 1.25% Call Option and 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Year Ended December 31, (In thousands) 2020 2019 2018 1.25% Call Option $ (84 ) $ (9,020 ) $ (37,474 ) 1.25% Embedded cash conversion option 185 9,789 37,803 Net income included in Other income, net $ 101 $ 769 $ 329

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments	17. Commitments Commitment with Strategic Partner We completed renegotiations with Atos to improve the operating cost structure of our private cloud hosting operations during 2019. The new agreement also provides for the payment of initial annual base fees of $ 35 Expenses under our agreements with Atos, which are included in cost of revenue in our consolidated statements of operations, are as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Expenses incurred under Atos agreements $ 102,730 $ 100,089 $ 55,903

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2020
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	18. Discontinued Operations EPSi and CarePort Discontinued Operations During 2020, we implemented a strategic initiative to sell two of our businesses, EPSi and CarePort. Since both businesses were part of the same strategic initiative and were sold within the same period, the combined sale of EPSi and CarePort represents a strategic shift that had a major effect on our operations and financial results. These businesses are now reported together as discontinued operations for all periods presented. On October 15, 2020, we completed the sale of our EPSi business in exchange for $365.0 million, which is subject to certain adjustments for liabilities assumed by Strata and net working capital as described in the EPSi Purchase Agreement. Prior to the sale, EPSi was part of the Unallocated category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into our two reportable segments. On its own, the divestiture of the EPSi business did not represent a strategic shift that had a major effect on our operations and financial results. However, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. Therefore, EPSi is treated as a discontinued operation. Refer to Note 5, “Business Combinations and Divestitures” for additional information about this transaction. On December 31, 2020, we completed the sale of our CarePort business in exchange for $1.35 billion, which is subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. Prior to the sale, CarePort was part of the Data, Analytics and Care Coordination reportable segment. On its own, the divestiture of the CarePort business represents a strategic shift that had a major effect on our operations and financial results. Refer to Note 5, “Business Combinations and Divestitures” for additional information about this transaction. The following table summarizes the major classes of assets and liabilities of EPSi and CarePort, as reported on the consolidated balance sheets as of December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Carrying amounts of major classes of assets associated with EPSi and CarePort included as part of discontinued operations: Accounts receivable, net of allowance of $1,874 as of December 31, 2019 $ 0 $ 35,336 Contract assets, net of allowance of $0 as of December 31, 2019 0 2,690 Prepaid expenses and other current assets 0 3,845 Total current assets attributable to discontinued operations 0 41,871 Fixed assets, net 0 386 Software development costs, net 0 21,237 Intangible assets, net 0 7,014 Goodwill 0 387,907 Contract assets - long-term, net of allowance of $0 as of December 31, 2019 0 4,034 Right-of-use assets - operating leases 0 2,263 Other assets 0 5,180 Total long-term assets attributable to discontinued operations $ 0 $ 428,021 Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations: Accounts payable $ 0 $ 1,190 Accrued expenses 6,669 381 Income tax payable 316,142 0 Accrued compensation and benefits 0 2,788 Deferred revenue 0 44,224 Current operating lease liabilities 0 809 Total current liabilities attributable to discontinued operations 322,811 49,392 Deferred revenue long-term 0 1,269 Long-term operating lease liabilities 0 1,574 Total long-term liabilities attributable to discontinued operations $ 0 $ 2,843 The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statement of operations for the years ended December 31, 2020, 2019 and 2018: Year ended December 31, (In thousands) 2020 2019 2018 Major income and expense line items related to EPSi and CarePort: Revenue: Software delivery, support and maintenance $ 122,791 $ 122,268 $ 116,639 Client services 14,030 16,763 15,482 Total revenue 136,821 139,031 132,121 Cost of revenue: Software delivery, support and maintenance 11,424 12,482 10,737 Client services 15,585 15,124 12,038 Amortization of software development and acquisition-related assets 9,053 8,166 6,194 Total cost of revenue 36,062 35,772 28,969 Gross profit 100,759 103,259 103,152 Selling, general and administrative expenses 15,539 18,964 18,118 Research and development 8,269 9,065 9,673 Amortization of intangible assets 29 29 29 Income from discontinued operations for EPSi and CarePort 76,922 75,201 75,332 Interest expense (5,241 ) 0 0 Other (expense) income, net (192 ) 2 5 Gain on sale of discontinued operations 1,156,504 0 0 Income from discontinued operations for EPSi and CarePort before income taxes 1,227,993 75,203 75,337 Income tax provision (1) (394,926 ) (19,417 ) (19,452 ) Income from discontinued operations, net of tax for EPSi and CarePort (2) $ 833,067 $ 55,786 $ 55,885 (1) (2) Netsmart Discontinued Operation On December 31, 2018, we sold all of the Class A Common Units of Netsmart held by the Company in exchange for $566.6 million in cash plus a final settlement as determined following the closing. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is reported as a discontinued operation as a result of the sale. Refer to Note 5, “Business Combinations and Divestitures” for additional information about this transaction. The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the year ended December 31, 2018: Year ended December 31, (In thousands) 2018 Major income and expense line items related to Netsmart: (1) Revenue: Software delivery, support and maintenance $ 214,065 Client services 131,166 Total revenue 345,231 Cost of revenue: Software delivery, support and maintenance 60,100 Client services 94,061 Amortization of software development and acquisition related assets 34,357 Total cost of revenue 188,518 Gross profit 156,713 Selling, general and administrative expenses 125,807 Research and development 25,315 Amortization of intangible and acquisition-related assets 24,029 Loss from discontinued operations of Netsmart (18,438 ) Interest expense (59,541 ) Other income 101 Gain on sale of discontinued operations 500,471 Income from discontinued operations of Netsmart before income taxes 422,593 Income tax provision (31,186 ) Income from discontinued operations, net of tax for Netsmart $ 391,407 (1) Activity includes both Netsmart and intercompany transactions that would not have been eliminated if Netsmart’s results were not consolidated. Horizon Clinicals and Series2000 Revenue Cycle Discontinued Operation Two of the product offerings acquired with the EIS Business in 2017, Horizon Clinicals and Series2000 Revenue Cycle, were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, they are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers transitioned to other platforms. No disposal gains or losses were recognized during the year ended December 31, 2018 related to these discontinued solutions. We had $ The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the year ended December 31, 2018: Year ended December 31, (In thousands) 2018 Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle: Revenue: Software delivery, support and maintenance $ 9,441 Client services 404 Total revenue 9,845 Cost of revenue: Software delivery, support and maintenance 2,322 Client services 830 Total cost of revenue 3,152 Gross profit 6,693 Research and development 1,651 Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes 5,042 Income tax provision (1,311 ) Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle $ 3,731

Business Segments

Business Segments	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Business Segments	19. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. During the first quarter of 2020, we realigned our reporting structure to organize the Company around strategic business units to maximize delivery of client commitments, operational effectiveness and competitiveness. As a result, we had three During the second quarter of 2020, (i) certain operations were moved between the Core Clinical and Financial Solutions segment, and the Data, Analytics and Care Coordination segment and (ii) a transfer price allocation was recorded between the Core Clinical and Financial Solutions segment and the Data, Analytics and Care Coordination segment. In addition, the (i) corporate general and administrative expenses (including marketing expenses) and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware, that were previously in the “Unallocated Amounts” were allocated between the three operating segments. The new reportable segments are (i) Core Clinical and Financial Solutions and (ii) Data, Analytics and Care Coordination. The new Core Clinical and Financial Solutions segment derives its revenue from the sale of software applications for patient engagement, integrated clinical and financial management solutions, which primarily include EHR-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting and revenue cycle management. The new Data, Analytics and Care Coordination segment derives its revenue from the sale of practice reimbursement and payer and life sciences solutions, which are mainly targeted at physician practices, payers, life sciences companies and other key healthcare stakeholders. These solutions enable clients to transition, analyze, coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The EPSi operating segment was included in the “Unallocated Amounts” category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into the two reportable segments. The segment disclosures below for the years ended December 31, 2019 and 2018 have been revised to conform to the current year presentation. On October 15, 2020, we completed the sale of our EPSi business . As noted above, p rior to the sale, EPSi was included in “Unallocated Amounts.” On December 3 1 , 2020, w e completed the sale of our CarePort business. Prior to the sale, CarePort was included in the Data, Analytics and Care Coordination reportable segment . The divestitures of EPSi and CarePort are being treated as discontinued operations as they were part of the same strategic initiative, were sold within the same period, and have a combined major effect on our consolidated financial statements and results of operations. Refer to Note 5, “Business Combinations and Divestitures ” and to Note 18, “Discontinued Operations ” for additional information. We sold all of our investment in Netsmart on December 31, 2018. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is reported as a discontinued operation as a result of the sale. In addition, the results of operations related to two of the product offerings acquired with the EIS Business (Horizon Clinicals and Series2000) that were sunset in 2018 are also presented throughout these financial statements as discontinued operations. These two product offerings were included within the historical Provider reportable segment, which is now reported within the Core Clinical and Financial Solutions segment. Refer to Note 18, “Discontinued Operations.” Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and loss from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment. Year Ended December 31, (In thousands) 2020 2019 2018 Revenue: Core Clinical and Financial Solutions $ 1,254,249 $ 1,377,147 $ 1,379,499 Data, Analytics and Care Coordination 261,321 262,664 246,718 Unallocated Amounts (12,870 ) (7,200 ) (8,376 ) Total revenue $ 1,502,700 $ 1,632,611 $ 1,617,841 Gross profit: Core Clinical and Financial Solutions $ 434,288 $ 473,033 $ 491,421 Data, Analytics and Care Coordination 131,407 137,254 129,970 Unallocated Amounts 0 0 0 Total gross profit $ 565,695 $ 610,287 $ 621,391 Loss from operations: Core Clinical and Financial Solutions $ (116,139 ) $ (80,465 ) $ (158,440 ) Data, Analytics and Care Coordination (14,741 ) (19,224 ) (9,944 ) Unallocated Amounts 0 0 0 Total loss from operations $ (130,880 ) $ (99,689 ) $ (168,384 )

Supplemental Disclosures

Supplemental Disclosures	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	20. Supplemental Disclosures The majority of the restricted cash balance as of December 31, 2020 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016 to be used by Netsmart to facilitate the integration of our Homecare TM December 31 (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 531,104 $ 129,668 Restricted cash 6,361 7,871 Total cash, cash equivalents and restricted cash $ 537,465 $ 137,539 Year Ended December 31, (In thousands) 2020 2019 2018 Cash paid during the period for: Interest, including convertible senior notes $ 24,616 $ 23,917 $ 33,200 Income taxes paid, net of tax refunds $ 76,595 $ 42,972 $ 10,108 Non-cash transactions: Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations $ 0 $ 0 $ 48,594 Obligations incurred to purchase capitalized software or enter into finance leases $ 0 $ 0 $ 1,501 Contributions of assets in exchange for equity interest $ 0 $ 0 $ 4,000 Issuance of treasury stock to commercial partner $ 752 $ 701 $ 1,121 Accrued expenses consist of the following: December 31, (In thousands) 2020 2019 Royalties, certain third-party product costs and licenses $ 37,841 $ 35,064 Practice Fusion settlement 0 145,000 Other 62,421 90,217 Total Accrued expenses $ 100,262 $ 270,281 Other consists of various accrued expenses and no individual item accounted for more than 5% of the current liabilities balance at the respective balance sheet dates. Prepaid and other current assets consists of the following: December 31, (In thousands) 2020 2019 Prepaid assets $ 132,944 $ 142,191 Other current assets 3,320 1,954 Total Prepaid and other current assets $ 136,264 $ 144,145 Other assets consist of the following: December 31, (In thousands) 2020 2019 Fair value of 1.25% Call Option $ 0 $ 84 Long-term deferred hosting fees 11,025 36,002 Long-term prepaid commissions 27,882 28,876 Investments in non-marketable securities 35,805 43,806 Long-term deposits and other assets 16,916 10,819 Total Other assets $ 91,628 $ 119,587

Geographic Information

Geographic Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Geographic Information	21. Geographic Information Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below: Year Ended December 31, (In thousands) 2020 2019 2018 United States $ 1,439,737 $ 1,562,107 $ 1,565,057 Canada 15,624 16,495 15,377 Other international 47,339 54,009 37,407 Total $ 1,502,700 $ 1,632,611 $ 1,617,841 A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below: December 31, (In thousands) 2020 2019 United States $ 62,016 $ 77,736 India 5,876 5,321 Israel 2,611 3,240 Canada 187 51 Other international 1,472 1,605 Total $ 72,162 $ 87,953

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Contingencies	22. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these additional legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On January 27, 2020, Practice Fusion entered into the Settlement Agreements resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. See risk factor entitled “

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	23. Quarterly Financial Information (Unaudited) The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters, which have been restated to illustrate CarePort and EPSi as discontinued operations. Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2020 2020 2020 2020 Revenue $ 386,414 $ 365,618 $ 369,304 $ 381,364 Cost of revenue 225,391 230,480 231,706 249,428 Gross profit 161,023 135,138 137,598 131,936 Selling, general and administrative expenses 93,777 93,442 109,897 92,825 Research and development 54,287 46,352 46,045 59,377 Asset impairment charges 74,759 210 0 0 Amortization of intangible and acquisition-related assets 6,278 6,295 6,321 6,710 Loss from operations (68,078 ) (11,161 ) (24,665 ) (26,976 ) Interest expense (6,458 ) (6,667 ) (10,314 ) (10,665 ) Other income (loss), net 9 398 (875 ) 522 Impairment of long-term investments 0 (1,025 ) (550 ) 0 Equity in net (loss) income of unconsolidated investments (223 ) 383 16,834 200 Loss from continuing operations before income taxes (74,750 ) (18,072 ) (19,570 ) (36,919 ) Income tax benefit (provision) 10,051 4,116 (2,009 ) 4,534 Loss from continuing operations, net of tax (64,699 ) (13,956 ) (21,579 ) (32,385 ) Income from discontinued operations 16,847 19,545 18,838 16,218 Gain on sale of discontinued operations 1,156,504 0 0 0 Income tax effect on discontinued operations (380,828 ) (5,047 ) (4,864 ) (4,187 ) Income from discontinued operations, net of tax 792,523 14,498 13,974 12,031 Net income (loss) 727,824 542 (7,605 ) (20,354 ) Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 727,824 $ 542 $ (7,605 ) $ (20,354 ) Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: (3) Basic Continuing operations $ (0.43 ) $ (0.09 ) $ (0.13 ) $ (0.20 ) Discontinued operations $ 5.25 $ 0.09 $ 0.08 $ 0.07 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ 4.82 $ 0.00 $ (0.05 ) $ (0.13 ) Diluted Continuing operations $ (0.43 ) $ (0.09 ) $ (0.13 ) $ (0.20 ) Discontinued operations $ 5.25 $ 0.09 $ 0.08 $ 0.07 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ 4.82 $ 0.00 $ (0.05 ) $ (0.13 ) Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2019 2019 (2) 2019 (1) 2019 Revenue $ 414,330 $ 408,280 $ 410,883 $ 399,118 Cost of revenue 261,711 259,767 251,680 249,166 Gross profit 152,619 148,513 159,203 149,952 Selling, general and administrative expenses 108,275 96,080 100,462 95,991 Research and development 60,112 61,062 61,922 62,347 Asset impairment charges 6,800 248 3,691 98 Goodwill impairment charge 25,700 0 0 0 Amortization of intangible and acquisition-related assets 6,834 6,840 6,724 6,790 Loss from operations (55,102 ) (15,717 ) (13,596 ) (15,274 ) Interest expense (11,725 ) (10,839 ) (10,424 ) (10,184 ) Other income (loss), net 4,796 781 (144,994 ) 513 (Impairment) recovery of long-term investments (1,696 ) 0 0 1,045 Equity in net income (loss) of unconsolidated investments 125 386 218 (64 ) Loss from continuing operations before income taxes (63,602 ) (25,389 ) (168,796 ) (23,964 ) Income tax benefit 29,738 5,645 5,262 2,695 Loss from continuing operations, net of tax (33,864 ) (19,744 ) (163,534 ) (21,269 ) Income from discontinued operations 20,078 18,899 18,339 17,919 Income tax effect on discontinued operations (5,184 ) (4,880 ) (4,735 ) (4,627 ) Income from discontinued operations, net of tax 14,894 14,019 13,604 13,292 Net loss (18,970 ) (5,725 ) (149,930 ) (7,977 ) Net loss attributable to non-controlling interest 0 0 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (18,970 ) $ (5,725 ) $ (149,930 ) $ (7,553 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: (3) Basic Continuing operations $ (0.21 ) $ (0.11 ) $ (0.98 ) $ (0.12 ) Discontinued operations $ 0.09 $ 0.08 $ 0.08 $ 0.08 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ (0.12 ) $ (0.03 ) $ (0.90 ) $ (0.04 ) Diluted Continuing operations $ (0.21 ) $ (0.11 ) $ (0.98 ) $ (0.12 ) Discontinued operations $ 0.09 $ 0.08 $ 0.08 $ 0.08 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ (0.12 ) $ (0.03 ) $ (0.90 ) $ (0.04 ) (1) Results of operations for the quarter include the results of operations of a third party engaged in a specialty prescription drug platform since June 10, 2019. (2) Results of operations for the quarter include the results of operations of Pinnacle and Diabetes and Collaborative Registries since July 2, 2019. ( 3 ) The sum of the quarterly per share amounts may not equal per share amounts reported for year to date periods. This is due to changes in the number of weighted-average shares outstanding and the effects of rounding for each period.

Schedule II-Valuation and Quali

Schedule II-Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2020
Valuation And Qualifying Accounts [Abstract]
Schedule II-Valuation and Qualifying Accounts	Schedule II—Valuation and Qualifying Accounts Charged to Balance at Expenses/ Write-Offs, Balance at Beginning of Against Net of End of (In thousands) Year Revenue Recoveries Year Allowance for doubtful accounts and sales credits Year ended December 31, 2019 $ 25,826 3,467 (7,288 ) $ 22,005 Year ended December 31, 2018 $ 12,317 21,081 (7,572 ) $ 25,826 All other schedules are omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the economic implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2020, we changed our reportable segments from Provider, Veradigm and Unallocated to Core Clinical and Financial Solutions, Data, Analytics and Care Coordination, and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 19 “Business Segments” for further discussion on the impact of the change. Certain reclassifications were made to prior period amounts in order to conform to the current period presentation. These reclassifications had no impact on the reported consolidated prior period financial results.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values.
Other Financial Assets and Liabilities	Other Financial Assets and Liabilities We have investments in equity instruments for which it is not practicable to estimate fair value primarily because of their illiquidity and restricted marketability. Such investments are recorded initially at cost, less impairment and changes resulting from observable price changes and equity methods of accounting. Refer to Note 6, “Fair Value Measurements and Other Investments” for additional information about these investments. Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. As of December 31, 2019, the carrying amount of the 1.25% Notes (as defined in Note 10, “Debt”) approximated fair value since the effective interest rate on the 1.25% Notes approximated current market rates. On July 1, 2020, the 1.25% Notes matured and were paid in full. See Note 10, “Debt” for further information regarding our long-term financial liabilities.
Derivative Financial Instruments	Derivative Financial Instruments Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation. See Note 16, “Derivative Financial Instruments” for information regarding gains and losses from derivative instruments during the years ended December 31, 2020, 2019 and 2018.
Trade Accounts Receivable	Trade Accounts Receivable Accounts receivable are recorded at the invoiced amounts and do not bear interest.
Contingent Liabilities	Contingent Liabilities A liability is contingent if the amount is not presently known but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments.
Fixed Assets	Fixed Assets Fixed assets are stated at cost. Depreciation and amortization are computed under the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred.
Business Combinations	Business Combinations Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated statements of operations.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than the carrying value, an impairment loss equal to the excess will be recorded not to exceed the carrying amount of goodwill assigned to the reporting unit. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of an asset to its estimated fair value. If we determine that the carrying value of an asset exceeds its estimated fair value, an impairment loss equal to the excess will be recorded. The determination of the fair value of our reporting units is based on a combination of a market approach, which considers benchmark company market multiples, and an income approach, which utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the combined fair values estimated for our reporting units. In accordance with GAAP, definite-lived intangible assets are required to be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize their value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time.
Long-Lived Assets and Long-Lived Assets to Be Disposed Of	Long-Lived Assets and Long-Lived Assets to Be Disposed Of We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Software Development Costs	Software Development Costs We capitalize purchased software upon acquisition if it is accounted for as internal-use software or if it meets the future alternative use criteria. For software to be sold, we capitalize incurred labor costs for software development from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal-use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is determined to be shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years. At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value is recorded as a charge to earnings. The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2020 2019 Software development costs $ 327,519 $ 393,728 Less: accumulated amortization (134,317 ) (171,036 ) Software development costs, net $ 193,202 $ 222,692 Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue are illustrated in the following table: Year Ended December 31, (In thousands) 2020 2019 2018 Capitalized software development costs $ 87,993 $ 103,317 $ 103,454 Write-offs and divestitures of capitalized software development costs $ 31,214 $ 0 $ 34,083 Amortization of capitalized software development costs $ 86,269 $ 72,840 $ 59,653
Income Taxes	Income Taxes We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors. In addition, we are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements. The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing authorities. To the extent we prevail in matters for which liabilities have been established or are required to pay amounts in excess of our liabilities, our effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution. We report interest and penalties related to uncertain income tax positions in the income tax (provision) benefit line of our consolidated statements of operations. We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United States.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation cost at the grant date based on the fair value of the award and recognize the expense over the requisite service period typically on a straight-line basis, net of estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We settle employee stock option exercises and stock awards with newly issued common shares. Refer to Note 12, “Stock Award Plan” for detailed discussion about our stock-based incentive plan.
Employee Benefit Plans	Employee Benefit Plans We provide employees with defined contribution savings plans. We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans: Year Ended December 31, (In thousands) 2020 2019 2018 Company contributions to employee benefit plans $ 21,143 $ 23,998 $ 28,803
Foreign Currency	Foreign Currency The determination of the functional currency of our foreign subsidiaries is made based on the appropriate economic and management indicators. Our foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our operating subsidiaries in India and Israel which use the United States dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into United States dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. We periodically enter into non-deliverable forward foreign currency exchange contracts in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. See Note 16, “Derivative Financial Instruments,” for information regarding these foreign currency exchange contracts.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally. We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In general, we do not require collateral from our clients, but we do enter into advance deposit agreements, if appropriate. The majority of our revenue is derived from clients located in the United States. The majority of long-lived assets are also located in the United States. For the year ended December 31, 2020, we had one client that accounted for 12% of our revenue. Other than this one client, no single client accounted for more than 10% of our revenue in the years ended December 31, 2020, 2019 and 2018. No client represented more than 10% of accounts receivable as of December 31, 2020 and 2019.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements We adopted Accounting Standards Update No. 2016-13, “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” In March 2020, the FASB issued Accounting Standards Update No. 2020-04, “Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. We adopted ASU 2020-04 on March 12, 2020, and the adoption had no impact on our consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued Accounting Standards Update No. 2019-12, “ Income Taxes (Topic 740) In August 2020, the FASB issued Accounting Standards Update No. 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment. The following table summarizes the pattern of revenue recognition for our most significant performance obligations: Performance Obligation Revenue Type Recurring or Non-recurring Nature Revenue Recognition Pattern Measure of progress Support and maintenance ("SMA") Software delivery, support and maintenance Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Software as a service ("SaaS") Software delivery, support and maintenance Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Private cloud hosting Client services Recurring Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Client/Education services Client services Non-recurring Over time Input method (cost to cost) – revenue is recognized proportionally over the service implementation based on hours Outsourcing services Client services Recurring Over time Input method (cost to cost) – revenue is recognized proportionally over the outsourcing period Payerpath (transaction volume) Software delivery, support and maintenance Recurring Over time Output method ("right-to-invoice" practical expedient) – value transferred to the customer is reflected on invoicing. Software licenses Software delivery, support and maintenance Non-recurring Point in time Upon electronic delivery Hardware Software delivery, support and maintenance Non-recurring Point in time Upon shipment Recurring software delivery, support and maintenance revenue consists of recurring subscription-based software sales, support and maintenance revenue, and recurring transaction-related revenue. Non-recurring software delivery, support and maintenance revenue consists of perpetual software licenses sales, resale of hardware and non-recurring transaction-related revenue. Recurring client services revenue consists of revenue from managed services solutions, such as outsourcing, private cloud hosting and revenue cycle management. Non-recurring client services revenue consists of project-based client services revenue. SMA, SaaS and private cloud hosting performance obligations are deemed to be performance obligations satisfied evenly over time as these are fulfilled as stand-ready obligations to perform. Client services, such as those relating to implementation, consulting, training or education, are generally not fulfilled evenly over the contract period, but rather over a shorter timeline where work effort can increase, or decline based upon stages of the project work effort. These client services are typically quoted to a customer as a fixed fee amount that covers the implementation effort. Delivery progress for these services is measured by establishing an approved cost budget with labor hour inputs utilized to gauge percentage of completion of the work effort. Therefore, revenue for our client, education and outsourcing services is recognized proportionally with the progress of the implementation work effort. Payerpath transaction volume and other transaction-based service obligations, such as revenue cycle management services, are fulfilled over time but are not provided evenly over the contract period and reliable inputs are not available to track progress of completion. We determined that value is provided to the customer throughout the contract period and the pricing charged to the customer varies on a monthly basis, based upon the volume of the customer’s transactions processed in that respective period. The invoiced amount to the customer represents this value and, accordingly, the practical expedient to recognize revenue based upon invoicing is most appropriate. We considered the specific implementation guidance for accounting for licenses of intellectual property (“IP”) to determine if point in time or over time recognition was more appropriate. The first step in the licensing framework is to determine whether the license is distinct or combined with other goods and services. For most of our software licensing products, the licenses are distinct, with the exception of one of our product offerings under our CareInMotion TM

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Unamortized Balances of Capitalized Software	The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2020 2019 Software development costs $ 327,519 $ 393,728 Less: accumulated amortization (134,317 ) (171,036 ) Software development costs, net $ 193,202 $ 222,692
Capitalized Software Development Costs, Write Offs and Amortization of Capitalized Software Development Costs	Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue are illustrated in the following table: Year Ended December 31, (In thousands) 2020 2019 2018 Capitalized software development costs $ 87,993 $ 103,317 $ 103,454 Write-offs and divestitures of capitalized software development costs $ 31,214 $ 0 $ 34,083 Amortization of capitalized software development costs $ 86,269 $ 72,840 $ 59,653
Company Contributions to Employee Benefit Plan	We provide employees with defined contribution savings plans. We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans: Year Ended December 31, (In thousands) 2020 2019 2018 Company contributions to employee benefit plans $ 21,143 $ 23,998 $ 28,803

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients	The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2020 Three Months Ended June 30, 2020 Three Months Ended September 30, 2020 Three Months Ended December 31, 2020 Revenue related to deferred revenue balance at beginning of period $ 105,366 $ 119,545 $ 118,300 $ 138,279 Revenue related to new performance obligations satisfied during the period 216,580 195,308 192,658 182,690 Revenue recognized under "right-to-invoice" expedient 58,059 54,082 54,313 65,108 Reimbursed travel expenses, shipping and other revenue 1,359 369 347 337 Total revenue $ 381,364 $ 369,304 $ 365,618 $ 386,414 (In thousands) Three Months Ended March 31, 2019 Three Months Ended June 30, 2019 Three Months Ended September 30, 2019 Three Months Ended December 31, 2019 Revenue related to deferred revenue balance at beginning of period $ 93,602 $ 113,288 $ 116,812 $ 136,460 Revenue related to new performance obligations satisfied during the period 248,126 233,293 227,954 214,952 Revenue recognized under "right-to-invoice" expedient 55,923 62,245 61,814 60,826 Reimbursed travel expenses, shipping and other revenue 1,467 2,057 1,700 2,092 Total revenue $ 399,118 $ 410,883 $ 408,280 $ 414,330
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Year Ended December 31, (In thousands) 2020 2019 2018 Revenue: Recurring revenue $ 1,222,731 $ 1,278,456 $ 1,313,281 Non-recurring revenue 279,969 354,155 304,560 Total revenue $ 1,502,700 $ 1,632,611 $ 1,617,841
Summary of Changes in Estimate of Credit Losses for Contract Assets	Changes in the estimate of credit losses for contract assets are presented in the table below. (In thousands) Total Balance at January 1, 2020 $ 5,341 Current period provision 0 Balance at December 31, 2020 $ 5,341 Less: Contract assets, short-term 1,068 Total contract assets, long-term $ 4,273
Revenue by Segment [Member]
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	Year Ended December 31, 2020 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 676,655 $ 250,877 $ (12,870 ) $ 914,662 Client services 577,594 10,444 0 588,038 Total revenue $ 1,254,249 $ 261,321 $ (12,870 ) $ 1,502,700 Year Ended December 31, 2019 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 761,836 $ 249,561 $ (7,202 ) $ 1,004,195 Client services 615,311 13,103 2 628,416 Total revenue $ 1,377,147 $ 262,664 $ (7,200 ) $ 1,632,611 Year Ended December 31, 2018 (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Unallocated Amounts Total Software delivery, support and maintenance $ 791,417 $ 237,320 $ (17,113 ) $ 1,011,624 Client services 588,082 9,398 8,737 606,217 Total revenue $ 1,379,499 $ 246,718 $ (8,376 ) $ 1,617,841

Accounts Receivables (Tables)

Accounts Receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Trade Accounts Receivable [Member]
Accounts Notes And Loans Receivable [Line Items]
Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable	Changes in the estimate of credit losses for trade accounts receivable are presented in the tables below. (In thousands) Total Balance at January 1, 2020 $ 33,256 Current period provision 8,726 Write-offs (10,484 ) Recoveries 98 Balance at December 31, 2020 $ 31,596

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Lessee Disclosure [Abstract]
Summary of Operating Costs Associated with Leased Assets	Operating costs associated with leased assets are as follows: (In thousands) Year Ended December 31, 2020 2019 Operating lease cost (1) $ 25,394 $ 27,235 Less: Sublease income (1,121 ) (3,265 ) Total operating lease costs $ 24,273 $ 23,970 (1)
Supplemental Information for Operating Leases	Supplemental information for operating leases is as follows: (In thousands) Year Ended December 31, 2020 2019 Operating cash flows from operating leases $ 26,638 $ 29,348 Right-of-use assets obtained in exchange for operating lease obligations $ 21,770 $ 141,787
Summary of Balance Sheet Location and Balances for Operating Leases	The balance sheet location and balances for operating leases are as follows: (In thousands, except lease term and discount rate) December 31, 2020 December 31, 2019 Right-of-use assets - operating leases $ 96,601 $ 95,757 Current operating lease liabilities $ 22,264 $ 22,328 Long-term operating lease liabilities $ 93,463 $ 93,588 Weighted average remaining lease term (in years) 6 6 Weighted average discount rate 3.6 % 4.4 %
Summary of Future Maturities of Lease and Non-Lease Components	The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of December 31, 2020. December 31, 2020 (In thousands) Operating Leases 2021 $ 26,090 2022 24,501 2023 22,752 2024 17,388 2025 14,927 Thereafter 22,069 Total lease liabilities 127,727 Less: Amount representing interest (12,000 ) Less: Short-term lease liabilities (22,264 ) Total long-term lease liabilities $ 93,463

Business Combinations and Div_2

Business Combinations and Divestitures (Tables)	12 Months Ended
	Dec. 31, 2020
Health Grid [Member]
Schedule of Consideration Funded by Sources of Funds	The consideration paid for Health Grid is shown below: (In thousands) Aggregate purchase price $ 60,000 First earnout payment paid by Allscripts 10,000 Fair value of contingent consideration payment 23,915 Closing purchase price adjustments 2,009 Total consideration paid for Health Grid $ 95,924
Assets Acquired and Liabilities Assumed	The allocation of the fair value of the consideration transferred as of the acquisition date of May 18, 2018 is shown in the table below. The allocation of purchase price was finalized in the fourth quarter of 2018. The goodwill is not deductible for tax purposes. (In thousands) Cash and cash equivalents $ 1,783 Accounts receivable, net 3,968 Prepaid expenses and other assets 185 Fixed assets 200 Intangible assets 41,000 Goodwill 53,953 Accounts payable and accrued expenses (478 ) Deferred revenue (700 ) Long-term deferred tax liability (3,987 ) Net assets acquired $ 95,924
Acquired Intangible Assets Amortization	The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships 15 $ 28,000 Technology 8 13,000 $ 41,000
Practice Fusion, Inc. [Member]
Schedule of Consideration Funded by Sources of Funds	The consideration paid for Practice Fusion is shown below: (In thousands) Aggregate purchase price $ 100,000 Add: Net working capital surplus 373 Add: Closing cash 14,951 Less: Adjustment to assumed indebtedness (1,684 ) Total consideration paid for Practice Fusion $ 113,640
Assets Acquired and Liabilities Assumed	The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. (In thousands) Cash and cash equivalents $ 14,951 Accounts receivable, net 13,328 Prepaid expenses and other current assets 809 Fixed assets 1,764 Intangible assets 67,100 Goodwill 35,092 Other assets 42 Accounts payable and accrued expenses (7,378 ) Deferred revenue (2,400 ) Long-term deferred tax liability (8,853 ) Other liabilities (815 ) Net assets acquired $ 113,640
Acquired Intangible Assets Amortization	The following table summarizes the fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships - Physician Practices 15 $ 29,000 Customer Relationships - Pharmaceutical Partners 20 19,400 Technology 8 14,800 Tradenames 10 3,900 $ 67,100

Fair Value Measurements and O_2

Fair Value Measurements and Other Investments (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet December 31, 2020 December 31, 2019 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Foreign exchange derivative assets Prepaid expenses and other current assets $ 0 $ 1,509 $ 0 $ 1,509 $ 0 $ 0 $ 0 $ 0 1.25% Call Option Other assets 0 0 0 0 0 0 84 84 Total assets $ 0 $ 1,509 $ 0 $ 1,509 $ 0 $ 0 $ 84 $ 84 Contingent consideration - current Accrued expenses $ 0 $ 0 $ 1,011 $ 1,011 $ 0 $ 0 $ 17,100 $ 17,100 Contingent consideration - long-term Other liabilities 0 0 0 0 0 0 2,415 2,415 1.25% Embedded cash conversion option Other liabilities 0 0 0 0 0 0 185 185 Total liabilities $ 0 $ 0 $ 1,011 $ 1,011 $ 0 $ 0 $ 19,700 $ 19,700
Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized as follows: (In thousands) Contingent Consideration 1.25% Notes Call Spread Overlay Balance at December 31, 2018 $ 25,624 $ (870 ) Additions 12,073 0 Payments/write-downs (1) (18,624 ) 0 Fair value adjustments 442 769 Balance at December 31, 2019 $ 19,515 $ (101 ) Additions 770 0 Payments/write-downs (2) (19,274 ) 0 Fair value adjustments 0 101 Balance at December 31, 2020 $ 1,011 $ 0 (1) Payments and write-downs for the year ended December 31, 2019 primarily consisted of $10.0 million in payments for the Health Grid earnout and a $5.0 million write-down related to the Pulse8 earnout. (2)
Summary of Quantitative Information About Fair Value Measurements	The following table summarizes the quantitative information about our Level 3 fair value measurements at December 31, 2020: December 31, 2020 (In thousands, except the discount rate) Fair Value Valuation Technique Significant Unobservable Inputs Ranges of Inputs Weighted Average (1) Financial instruments: Contingent consideration $ 1,011 Probability Weighted Discounted cash flow Discount rate 5.3% to 5.5% 5.4 % Registry members 0 to 1,551 776 Patient data volume 0 to 52,845 26,422 Projected year of payment 2020 to 2021 Total financial instruments $ 1,011 (1) The weighted average is calculated based upon the absolute fair value of the instruments.
Long-Term Equity and Cost Method Investments [Member]
Summary of Other Equity Investments Included in Other Assets	The following table summarizes our other equity investments which are included in Other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except for number of investees) at December 31, 2020 Cost December 31, 2020 December 31, 2019 Equity method investments (1) 3 $ 7,099 $ 10,744 $ 11,332 Cost less impairment 8 37,568 25,059 32,462 Total long-term equity investments 11 $ 44,667 $ 35,803 $ 43,794 (1)

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Fixed Assets	Fixed assets consist of the following: Estimated December 31, December 31, (Dollar amounts in thousands) Useful Life 2020 2019 Computer equipment and software 3 to 10 years $ 329,564 $ 343,756 Facility furniture, fixtures and equipment 5 to 7 years 25,932 24,282 Leasehold improvements Shorter of 7 years or life of lease 40,115 38,948 Assets under finance leases 1 to 3 years 524 524 Fixed assets, gross 396,135 407,510 Less: Accumulated depreciation and amortization (323,973 ) (319,557 ) Fixed assets, net $ 72,162 $ 87,953
Depreciation and Amortization Expense	Year Ended December 31, (In thousands) 2020 2019 2018 Fixed assets depreciation and amortization expense, including finance leases $ 32,324 $ 46,705 $ 46,951

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: December 31, 2020 December 31, 2019 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 535,092 $ (465,292 ) $ 69,800 $ 534,873 $ (433,017 ) $ 101,856 Customer contracts and relationships 674,336 (509,534 ) 164,802 701,805 (488,533 ) 213,272 Total $ 1,209,428 $ (974,826 ) $ 234,602 $ 1,236,678 $ (921,550 ) $ 315,128 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 974,729 974,110 Total $ 1,026,729 $ 1,026,110
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2020 and 2019 were as follows: (In thousands) Core Clinical and Financial Solutions Data, Analytics and Care Coordination Total Balance as of December 31, 2018 $ 760,294 $ 225,543 $ 985,837 Additions 0 13,684 13,684 Goodwill impairment charge (25,700 ) 0 (25,700 ) Foreign exchange translation 289 0 289 Balance as of December 31, 2019 734,883 239,227 974,110 Goodwill impairment charge 0 0 0 Foreign exchange translation 619 0 619 Balance as of December 31, 2020 $ 735,502 $ 239,227 $ 974,729
Amortization Expense Related to Intangible Assets	Intangible assets are being amortized over their estimated useful lives, and amortization expense related to intangible assets was as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Proprietary technology amortization included in cost of revenue $ 32,130 $ 35,034 $ 37,029 Intangible amortization included in operating expenses 25,604 27,188 26,558 Total intangible amortization expense $ 57,734 $ 62,222 $ 63,587
Future Amortization Expense for Intangible Assets	Future amortization expense for the intangible assets as of December 31, 2020, based on foreign currency exchange rates in effect as of such date, is as follows: Year Ended December 31, (In thousands) 2021 $ 50,556 2022 44,155 2023 27,943 2024 23,799 2025 20,180 Thereafter 67,969 Total $ 234,602

Asset Impairment Charges (Table

Asset Impairment Charges (Tables)	12 Months Ended
	Dec. 31, 2020
Asset Impairment Charges [Abstract]
Summary of Non-Cash Asset Impairment Charges	The following table summarizes the non-cash asset impairment charges recorded during the periods indicated and where they appear in the corresponding consolidated statements of operations: Year Ended December 31, (In thousands) 2020 2019 2018 Asset impairment charges $ 74,969 $ 10,837 $ 58,166 Goodwill impairment charge $ 0 $ 25,700 $ 13,466 Impairment of long-term investments $ 1,575 $ 651 $ 15,487

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Instrument [Line Items]
Debt Outstanding Excluding Lease Obligations	Debt outstanding, excluding lease obligations, consisted of the following: December 31, 2020 December 31, 2019 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 0.875% Convertible Senior Notes (1) $ 167,853 $ (3,166 ) $ 171,019 $ 177,942 $ 4,697 $ 173,245 1.25% Cash Convertible Senior Notes 0 0 0 345,000 7,552 337,448 Senior Secured Credit Facility 0 3,432 (3,432 ) 410,000 5,224 404,776 Total debt $ 167,853 $ 266 $ 167,587 $ 932,942 $ 17,473 $ 915,469 Less: Debt payable within one year 0 0 0 364,653 188 364,465 Total long-term debt, less current maturities $ 167,853 $ 266 $ 167,587 $ 568,289 $ 17,285 $ 551,004 (1) Principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital.
Interest Expense	Interest expense consisted of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Interest expense $ 18,113 $ 26,648 $ 35,366 Amortization of discounts and debt issuance costs 15,991 16,524 15,548 Total interest expense $ 34,104 $ 43,172 $ 50,914
Summary of Future Debt Payments	The following table summarizes future debt payments as of December 31, 2020: (In thousands) Total 2021 2022 2023 2024 2025 Thereafter 0.875% Convertible Senior Notes (1) $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 Total debt $ 207,911 $ 0 $ 0 $ 0 $ 0 $ 0 $ 207,911 (1) Amount represents the face value of the 0.875% Convertible Senior Notes, which includes both the liability and equity portions.
0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes	Interest expense related to the 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes, which is included in total interest expense above, consisted of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Coupon interest $ 4,016 $ 4,429 $ 4,312 Amortization of discounts and debt issuance costs 13,484 14,926 13,867 Total interest expense related to the convertible notes $ 17,500 $ 19,355 $ 18,179

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Geographic Breakdown of Loss From Continuing Operations Before Income Tax Benefits	The following is a geographic breakdown of loss from continuing operations before income tax benefits: Year Ended December 31, (In thousands) 2020 2019 2018 United States $ (148,174 ) $ (287,088 ) $ (61,292 ) Foreign (1,137 ) 5,337 (907 ) Loss from continuing operations before income taxes $ (149,311 ) $ (281,751 ) $ (62,199 )
Components of Benefit for Income Taxes	The following is a summary of the components of the benefit for income taxes: Year Ended December 31, (In thousands) 2020 2019 2018 Current tax provision Federal $ (19,346 ) $ (8,232 ) $ (14,018 ) State (219 ) (1,809 ) (3,859 ) Foreign 3,803 5,054 5,015 (15,762 ) (4,987 ) (12,862 ) Deferred tax provision Federal 2,931 (28,732 ) (5,781 ) State (2,981 ) (8,763 ) 236 Foreign (880 ) (858 ) (576 ) (930 ) (38,353 ) (6,121 ) Income tax benefit $ (16,692 ) $ (43,340 ) $ (18,983 )
Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes	Taxes computed at the statutory federal income tax rate of 21% for the years ended December 31, 2020, 2019 and 2018 are reconciled to the provision for income taxes as follows: Year Ended December 31, (In thousands) 2020 2019 2018 United States federal tax at statutory rate $ (31,355 ) $ (59,170 ) $ (13,062 ) Items affecting federal income tax rate Non-deductible acquisition and reorganization expenses 0 31 291 Non-deductible portion of Department of Justice Settlement 0 18,546 0 Research credits (6,500 ) (6,126 ) (6,185 ) Change in unrecognized tax benefits 3,204 1,046 3 State income taxes, net of federal benefit (2,940 ) (7,411 ) (2,916 ) Compensation 5,314 4,664 3,213 Meals and entertainment 118 549 616 Impact of foreign operations 1,443 3,079 3,627 Provision-to-Return adjustments (2,362 ) (383 ) (2,140 ) Deemed Dividends 352 473 373 Federal, state and local rate changes 0 (630 ) 0 US Tax reform impact 0 (2,972 ) 0 Goodwill impairment 0 5,397 0 Non-deductible items 28 43 34 Noncontrolling interest 0 0 951 True-up of prior year income of Consolidated Investment 0 0 913 Valuation allowance 16,949 922 (5,208 ) Other (943 ) (1,398 ) 507 Income tax benefit $ (16,692 ) $ (43,340 ) $ (18,983 )
Components of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets and liabilities consist of the following: December 31, (In thousands) 2020 2019 Deferred tax assets Accruals and reserves, net $ 18,260 $ 29,627 Allowance for doubtful accounts 9,571 11,507 Stock-based compensation, net 8,428 10,382 Deferred revenue 35,016 21,786 Operating and finance lease liabilities 22,902 22,085 Net operating loss carryforwards 35,695 37,717 Research and development tax credit 251 899 Other 4,519 7,488 Less: Valuation Allowance (35,491 ) (19,219 ) Total deferred tax assets 99,151 122,272 Deferred tax liabilities Prepaid expense (4,329 ) (5,372 ) Property and equipment, net (2,062 ) (3,695 ) Acquired intangibles, net (86,841 ) (111,284 ) Operating and finance right-of-use assets (18,315 ) (17,255 ) Total deferred tax liabilities (111,547 ) (137,606 ) Net deferred tax liabilities $ (12,396 ) $ (15,334 )
Schedule Of Deferred Tax Assets And Liabilities Classified In Consolidated Balance Sheets	The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows: December 31, (In thousands) 2020 2019 Non-current deferred tax assets, net $ 5,790 $ 5,704 Non-current deferred tax liabilities, net (18,186 ) (21,038 ) Non-current deferred tax liabilities, net $ (12,396 ) $ (15,334 )
Change in the Amount of Unrecognized Tax Benefits	Changes in the amounts of unrecognized tax benefits were as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Beginning balance as of January 1 $ 20,604 $ 19,821 $ 10,939 Increases for tax positions related to the current year 8,053 1,240 8,977 Increases for tax positions related to prior years 427 95 367 Increases acquired in business acquisitions 0 0 540 Foreign currency translation 2 3 (5 ) Reductions due to lapsed statute of limitations (201 ) (555 ) (997 ) Ending balance as of December 31 $ 28,885 $ 20,604 $ 19,821
Recognized Interest and Penalties Related to Uncertain Tax Positions	We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Interest and penalties included in the provision for income taxes $ 1,620 $ 229 $ 543
Amount of Interest and Penalties Included in Consolidated Balance Sheets	The amount of interest and penalties included in our consolidated balance sheets is as follows: December 31, (In thousands) 2020 2019 Interest and penalties included in the liability for uncertain tax positions $ 2,048 $ 427

Stock Award Plan (Tables)

Stock Award Plan (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation Expense	Total recognized stock-based compensation expense is included in our consolidated statements of operations as shown in the table below. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. Year Ended December 31, (In thousands) 2020 2019 2018 Cost of revenue: Software delivery, support and maintenance $ 1,640 $ 2,075 $ 2,184 Client services 4,421 4,067 3,997 Total cost of revenue 6,061 6,142 6,181 Selling, general and administrative expenses 25,002 27,348 24,213 Research and development 7,827 9,200 8,937 Total stock-based compensation expense $ 38,890 $ 42,690 $ 39,331
Activity for Restricted Stock Awards	The following table summarizes the activity for restricted stock units during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock units as of December 31, 2017 7,259 $ 12.57 Awarded 4,024 13.25 Vested (2,222 ) 13.03 Forfeited (1,111 ) 12.43 Unvested restricted stock units as of December 31, 2018 7,950 12.81 Awarded 4,777 10.15 Vested (2,360 ) 12.62 Forfeited (1,453 ) 12.20 Unvested restricted stock units as of December 31, 2019 8,914 11.53 Awarded 5,607 6.88 Vested (2,756 ) 11.69 Forfeited (2,097 ) 10.79 Unvested restricted stock units as of December 31, 2020 9,668 $ 8.95
Stock Options Outstanding	The following table summarizes the status of stock options outstanding and the changes during the periods presented: Options Weighted-Average Options Weighted-Average (In thousands, except per share amounts) Outstanding Exercise Price Exercisable Exercise Price Balance as of December 31, 2017 1,635 $ 13.85 1,635 $ 13.85 Options granted 0 0.00 Options exercised (92 ) 14.01 Options forfeited (211 ) 14.74 Balance as of December 31, 2018 1,332 13.69 1,332 13.69 Options granted 0 0 Options exercised 0 0 Options forfeited (98 ) 14.01 Balance as of December 31, 2019 1,234 13.67 1,234 13.67 Options granted 0 0 Options exercised 0 0 Options forfeited (1,234 ) 13.67 Balance as of December 31, 2020 0 $ 0.00 0 $ 0.00
Stock Option Activity	The following activity occurred under the Plan: Year Ended December 31, (In thousands) 2020 2019 2018 Total intrinsic value of stock options exercised $ 0 $ 0 $ 69 Total fair value of share awards vested $ 32,218 $ 29,793 $ 28,954

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Year Ended December 31, (In thousands, except per share amounts) 2020 2019 2018 Basic income (loss) per Common Share: Loss from continuing operations, net of tax $ (132,619 ) $ (238,411 ) $ (43,216 ) Net loss attributable to non-controlling interests 0 424 4,527 Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (132,619 ) $ (237,987 ) $ (38,689 ) Income from discontinued operations, net of tax 833,026 55,809 451,023 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations 0 0 (48,594 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 833,026 55,809 402,429 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 700,407 $ (182,178 ) $ 363,740 Weighted-average common shares outstanding 159,281 166,306 176,038 Basic loss from continuing operations per Common Share $ (0.83 ) $ (1.43 ) $ (0.22 ) Basic income from discontinued operations per Common Share $ 5.23 $ 0.33 $ 2.29 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 4.40 $ (1.10 ) $ 2.07 Diluted income (loss) per Common Share: Loss from continuing operations, net of tax $ (132,619 ) $ (238,411 ) $ (43,216 ) Net loss attributable to non-controlling interests 0 424 4,527 Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (132,619 ) $ (237,987 ) $ (38,689 ) Income from discontinued operations, net of tax $ 833,026 $ 55,809 $ 451,023 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations 0 0 (48,594 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 833,026 55,809 402,429 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 700,407 $ (182,178 ) $ 363,740 Weighted-average common shares outstanding 159,281 166,306 176,038 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 Weighted-average common shares outstanding assuming dilution 159,281 166,306 176,038 Diluted (loss) income from continuing operations per Common Share $ (0.83 ) $ (1.43 ) $ (0.22 ) Diluted income from discontinued operations per Common Share $ 5.23 $ 0.33 $ 2.29 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ 4.40 $ (1.10 ) $ 2.07
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Year Ended December 31, (In thousands) 2020 2019 2018 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 42,845 27,945 26,175

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in accumulated other comprehensive loss (“AOCI”) are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2017 (1) (2,676 ) 691 (1,985 ) Other comprehensive (loss) income before reclassifications (2,908 ) (264 ) (3,172 ) Net (gains) losses reclassified from accumulated other comprehensive loss 0 (232 ) (232 ) Net other comprehensive (loss) income (2,908 ) (496 ) (3,404 ) Balance as of December 31, 2018 (2) (5,584 ) 195 (5,389 ) Other comprehensive income (loss) before reclassifications 1,192 61 1,253 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (256 ) (256 ) Net other comprehensive income (loss) 1,192 (195 ) 997 Balance as of December 31, 2019 (2) (4,392 ) 0 (4,392 ) Other comprehensive income (loss) before reclassifications 1,435 1,587 3,022 Net (gains) losses reclassified from accumulated other comprehensive loss 0 (468 ) (468 ) Net other comprehensive income (loss) 1,435 1,119 2,554 Balance as of December 31, 2020 (3) $ (2,957 ) $ 1,119 $ (1,838 ) (1) (2) Tax effects for the years ended December 31, 2019 and 2018 include $149 (3) Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.
Income Tax Effects Related to Components of Other Comprehensive Loss	The following tables reflect the tax effects allocated to each component of other comprehensive loss (“OCI”) Year Ended December 31, 2020 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,435 $ 0 $ 1,435 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 2,139 (552 ) 1,587 Net (gains) losses reclassified into income (630 ) 162 (468 ) Net change in unrealized gains (losses) on foreign exchange contracts 1,509 (390 ) 1,119 Other comprehensive income (loss) $ 2,944 $ (390 ) $ 2,554 Year Ended December 31, 2019 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,192 $ 0 $ 1,192 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 82 (21 ) 61 Net (gains) losses reclassified into income (344 ) 88 (256 ) Net change in unrealized (losses) gains on foreign exchange contracts (262 ) 67 (195 ) Other comprehensive income $ 930 $ 67 $ 997 Year Ended December 31, 2018 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,908 ) $ 0 $ (2,908 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period (357 ) 93 (264 ) Net (gains) losses reclassified into income (1) (516 ) 284 (232 ) Net change in unrealized (losses) gains on foreign exchange contracts (873 ) 377 (496 ) Other comprehensive (loss) income $ (3,781 ) $ 377 $ (3,404 ) (1) Net of taxes of $68 thousand for unrealized net gains on foreign exchange contract derivatives

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: December 31, 2020 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,509 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 0 N/A 1.25% Embedded cash conversion option N/A Other liabilities 0 Total derivatives $ 1,509 $ 0 December 31, 2019 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 0 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 84 N/A 1.25% Embedded cash conversion option N/A Other liabilities 185 Total derivatives $ 84 $ 185 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss): Amount of Gain (Loss) Recognized in OCI Location of Gain (Loss) Reclassified from AOCI into Income Amount of Gain (Loss) Reclassified from AOCI into Income Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 2018 2020 2019 2018 Foreign exchange contracts $ 2,139 $ 82 $ (357 ) Cost of Revenue $ 249 $ 124 $ 165 Selling, general and administrative expenses 122 83 138 Research and development 259 137 214
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Year Ended December 31, (In thousands) 2020 2019 2018 1.25% Call Option $ (84 ) $ (9,020 ) $ (37,474 ) 1.25% Embedded cash conversion option 185 9,789 37,803 Net income included in Other income, net $ 101 $ 769 $ 329

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Expense Incurred under Atos Agreement	Year Ended December 31, (In thousands) 2020 2019 2018 Expenses incurred under Atos agreements $ 102,730 $ 100,089 $ 55,903

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2020
EPSi and CarePort [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major classes of assets and liabilities of EPSi and CarePort, as reported on the consolidated balance sheets as of December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Carrying amounts of major classes of assets associated with EPSi and CarePort included as part of discontinued operations: Accounts receivable, net of allowance of $1,874 as of December 31, 2019 $ 0 $ 35,336 Contract assets, net of allowance of $0 as of December 31, 2019 0 2,690 Prepaid expenses and other current assets 0 3,845 Total current assets attributable to discontinued operations 0 41,871 Fixed assets, net 0 386 Software development costs, net 0 21,237 Intangible assets, net 0 7,014 Goodwill 0 387,907 Contract assets - long-term, net of allowance of $0 as of December 31, 2019 0 4,034 Right-of-use assets - operating leases 0 2,263 Other assets 0 5,180 Total long-term assets attributable to discontinued operations $ 0 $ 428,021 Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations: Accounts payable $ 0 $ 1,190 Accrued expenses 6,669 381 Income tax payable 316,142 0 Accrued compensation and benefits 0 2,788 Deferred revenue 0 44,224 Current operating lease liabilities 0 809 Total current liabilities attributable to discontinued operations 322,811 49,392 Deferred revenue long-term 0 1,269 Long-term operating lease liabilities 0 1,574 Total long-term liabilities attributable to discontinued operations $ 0 $ 2,843 The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statement of operations for the years ended December 31, 2020, 2019 and 2018: Year ended December 31, (In thousands) 2020 2019 2018 Major income and expense line items related to EPSi and CarePort: Revenue: Software delivery, support and maintenance $ 122,791 $ 122,268 $ 116,639 Client services 14,030 16,763 15,482 Total revenue 136,821 139,031 132,121 Cost of revenue: Software delivery, support and maintenance 11,424 12,482 10,737 Client services 15,585 15,124 12,038 Amortization of software development and acquisition-related assets 9,053 8,166 6,194 Total cost of revenue 36,062 35,772 28,969 Gross profit 100,759 103,259 103,152 Selling, general and administrative expenses 15,539 18,964 18,118 Research and development 8,269 9,065 9,673 Amortization of intangible assets 29 29 29 Income from discontinued operations for EPSi and CarePort 76,922 75,201 75,332 Interest expense (5,241 ) 0 0 Other (expense) income, net (192 ) 2 5 Gain on sale of discontinued operations 1,156,504 0 0 Income from discontinued operations for EPSi and CarePort before income taxes 1,227,993 75,203 75,337 Income tax provision (1) (394,926 ) (19,417 ) (19,452 ) Income from discontinued operations, net of tax for EPSi and CarePort (2) $ 833,067 $ 55,786 $ 55,885 (1) (2)
Netsmart [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the year ended December 31, 2018: Year ended December 31, (In thousands) 2018 Major income and expense line items related to Netsmart: (1) Revenue: Software delivery, support and maintenance $ 214,065 Client services 131,166 Total revenue 345,231 Cost of revenue: Software delivery, support and maintenance 60,100 Client services 94,061 Amortization of software development and acquisition related assets 34,357 Total cost of revenue 188,518 Gross profit 156,713 Selling, general and administrative expenses 125,807 Research and development 25,315 Amortization of intangible and acquisition-related assets 24,029 Loss from discontinued operations of Netsmart (18,438 ) Interest expense (59,541 ) Other income 101 Gain on sale of discontinued operations 500,471 Income from discontinued operations of Netsmart before income taxes 422,593 Income tax provision (31,186 ) Income from discontinued operations, net of tax for Netsmart $ 391,407 (1) Activity includes both Netsmart and intercompany transactions that would not have been eliminated if Netsmart’s results were not consolidated.
Horizon Clinicals and Series2000 [Member]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major income and expense line items of these discontinued solutions, as reported in the consolidated statements of operations for the year ended December 31, 2018: Year ended December 31, (In thousands) 2018 Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle: Revenue: Software delivery, support and maintenance $ 9,441 Client services 404 Total revenue 9,845 Cost of revenue: Software delivery, support and maintenance 2,322 Client services 830 Total cost of revenue 3,152 Gross profit 6,693 Research and development 1,651 Income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes 5,042 Income tax provision (1,311 ) Income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle $ 3,731

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Year Ended December 31, (In thousands) 2020 2019 2018 Revenue: Core Clinical and Financial Solutions $ 1,254,249 $ 1,377,147 $ 1,379,499 Data, Analytics and Care Coordination 261,321 262,664 246,718 Unallocated Amounts (12,870 ) (7,200 ) (8,376 ) Total revenue $ 1,502,700 $ 1,632,611 $ 1,617,841 Gross profit: Core Clinical and Financial Solutions $ 434,288 $ 473,033 $ 491,421 Data, Analytics and Care Coordination 131,407 137,254 129,970 Unallocated Amounts 0 0 0 Total gross profit $ 565,695 $ 610,287 $ 621,391 Loss from operations: Core Clinical and Financial Solutions $ (116,139 ) $ (80,465 ) $ (158,440 ) Data, Analytics and Care Coordination (14,741 ) (19,224 ) (9,944 ) Unallocated Amounts 0 0 0 Total loss from operations $ (130,880 ) $ (99,689 ) $ (168,384 )

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of December 31, 2020 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016 to be used by Netsmart to facilitate the integration of our Homecare TM December 31 (In thousands) 2020 2019 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 531,104 $ 129,668 Restricted cash 6,361 7,871 Total cash, cash equivalents and restricted cash $ 537,465 $ 137,539 Year Ended December 31, (In thousands) 2020 2019 2018 Cash paid during the period for: Interest, including convertible senior notes $ 24,616 $ 23,917 $ 33,200 Income taxes paid, net of tax refunds $ 76,595 $ 42,972 $ 10,108 Non-cash transactions: Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations $ 0 $ 0 $ 48,594 Obligations incurred to purchase capitalized software or enter into finance leases $ 0 $ 0 $ 1,501 Contributions of assets in exchange for equity interest $ 0 $ 0 $ 4,000 Issuance of treasury stock to commercial partner $ 752 $ 701 $ 1,121
Accrued Expenses	Accrued expenses consist of the following: December 31, (In thousands) 2020 2019 Royalties, certain third-party product costs and licenses $ 37,841 $ 35,064 Practice Fusion settlement 0 145,000 Other 62,421 90,217 Total Accrued expenses $ 100,262 $ 270,281
Prepaid and other current assets	Prepaid and other current assets consists of the following: December 31, (In thousands) 2020 2019 Prepaid assets $ 132,944 $ 142,191 Other current assets 3,320 1,954 Total Prepaid and other current assets $ 136,264 $ 144,145
Other Assets	Other assets consist of the following: December 31, (In thousands) 2020 2019 Fair value of 1.25% Call Option $ 0 $ 84 Long-term deferred hosting fees 11,025 36,002 Long-term prepaid commissions 27,882 28,876 Investments in non-marketable securities 35,805 43,806 Long-term deposits and other assets 16,916 10,819 Total Other assets $ 91,628 $ 119,587

Geographic Information (Tables)

Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Revenues by Geographic Area	Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below: Year Ended December 31, (In thousands) 2020 2019 2018 United States $ 1,439,737 $ 1,562,107 $ 1,565,057 Canada 15,624 16,495 15,377 Other international 47,339 54,009 37,407 Total $ 1,502,700 $ 1,632,611 $ 1,617,841
Long-Lived Assets by Geographic Area	A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below: December 31, (In thousands) 2020 2019 United States $ 62,016 $ 77,736 India 5,876 5,321 Israel 2,611 3,240 Canada 187 51 Other international 1,472 1,605 Total $ 72,162 $ 87,953

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Information	The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters, which have been restated to illustrate CarePort and EPSi as discontinued operations. Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2020 2020 2020 2020 Revenue $ 386,414 $ 365,618 $ 369,304 $ 381,364 Cost of revenue 225,391 230,480 231,706 249,428 Gross profit 161,023 135,138 137,598 131,936 Selling, general and administrative expenses 93,777 93,442 109,897 92,825 Research and development 54,287 46,352 46,045 59,377 Asset impairment charges 74,759 210 0 0 Amortization of intangible and acquisition-related assets 6,278 6,295 6,321 6,710 Loss from operations (68,078 ) (11,161 ) (24,665 ) (26,976 ) Interest expense (6,458 ) (6,667 ) (10,314 ) (10,665 ) Other income (loss), net 9 398 (875 ) 522 Impairment of long-term investments 0 (1,025 ) (550 ) 0 Equity in net (loss) income of unconsolidated investments (223 ) 383 16,834 200 Loss from continuing operations before income taxes (74,750 ) (18,072 ) (19,570 ) (36,919 ) Income tax benefit (provision) 10,051 4,116 (2,009 ) 4,534 Loss from continuing operations, net of tax (64,699 ) (13,956 ) (21,579 ) (32,385 ) Income from discontinued operations 16,847 19,545 18,838 16,218 Gain on sale of discontinued operations 1,156,504 0 0 0 Income tax effect on discontinued operations (380,828 ) (5,047 ) (4,864 ) (4,187 ) Income from discontinued operations, net of tax 792,523 14,498 13,974 12,031 Net income (loss) 727,824 542 (7,605 ) (20,354 ) Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 727,824 $ 542 $ (7,605 ) $ (20,354 ) Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: (3) Basic Continuing operations $ (0.43 ) $ (0.09 ) $ (0.13 ) $ (0.20 ) Discontinued operations $ 5.25 $ 0.09 $ 0.08 $ 0.07 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ 4.82 $ 0.00 $ (0.05 ) $ (0.13 ) Diluted Continuing operations $ (0.43 ) $ (0.09 ) $ (0.13 ) $ (0.20 ) Discontinued operations $ 5.25 $ 0.09 $ 0.08 $ 0.07 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ 4.82 $ 0.00 $ (0.05 ) $ (0.13 ) Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2019 2019 (2) 2019 (1) 2019 Revenue $ 414,330 $ 408,280 $ 410,883 $ 399,118 Cost of revenue 261,711 259,767 251,680 249,166 Gross profit 152,619 148,513 159,203 149,952 Selling, general and administrative expenses 108,275 96,080 100,462 95,991 Research and development 60,112 61,062 61,922 62,347 Asset impairment charges 6,800 248 3,691 98 Goodwill impairment charge 25,700 0 0 0 Amortization of intangible and acquisition-related assets 6,834 6,840 6,724 6,790 Loss from operations (55,102 ) (15,717 ) (13,596 ) (15,274 ) Interest expense (11,725 ) (10,839 ) (10,424 ) (10,184 ) Other income (loss), net 4,796 781 (144,994 ) 513 (Impairment) recovery of long-term investments (1,696 ) 0 0 1,045 Equity in net income (loss) of unconsolidated investments 125 386 218 (64 ) Loss from continuing operations before income taxes (63,602 ) (25,389 ) (168,796 ) (23,964 ) Income tax benefit 29,738 5,645 5,262 2,695 Loss from continuing operations, net of tax (33,864 ) (19,744 ) (163,534 ) (21,269 ) Income from discontinued operations 20,078 18,899 18,339 17,919 Income tax effect on discontinued operations (5,184 ) (4,880 ) (4,735 ) (4,627 ) Income from discontinued operations, net of tax 14,894 14,019 13,604 13,292 Net loss (18,970 ) (5,725 ) (149,930 ) (7,977 ) Net loss attributable to non-controlling interest 0 0 0 424 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (18,970 ) $ (5,725 ) $ (149,930 ) $ (7,553 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: (3) Basic Continuing operations $ (0.21 ) $ (0.11 ) $ (0.98 ) $ (0.12 ) Discontinued operations $ 0.09 $ 0.08 $ 0.08 $ 0.08 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ (0.12 ) $ (0.03 ) $ (0.90 ) $ (0.04 ) Diluted Continuing operations $ (0.21 ) $ (0.11 ) $ (0.98 ) $ (0.12 ) Discontinued operations $ 0.09 $ 0.08 $ 0.08 $ 0.08 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share $ (0.12 ) $ (0.03 ) $ (0.90 ) $ (0.04 ) (1) Results of operations for the quarter include the results of operations of a third party engaged in a specialty prescription drug platform since June 10, 2019. (2) Results of operations for the quarter include the results of operations of Pinnacle and Diabetes and Collaborative Registries since July 2, 2019. ( 3 ) The sum of the quarterly per share amounts may not equal per share amounts reported for year to date periods. This is due to changes in the number of weighted-average shares outstanding and the effects of rounding for each period.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)	Jul. 01, 2020	Dec. 31, 2020	Dec. 31, 2019	Jun. 18, 2013
Basis Of Presentation And Significant Accounting Policies [Line Items]
Maturity date		Jul. 1, 2020
Percentage of revenues		For the year ended December 31, 2020, we had one client that accounted for 12% of our revenue. Other than this one client, no single client accounted for more than 10% of our revenue in the years ended December 31, 2020, 2019 and 2018.
Customer concentration		No client represented more than 10% of accounts receivable as of December 31, 2020 and 2019.
Accounting Standards Update 2016-13 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Jan. 1, 2020
Accounting Standards Update 2018-13 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Jan. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]		true
Accounting Standards Update 2020-04 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Mar. 12, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]		true
Minimum [Member] | Capitalized Software [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Capitalized software estimated economic life		3 years
Maximum [Member] | Capitalized Software [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Capitalized software estimated economic life		5 years
1.25% Cash Convertible Senior Notes [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Interest rate	1.25%	1.25%	1.25%	1.25%
Maturity date	Jul. 1, 2020	Jul. 1, 2020

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Unamortized Balances of Capitalized Software (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Software development costs	$ 327,519	$ 393,728
Less: accumulated amortization	(134,317)	(171,036)
Software development costs, net	$ 193,202	$ 222,692

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Capitalized Software Development Costs, Write Offs and Amortization of Capitalized Software Development Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Capitalized software development costs	$ 87,993	$ 103,317	$ 103,454
Write-offs and divestitures of capitalized software development costs	31,214	0	34,083
Amortization of capitalized software development costs	$ 86,269	$ 72,840	$ 59,653

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies - Company Contributions to Employee Benefit Plan (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Company contributions to employee benefit plans	$ 21,143	$ 23,998	$ 28,803

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)Revenue_Stream	Dec. 31, 2019USD ($)	Jan. 01, 2020USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams | Revenue_Stream	2
Total backlog	$ 4,100,000
Total backlog, percentage, year one	35.00%
Total backlog, percentage after year one	65.00%
Cumulative impact on retained earnings (accumulated deficit)	$ 1,666,243	$ 1,285,188		$ 1,580,427	$ 1,160,072
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	23,600	30,500
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	16,800	18,400
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 27,900	$ 28,900
ASC 606 [Member] | Minimum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	2 years
ASC 606 [Member] | Maximum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	6 years
Accounting Standards Update 2016-13 [Member] | Cumulative Effect Period Of Adoption Adjustment [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative impact on retained earnings (accumulated deficit)			$ (5,300)

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 138,279	$ 118,300	$ 119,545	$ 105,366	$ 136,460	$ 116,812	$ 113,288	$ 93,602
Revenue related to new performance obligations satisfied during the period	182,690	192,658	195,308	216,580	214,952	227,954	233,293	248,126
Revenue recognized under "right-to-invoice" expedient	65,108	54,313	54,082	58,059	60,826	61,814	62,245	55,923
Reimbursed travel expenses, shipping and other revenue	337	347	369	1,359	2,092	1,700	2,057	1,467
Total revenue	$ 386,414	$ 365,618	$ 369,304	$ 381,364	$ 414,330	$ 408,280	$ 410,883	$ 399,118	$ 1,502,700	$ 1,632,611	$ 1,617,841

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Recurring revenue									$ 1,222,731	$ 1,278,456	$ 1,313,281
Non-recurring revenue									279,969	354,155	304,560
Total revenue	$ 386,414	$ 365,618	$ 369,304	$ 381,364	$ 414,330	$ 408,280	$ 410,883	$ 399,118	1,502,700	1,632,611	1,617,841
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									(12,870)	(7,200)	(8,376)
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									1,254,249	1,377,147	1,379,499
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									261,321	262,664	246,718
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									914,662	1,004,195	1,011,624
Software delivery, Support and Maintenance [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									(12,870)	(7,202)	(17,113)
Software delivery, Support and Maintenance [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									676,655	761,836	791,417
Software delivery, Support and Maintenance [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									250,877	249,561	237,320
Client services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									588,038	628,416	606,217
Client services [Member] | Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									0	2	8,737
Client services [Member] | Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									577,594	615,311	588,082
Client services [Member] | Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue									$ 10,444	$ 13,103	$ 9,398

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Balance at January 1, 2020	$ 5,341
Current period provision	0
Balance at December 31, 2020	5,341
Contract assets, allowance	1,068	$ 0
Total contract assets, long-term	$ 4,273	$ 0

Accounts Receivables - Addition

Accounts Receivables - Additional Information (Detail) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss	$ 31,596		$ 33,256
Accounting Standards Update 2016-13 [Member]
Accounts Notes And Loans Receivable [Line Items]
Accounts receivable, allowance for credit loss		$ 12,600

Accounts Receivables - Schedule

Accounts Receivables - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Detail) - Trade Accounts Receivable [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Accounts Notes And Loans Receivable [Line Items]
Balance at January 1, 2020	$ 33,256
Current period provision	8,726
Write-offs	(10,484)
Recoveries	98
Balance at December 31, 2020	$ 31,596

Leases - Additional Information

Leases - Additional Information (Detail) - Maximum [Member]	12 Months Ended
	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	8 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating C

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	[1]	$ 25,394	$ 27,235
Less: Sublease income		(1,121)	(3,265)
Total operating lease costs		$ 24,273	$ 23,970
[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.

Leases - Supplemental Informati

Leases - Supplemental Information for Operating Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating cash flows from operating leases	$ 26,638	$ 29,348
Right-of-use assets obtained in exchange for operating lease obligations	$ 21,770	$ 141,787

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Right-of-use assets - operating leases	$ 96,601	$ 95,757
Current operating lease liabilities	22,264	22,328
Long-term operating lease liabilities	$ 93,463	$ 93,588
Weighted average remaining lease term (in years)	6 years	6 years
Weighted average discount rate	3.60%	4.40%

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Operating Leases [Abstract]
Operating Leases, 2021	$ 26,090
Operating Leases, 2022	24,501
Operating Leases, 2023	22,752
Operating Leases, 2024	17,388
Operating Leases, 2025	14,927
Operating Leases, Thereafter	22,069
Operating Leases, Total lease liabilities	127,727
Operating Leases, Less: Amount representing interest	(12,000)
Operating Leases, Less: Short-term lease liabilities	(22,264)	$ (22,328)
Operating Leases, Total long-term lease liabilities	$ 93,463	$ 93,588

Business Combinations and Div_3

Business Combinations and Divestitures - 2020 Divestitures - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Oct. 29, 2020	Oct. 15, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business				$ 0	$ 0	$ 172,258
CarePort Purchase Agreement [Member] | WellSky Corp [Member]
Business Acquisition [Line Items]
Sale of business unit	$ 1,350,000
Pre-tax gain (loss) on sale of business	933,900
CarePort Purchase Agreement [Member] | WellSky Corp [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt	$ 161,000
EPSi Purchase Agreement [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt		$ 19,000
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Sale of business unit			$ 365,000
Pre-tax gain (loss) on sale of business				$ 222,600
EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member] | Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt		$ 19,000

Business Combinations and Div_4

Business Combinations and Divestitures - 2019 Business Combinations - Additional Information (Detail) - USD ($)	Jul. 02, 2019	Mar. 01, 2019	Jun. 15, 2018
Business Acquisition [Line Items]
Acquisition of outstanding minority interest			$ 6,900,000
ACC Pinnacle and Diabetes Collaborative Registries [Member]
Business Acquisition [Line Items]
Total purchase price	$ 19,700,000
Purchase price initial payment	11,700,000
Potential milestone/earnout payments	5,000,000
ACC Pinnacle and Diabetes Collaborative Registries [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments	$ 8,000,000
Pulse8, Inc. [Member]
Business Acquisition [Line Items]
Acquisition of outstanding minority interest		$ 53,800,000
Pulse8, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments		$ 5,000,000

Business Combinations and Div_5

Business Combinations and Divestitures - Acquisition of Health Grid - Additional Information (Detail) - Health Grid [Member] - USD ($)	May 18, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Date of acquisition	May 18, 2018
Purchase price in cash	$ 110,000,000
Purchase price transferred, initial payment	60,000,000
Potential earnout payments	23,915,000
Pre-paid potential earnout payments	10,000,000
Goodwill expected to be tax deductible		$ 0
Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 500,000
Level 3 [Member]
Business Acquisition [Line Items]
Potential earnout payments	23,900,000
Maximum [Member]
Business Acquisition [Line Items]
Potential earnout payments	50,000,000
Remaining potential payments	$ 40,000,000

Business Combinations and Div_6

Business Combinations and Divestitures - Schedule of Consideration Transaction (Detail) - USD ($) $ in Thousands	May 18, 2018	Feb. 13, 2018
Health Grid [Member]
Business Acquisition [Line Items]
Aggregate purchase price	$ 60,000
First earnout payment paid by Allscripts	10,000
Fair value of contingent consideration payment	23,915
Closing purchase price adjustments	2,009
Aggregate purchase price	110,000
Add: Closing cash	1,783
Total consideration paid	$ 95,924
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Aggregate purchase price		$ 100,000
Add: Net working capital surplus		373
Add: Closing cash		14,951
Less: Adjustment to assumed indebtedness		(1,684)
Total consideration paid		$ 113,640

Business Combinations and Div_7

Business Combinations and Divestitures - Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 18, 2018	Feb. 13, 2018
Business Acquisition [Line Items]
Goodwill	$ 974,729	$ 974,110	$ 985,837
Health Grid [Member]
Business Acquisition [Line Items]
Cash and cash equivalents				$ 1,783
Accounts receivable, net				3,968
Prepaid expenses and other assets				185
Fixed assets				200
Intangible assets				41,000
Goodwill				53,953
Accounts payable and accrued expenses				(478)
Deferred revenue				(700)
Long-term deferred tax liability				(3,987)
Net assets acquired				$ 95,924
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents					$ 14,951
Accounts receivable, net					13,328
Prepaid expenses and other assets					809
Fixed assets					1,764
Intangible assets					67,100
Goodwill					35,092
Other assets					42
Accounts payable and accrued expenses					(7,378)
Deferred revenue					(2,400)
Long-term deferred tax liability					(8,853)
Other liabilities					(815)
Net assets acquired					$ 113,640

Business Combinations and Div_8

Business Combinations and Divestitures - Acquired Intangible Assets Amortization (Detail) - USD ($) $ in Thousands	May 18, 2018	Feb. 13, 2018
Health Grid [Member]
Business Acquisition [Line Items]
Intangible assets	$ 41,000
Health Grid [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life	15 years
Intangible assets, Fair Value	$ 28,000
Health Grid [Member] | Technology [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life	8 years
Intangible assets, Fair Value	$ 13,000
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Intangible assets		$ 67,100
Practice Fusion, Inc. [Member] | Customer Relationships - Physician Practices [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life		15 years
Intangible assets, Fair Value		$ 29,000
Practice Fusion, Inc. [Member] | Customer Relationships - Pharmaceutical Partners [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life		20 years
Intangible assets, Fair Value		$ 19,400
Practice Fusion, Inc. [Member] | Technology [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life		8 years
Intangible assets, Fair Value		$ 14,800
Practice Fusion, Inc. [Member] | Tradenames [Member]
Business Acquisition [Line Items]
Intangible assets, Useful Life		10 years
Intangible assets, Fair Value		$ 3,900

Business Combinations and Div_9

Business Combinations and Divestitures - Acquisition of Practice Fusion, Inc - Additional Information (Detail) - Practice Fusion, Inc. [Member] - USD ($)	Feb. 13, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Date of acquisition	Feb. 13, 2018
Total consideration paid	$ 113,640,000
Goodwill expected to be tax deductible		$ 0
Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 1,200,000

Business Combinations and Di_10

Business Combinations and Divestitures - Netsmart LLC Divestiture - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business	$ 0	$ 0	$ 172,258
Netsmart [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business			500,500
Netsmart [Member] | Class A Common Units [Member]
Business Acquisition [Line Items]
Consideration for sale			$ 566,600

Business Combinations and Di_11

Business Combinations and Divestitures - Other Acquisitions and Divestitures - Additional Information (Detail) - USD ($) $ in Thousands		Jun. 15, 2018	Apr. 02, 2018	Mar. 15, 2018	Feb. 06, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Acquisition of outstanding minority interest in third party		$ 6,900
Pre-tax gain (loss) on sale of business						$ 0	$ 0	$ 172,258
Equity method investments	[1]					10,744	11,332
Cash paid for business acquisitions						0	23,443	177,233
Goodwill						$ 974,729	$ 974,110	985,837
Strategic Sourcing Business [Member]
Business Acquisition [Line Items]
Effective date of divestiture				March 15, 2018
Payment to acquire additional interest in a new entity				$ 2,700
Minority interest percentage				35.70%
Equity method investments								4,000
Initial pre-tax loss on sale of business								900
Additional pre-tax loss on sale of business								4,700
Cloud-based Analytics Software Platform Provider [Member]
Business Acquisition [Line Items]
Date of acquisition					Feb. 6, 2018
Cash paid for business acquisitions					$ 8,000
Goodwill					6,600
Liabilities assumed, account receivable					800
Liabilities assumed, deferred revenue					600
Liabilities assumed, deferred tax liabilities net					500
Goodwill expected to be tax deductible					0
Cloud-based Analytics Software Platform Provider [Member] | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets					1,100
Intangible assets, useful life						8 years
Cloud-based Analytics Software Platform Provider [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets					$ 600
Intangible assets, useful life						1 year
One Content Business [Member]
Business Acquisition [Line Items]
Date of divestiture			Apr. 2, 2018
Total consideration paid			$ 260,000
Pre-tax gain (loss) on sale of business								$ 177,900
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and O_3

Fair Value Measurements and Other Investments - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 01, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jun. 18, 2013
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Maturity date				Jul. 1, 2020
Gain from sale of a third-party equity method investment				$ 16,800
Total consideration for non marketable equity securities and convertible note				7,097	$ 8,235	$ 16,934
Impairment (recovery) of long-term investments		$ 1,000	$ 600	1,575	651	15,487
Cost Method Equity Investments [Member] | 2018 Convertible Note [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total consideration for non marketable equity securities and convertible note						1,800
Long-term Equity Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment (recovery) of long-term investments				600	1,700
Cost Method Investment [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment (recovery) of long-term investments				$ 1,000	$ (1,000)
2018 Business Acquisitions [Member] | Cost Method Equity Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total consideration for non marketable equity securities and convertible note						$ 11,700
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%			1.25%	1.25%		1.25%
Maturity date	Jul. 1, 2020			Jul. 1, 2020
1.25% Call Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate				1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate				1.25%

Fair Value Measurements and O_4

Fair Value Measurements and Other Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 136,264	$ 144,145
Total assets	1,509	84
Total liabilities	1,011	19,700
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,509	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	1,011	17,100
Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	2,415
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	185
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	1,509	0
Total liabilities	0	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	1,509	0
Level 2 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	84
Total liabilities	1,011	19,700
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	1,011	17,100
Level 3 [Member] | Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	2,415
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	185
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	84
1.25% Call Option [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 0	$ 84

Fair Value Measurements and O_5

Fair Value Measurements and Other Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)	Dec. 31, 2020	Dec. 31, 2019
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%	1.25%

Fair Value Measurements and O_6

Fair Value Measurements and Other Investments - Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020		Dec. 31, 2019
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 19,515		$ 25,624
Additions	770		12,073
Payments/write-downs	(19,274)	[1]	(18,624)	[2]
Fair value adjustments	0		442
Balance	1,011		19,515
1.25% Notes Call Spread Overlay [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance	(101)		(870)
Additions	0		0
Payments/write-downs	0	[1]	0	[2]
Fair value adjustments	101		769
Balance	$ 0		$ (101)
[1]	Payments and write-downs for the year ended December 31, 2020 primarily consisted of $4.0 million in payments for the ACC earnout and a $13.9 million write-down related to the Health Grid earnout.
[2]	Payments and write-downs for the year ended December 31, 2019 primarily consisted of $10.0 million in payments for the Health Grid earnout and a $5.0 million write-down related to the Pulse8 earnout.

Fair Value Measurements and O_7

Fair Value Measurements and Other Investments - Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Health Grid [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payments/write-downs	$ 13.9	$ 10
Pulse8, Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payments/write-downs		$ 5
ACC [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Payments/write-downs	$ 4

Fair Value Measurements and O_8

Fair Value Measurements and Other Investments - Summary of Quantitative Information About Fair Value Measurements (Detail) - Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)RegistryMemberPatientDataVolume
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments | $	$ 1,011
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2020
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Projected year of payment	2021
Registry Members [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	0
Registry Members [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | RegistryMember	1,551,000
Registry Members [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | $	776	[1]
Patient Data Volume [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	0
Patient Data Volume [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	52,845,000
Patient Data Volume [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs | PatientDataVolume	26,422,000	[1]
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total financial instruments | $	$ 1,011
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	5.3
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	5.5
Contingent Consideration [Member] | Probability Weighted Discounted Cash Flow [Member] | Discount Rate [Member] | Weighted Average [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ranges of Inputs	5.4	[1]
[1]	The weighted average is calculated based upon the absolute fair value of the instruments.

Fair Value Measurements and O_9

Fair Value Measurements and Other Investments - Summary of Other Equity Investments Included in Other Assets (Detail) $ in Thousands		12 Months Ended
		Dec. 31, 2020USD ($)Investment	Dec. 31, 2019USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	3
Cost less impairments, Number of investees | Investment		8
Total long-term equity investments, Number of Investees | Investment		11
Equity method investments, Original Cost	[1]	$ 7,099
Cost less impairment, Original Cost		37,568
Total long-term equity investments, Original Cost		44,667
Equity method investments	[1]	10,744	$ 11,332
Cost less impairment, Carrying Value		25,059	32,462
Total long-term equity investments, Carrying Value		$ 35,803	$ 43,794
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fixed Assets - Fixed Assets (De

Fixed Assets - Fixed Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 396,135	$ 407,510
Less: Accumulated depreciation and amortization	(323,973)	(319,557)
Fixed assets, net	72,162	87,953
Computer Equipment and Software [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 329,564	343,756
Computer Equipment and Software [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	10 years
Facility Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 25,932	24,282
Facility Furniture, Fixtures and Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	5 years
Facility Furniture, Fixtures and Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	7 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 40,115	38,948
Estimated useful life (in years)	Shorter of 7 years or life of lease
Assets Under Finance Lease [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 524	524
Less: Accumulated depreciation and amortization	$ (500)	$ (400)
Assets Under Finance Lease [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	1 year
Assets Under Finance Lease [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	3 years

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Accumulated depreciation and amortization	$ 323,973	$ 319,557
Assets Under Finance Lease [Member]
Property Plant And Equipment [Line Items]
Accumulated depreciation and amortization	$ 500	$ 400

Fixed Assets - Depreciation and

Fixed Assets - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Fixed assets depreciation and amortization expense, including finance leases	$ 32,324	$ 46,705	$ 46,951

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,209,428	$ 1,236,678
Accumulated Amortization	(974,826)	(921,550)
Intangible Assets, Net	234,602	315,128
Registered trademarks	52,000	52,000
Goodwill	974,729	974,110	$ 985,837
Total	1,026,729	1,026,110
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	535,092	534,873
Accumulated Amortization	(465,292)	(433,017)
Intangible Assets, Net	69,800	101,856
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	674,336	701,805
Accumulated Amortization	(509,534)	(488,533)
Intangible Assets, Net	$ 164,802	$ 213,272

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Oct. 01, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge		$ 25,700,000	$ 0	$ 0	$ 0	$ 0	$ 25,700,000	$ 13,466,000
Goodwill		974,110,000				974,729,000	974,110,000	985,837,000
Accumulated impairment losses associated with goodwill		39,200,000				0	39,200,000	13,500,000
NantHealth, Inc. [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge								13,500,000
NantHealth, Inc. [Member] | Customer Relationship Intangible [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Intangible asset impairment charges						$ 23,100,000	8,100,000
NantHealth, Inc. [Member] | Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Intangible asset impairment charges								$ 2,200,000
Hospital and Health Systems [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge	$ 25,700,000						25,700,000
Goodwill		$ 485,500,000					$ 485,500,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Line Items]
Goodwill				$ 985,837	$ 974,110	$ 985,837
Additions						13,684
Goodwill impairment charge	$ (25,700)	$ 0	$ 0	0	0	(25,700)	$ (13,466)
Foreign exchange translation					619	289
Goodwill, net	974,110				974,729	974,110	985,837
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill				760,294	734,883	760,294
Additions						0
Goodwill impairment charge					0	(25,700)
Foreign exchange translation					619	289
Goodwill, net	734,883				735,502	734,883	760,294
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Goodwill [Line Items]
Goodwill				$ 225,543	239,227	225,543
Additions						13,684
Goodwill impairment charge					0	0
Foreign exchange translation					0	0
Goodwill, net	$ 239,227				$ 239,227	$ 239,227	$ 225,543

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite Lived Intangible Assets [Line Items]
Total intangible amortization expense	$ 57,734	$ 62,222	$ 63,587
Proprietary Technology Amortization Included in Cost of Revenue [Member]
Finite Lived Intangible Assets [Line Items]
Total intangible amortization expense	32,130	35,034	37,029
Intangible Amortization Included in Operating Expenses [Member]
Finite Lived Intangible Assets [Line Items]
Total intangible amortization expense	$ 25,604	$ 27,188	$ 26,558

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Future Amortization Expense for Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
2021	$ 50,556
2022	44,155
2023	27,943
2024	23,799
2025	20,180
Thereafter	67,969
Intangible Assets, Net	$ 234,602	$ 315,128

Asset Impairment Charges - Addi

Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 01, 2019	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Asset Impairment Charges [Line Items]
Asset impairment charges								$ 74,969	$ 10,837	$ 58,166
Impairment (recovery) of long-term investments		$ 1,000	$ 600					1,575	651	15,487
Non-cash asset impairment charges related to disposal of fixed assets									2,700	2,100
Goodwill impairment charge				$ 25,700	$ 0	$ 0	$ 0	0	25,700	13,466
Hospital and Health Systems [Member]
Asset Impairment Charges [Line Items]
Goodwill impairment charge	$ 25,700								25,700
Health Grid [Member] | Customer Relationship Intangible [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges								23,100
NantHealth, Inc. [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges										22,900
Goodwill impairment charge										13,500
Unamortized value assigned to modification of existing commercial agreement with Nanhealth										20,700
NantHealth, Inc. [Member] | Customer Relationship Intangible [Member]
Asset Impairment Charges [Line Items]
Intangible asset impairment charges								23,100	8,100
NantHealth, Inc. [Member] | Proprietary Technology [Member]
Asset Impairment Charges [Line Items]
Intangible asset impairment charges										2,200
Cost Method Investment [Member]
Asset Impairment Charges [Line Items]
Impairment (recovery) of long-term investments								1,000	(1,000)
Long-term Equity Investments [Member]
Asset Impairment Charges [Line Items]
Impairment (recovery) of long-term investments								600	1,700
Impairment recoveries									$ 1,000
Health Grid Contingent Consideration Accrual [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges								13,900
Capitalized Software [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges								31,200
Deferred Costs Related Private Cloud Hosting Operations [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges								$ 34,300
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges										$ 33,200

Asset Impairment Charges - Summ

Asset Impairment Charges - Summary of Non-Cash Asset Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended						12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Asset Impairment Charges [Abstract]
Asset impairment charges							$ 74,969	$ 10,837	$ 58,166
Goodwill impairment charge			$ 25,700	$ 0	$ 0	$ 0	0	25,700	13,466
Impairment of long-term investments	$ 1,000	$ 600					$ 1,575	$ 651	$ 15,487

Debt - Debt Outstanding Excludi

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Principal Balance	$ 167,853	$ 932,942
Unamortized Discount and Debt Issuance Costs	266	17,473
Net Carrying Amount	167,587	915,469
Principal Balance, Current	0	364,653
Unamortized Discount and Debt Issuance Costs, Current	0	188
Net Carrying Amount, Current	0	364,465
Principal Balance, Noncurrent	167,853	568,289
Unamortized Discount and Debt Issuance Costs, Noncurrent	266	17,285
Net Carrying Amount, Noncurrent	167,587	551,004
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	167,853	177,942
Unamortized Discount and Debt Issuance Costs	(3,166)	4,697
Net Carrying Amount	171,019	173,245
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	0	345,000
Unamortized Discount and Debt Issuance Costs	0	7,552
Net Carrying Amount	0	337,448
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	0	410,000
Unamortized Discount and Debt Issuance Costs	3,432	5,224
Net Carrying Amount	$ (3,432)	$ 404,776

Debt - Debt Outstanding Exclu_2

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 20, 2019	Dec. 09, 2019
Debt Instrument [Line Items]
Debt recognized	$ 167,853,000	$ 932,942,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,911,000	218,000,000	$ 18,000,000	$ 200,000,000
Debt recognized	167,853,000	177,942,000
Additional paid-in capital recognized	16,100,000			$ 1,000
Additional Paid-In Capital [Member] | 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Additional paid-in capital recognized	$ 40,058,000	$ 40,058,000

Debt - Interest Expense (Detail

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total interest expense	$ 6,458	$ 6,667	$ 10,314	$ 10,665	$ 11,725	$ 10,839	$ 10,424	$ 10,184	$ 34,104	$ 43,172	$ 50,914
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense									18,113	26,648	35,366
Amortization of discounts and debt issuance costs									15,991	16,524	15,548
Total interest expense									$ 34,104	$ 43,172	$ 50,914

Debt - Interest Expense Related

Debt - Interest Expense Related to 0.875% Convertible Senior Notes and 1.25% Cash Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes and the 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Coupon interest	$ 4,016	$ 4,429	$ 4,312
Amortization of discounts and debt issuance costs	13,484	14,926	13,867
Total interest expense related to the convertible notes	$ 17,500	$ 19,355	$ 18,179

Debt - Additional Information (

Debt - Additional Information (Detail)	Dec. 31, 2020USD ($)$ / shares	Oct. 29, 2020USD ($)	Jul. 20, 2020USD ($)	Jul. 01, 2020USD ($)	Dec. 20, 2019USD ($)	Dec. 09, 2019USD ($)$ / shares	Aug. 07, 2019USD ($)	Feb. 15, 2018USD ($)	Jun. 18, 2013USD ($)$ / shares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares	Jun. 30, 2013USD ($)	Dec. 31, 2020USD ($)TradingDay$ / shares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)	Dec. 31, 2013USD ($)
Debt Instrument [Line Items]
Maturity date													Jul. 1, 2020
Debt issuance costs													$ 758,000	$ 5,445,000	$ 0
Maximum percentage of foreign subsidiary capital stock guaranteeing credit facility	65.00%												65.00%
Debt instrument principal amount	$ 167,853,000										$ 932,942,000		$ 167,853,000	932,942,000
Payments for 1.25% Call Option												$ 82,800,000
Proceeds from issuance of warrants, net of issuance costs												51,200,000
Net cash payment for 1.25% Notes call spread overlay												$ 31,600,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity								$ 900,000,000
Senior secured credit facilities term, years								5 years
Fees and other costs, incurred			$ 1,400,000				$ 800,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity								$ 400,000,000
Senior secured credit facilities term, years								5 years
Line of credit facility, frequency of payments													The Term Loan is repayable in quarterly installments, which commenced on June 30, 2018.
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance								$ 50,000,000
Swing Loans [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance								10,000,000
Foreign Currencies [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance								100,000,000
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate amount of additional credit facilities authorized								$ 600,000,000
Maximum [Member] | Second Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Leverage ratio	425.00%												425.00%
Maximum [Member] | Second Amended Credit Agreement [Member] | Covenant On Potential Acquisition [Member]
Debt Instrument [Line Items]
Leverage ratio	450.00%												450.00%
Minimum [Member] | Second Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Interest coverage ratio	350.00%												350.00%
Minimum [Member] | Second Amended Credit Agreement [Member] | Covenant On Potential Acquisition [Member]
Debt Instrument [Line Items]
Consideration to be paid for acquisitions													$ 100,000,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	$ 207,911,000				$ 18,000,000	$ 200,000,000					$ 218,000,000		$ 207,911,000	$ 218,000,000
Interest rate	0.875%					0.875%				0.875%	0.875%		0.875%	0.875%
Interest payment, terms													The 0.875% Notes are Allscripts’ senior, unsecured obligations that bear interest at a rate of 0.875% per year, payable semiannually in arrears on January 1 and July 1 of each year
Debt instrument payment commencement date						Jul. 1, 2020
Maturity date						Jan. 1, 2027					Jan. 1, 2027
Debt instrument convertible, principal amount	$ 16,100,000					$ 1,000							$ 16,100,000
Convertible number of equity instrument						75.0962
Conversion price per common stock | $ / shares						$ 13.32					$ 13.32			$ 13.32
Percentage of common stock sale price for initial conversion price						32.50%
Common stock sale price per share | $ / shares						$ 10.05					10.05			$ 10.05
Debt instrument convertible, principal amount						$ 1,000
Repurchase percentage on principal						100.00%
Initial cap price of capped call transactions | $ / shares											$ 17.5875
Cap interest rate											75.00%			75.00%
Proceeds from debt					17,500,000						$ 195,000,000
Debt instrument, initial purchaser's discounts deduction amount											5,000,000
Net proceeds used to payments for capped call transactions cost					1,400,000	$ 15,800,000
Debt issuance costs					500,000
Debt issuance costs incurred											$ 700,000
Percentage of interest rate used to to compute the initial fair value of the liability component											1.95%
Debt instrument, initial fair value of liability component											$ 177,900,000			$ 177,900,000
Payments for repurchase debt instrument										$ 7,700,000
Debt instrument aggregate principal amount repurchased										10,100,000
Gain on repurchase of debt instrument										500,000
Proceeds due to termination of capped call transaction										300,000
Reduction to capped call fees										800,000
Loss in capped call										$ 500,000
Debt instrument, net carrying value of equity component	16,100,000												16,100,000
Debt instrument principal amount	167,853,000										177,942,000		167,853,000	177,942,000
Proceeds from debt					$ 17,500,000						195,000,000
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument convertible, principal amount	40,058,000										40,058,000		$ 40,058,000	40,058,000
Payments of capped call fees											17,200,000
Debt discounts and issuance costs											1,100,000
0.875% Convertible Senior Notes [Member] | Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Repayment of outstanding borrowing						$ 179,200,000
0.875% Convertible Senior Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Percentage of aggregate principal amount required to be held by trustee or holders to declare notes immediately due and payable						25.00%
0.875% Convertible Senior Notes [Member] | Condition One [Member]
Debt Instrument [Line Items]
Threshold trading days | TradingDay													20
Threshold consecutive trading days | TradingDay													30
Debt instrument conversion price percentage													130.00%
0.875% Convertible Senior Notes [Member] | Condition Two [Member]
Debt Instrument [Line Items]
Threshold trading days | TradingDay													5
Threshold consecutive trading days | TradingDay													5
Debt instrument conversion price percentage													98.00%
Debt instrument convertible, principal amount	1,000												$ 1,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility borrowing capacity, amount available	898,900,000												898,900,000
Senior Secured Revolving Facility [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Initial margin for borrowings								1.00%
Senior Secured Revolving Facility [Member] | Eurocurrency Rate [Member]
Debt Instrument [Line Items]
Initial margin for borrowings								2.00%
Senior Secured Revolving Facility [Member] | Second Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	0												0
Senior Secured Revolving Facility [Member] | Maximum [Member] | Second Amended Credit Agreement [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread								1.25%
Senior Secured Revolving Facility [Member] | Maximum [Member] | Second Amended Credit Agreement [Member] | Eurocurrency Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread								2.25%
Senior Secured Revolving Facility [Member] | Minimum [Member] | Second Amended Credit Agreement [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread								0.50%
Senior Secured Revolving Facility [Member] | Minimum [Member] | Second Amended Credit Agreement [Member] | Eurocurrency Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread								1.50%
Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	0												0
Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member] | EPSi Purchase Agreement [Member]
Debt Instrument [Line Items]
Prepayment of debt		$ 19,000,000
Senior Secured Term Loan [Member] | Second Amended Credit Agreement [Member] | CarePort [Member]
Debt Instrument [Line Items]
Prepayment of debt	161,000,000
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	0										$ 410,000,000		0	$ 410,000,000
Senior Secured Credit Facility [Member] | Second Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Letters of credit outstanding	$ 1,100,000												$ 1,100,000
Senior Secured Credit Facility [Member] | Second Amended Credit Agreement [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	2.15%												2.15%
Senior Secured Credit Facility [Member] | Second Amended Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread													2.00%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount									$ 345,000,000
Interest rate	1.25%			1.25%					1.25%		1.25%		1.25%	1.25%
Interest payment, terms													Interest on the 1.25% Notes was payable semiannually in arrears on January 1st and July 1st of each year
Maturity date				Jul. 1, 2020									Jul. 1, 2020
Debt instrument convertible, principal amount									$ 1,000
Convertible number of equity instrument									58.1869
Conversion price per common stock | $ / shares	$ 17.19								$ 17.19				$ 17.19
Repurchase percentage on principal									100.00%
Proceeds from debt									$ 305,100,000
Debt issuance costs									$ 8,400,000
Debt instrument principal amount	$ 0										$ 345,000,000		$ 0	$ 345,000,000
Debt instrument, interest rate, effective percentage									5.40%
Proceeds from debt									$ 305,100,000
Repayment of cash convertible senior notes				$ 345,000,000
Fair value liability of embedded cash conversion option									82,800,000
Debt instrument capitalized amount									$ 8,300,000
Payments for 1.25% Call Option																$ 82,800,000
1.25% Cash Convertible Senior Notes [Member] | Condition One [Member]
Debt Instrument [Line Items]
Threshold trading days | TradingDay													20
Threshold consecutive trading days | TradingDay													30
Debt instrument conversion price percentage													130.00%
1.25% Cash Convertible Senior Notes [Member] | Condition Two [Member]
Debt Instrument [Line Items]
Threshold trading days | TradingDay													5
Threshold consecutive trading days | TradingDay													5
Debt instrument conversion price percentage													98.00%
Debt instrument convertible, principal amount	$ 1,000												$ 1,000

Debt - Summary of Future Debt P

Debt - Summary of Future Debt Payments (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Total	$ 207,911
2021	0
2022	0
2023	0
2024	0
2025	0
Thereafter	207,911
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	207,911
2021	0
2022	0
2023	0
2024	0
2025	0
Thereafter	$ 207,911

Income Taxes - Geographic Break

Income Taxes - Geographic Breakdown of Loss From Continuing Operations Before Income Tax Benefits (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States									$ (148,174)	$ (287,088)	$ (61,292)
Foreign									(1,137)	5,337	(907)
Loss from continuing operations before income taxes	$ (74,750)	$ (18,072)	$ (19,570)	$ (36,919)	$ (63,602)	$ (25,389)	$ (168,796)	$ (23,964)	$ (149,311)	$ (281,751)	$ (62,199)

Income Taxes - Components of Be

Income Taxes - Components of Benefit for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Current tax provision, Federal									$ (19,346)	$ (8,232)	$ (14,018)
Current tax provision, State									(219)	(1,809)	(3,859)
Current tax provision, Foreign									3,803	5,054	5,015
Current tax provision									(15,762)	(4,987)	(12,862)
Deferred tax provision, Federal									2,931	(28,732)	(5,781)
Deferred tax provision, State									(2,981)	(8,763)	236
Deferred tax provision, Foreign									(880)	(858)	(576)
Deferred tax provision									(930)	(38,353)	(6,121)
Income tax benefit	$ (10,051)	$ (4,116)	$ 2,009	$ (4,534)	$ (29,738)	$ (5,645)	$ (5,262)	$ (2,695)	$ (16,692)	$ (43,340)	$ (18,983)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Statutory tax rate	21.00%	21.00%	21.00%
Net operating loss carryforwards expiry beginning period	2021
Tax holiday savings				$ 400,000
Diluted earnings per share, increase				$ 0.01
Partial tax holiday period	5 years
Tax savings impact	$ 200,000
Unrecognized tax benefits	28,885,000	$ 20,604,000	$ 19,821,000	$ 10,939,000
State tax gain on sale of business	6,400
Estimated increase in income tax benefit	30,800,000	20,700,000
Unrecognized tax benefits, accrued interest and penalties	2,048,000	427,000
Other Tax Expense (Benefit)	200,000
Valuation allowance	$ 16,949,000	922,000	$ (5,208,000)
Cumulative operating income loss period considered	3 years
U.S and Foreign Deferred Tax Asset [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance	$ 17,900,000
Unvested Stock Compensation of Covered Officers [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance	$ (1,000,000)
India [Member] | Partially Expire [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax holiday expiration date	2012
India [Member] | Fully Expire [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax holiday expiration date	2017
State [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards	$ 2,500,000	2,500,000
State [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years	2017
State [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years	2020
US [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards	$ 4,300,000
Israeli [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards	$ 49,000,000
Foreign Jurisdictions [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years	2015
Federal [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards	$ 164,000,000	$ 174,000,000
Federal [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years	2017
Federal [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years	2020

Income Taxes - Taxes Computed a

Income Taxes - Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States federal tax at statutory rate									$ (31,355)	$ (59,170)	$ (13,062)
Non-deductible acquisition and reorganization expenses									0	31	291
Non-deductible portion of Department of Justice Settlement									0	18,546	0
Research credits									(6,500)	(6,126)	(6,185)
Change in unrecognized tax benefits									3,204	1,046	3
State income taxes, net of federal benefit									(2,940)	(7,411)	(2,916)
Compensation									5,314	4,664	3,213
Meals and entertainment									118	549	616
Impact of foreign operations									1,443	3,079	3,627
Provision-to-Return adjustments									(2,362)	(383)	(2,140)
Deemed Dividends									352	473	373
Federal, state and local rate changes									0	(630)	0
US Tax reform impact									0	(2,972)	0
Goodwill impairment									0	5,397	0
Non-deductible items									28	43	34
Noncontrolling interest									0	0	951
True-up of prior year income of Consolidated Investment									0	0	913
Valuation allowance									16,949	922	(5,208)
Other									(943)	(1,398)	507
Income tax benefit	$ (10,051)	$ (4,116)	$ 2,009	$ (4,534)	$ (29,738)	$ (5,645)	$ (5,262)	$ (2,695)	$ (16,692)	$ (43,340)	$ (18,983)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets
Accruals and reserves, net	$ 18,260	$ 29,627
Allowance for doubtful accounts	9,571	11,507
Stock-based compensation, net	8,428	10,382
Deferred revenue	35,016	21,786
Operating and finance lease liabilities	22,902	22,085
Net operating loss carryforwards	35,695	37,717
Research and development tax credit	251	899
Other	4,519	7,488
Less: Valuation Allowance	(35,491)	(19,219)
Total deferred tax assets	99,151	122,272
Deferred tax liabilities
Prepaid expense	(4,329)	(5,372)
Property and equipment, net	(2,062)	(3,695)
Acquired intangibles, net	(86,841)	(111,284)
Operating and finance right-of-use assets	(18,315)	(17,255)
Total deferred tax liabilities	(111,547)	(137,606)
Net deferred tax liabilities	$ (12,396)	$ (15,334)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Liabilities) Classified in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Non-current deferred tax assets, net	$ 5,790	$ 5,704
Non-current deferred tax liabilities, net	(18,186)	(21,038)
Net deferred tax liabilities	$ (12,396)	$ (15,334)

Income Taxes - Change in the Am

Income Taxes - Change in the Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Unrecognized tax benefit, beginning balance	$ 20,604	$ 19,821	$ 10,939
Increases for tax positions related to the current year	8,053	1,240	8,977
Increases for tax positions related to prior years	427	95	367
Increases acquired in business acquisitions	0	0	540
Foreign currency translation	2	3	(5)
Reductions due to lapsed statute of limitations	(201)	(555)	(997)
Unrecognized tax benefit, ending balance	$ 28,885	$ 20,604	$ 19,821

Income Taxes - Recognized Inter

Income Taxes - Recognized Interest and Penalties Related to Uncertain Tax Positions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Interest and penalties included in the provision for income taxes	$ 1,620	$ 229	$ 543

Income Taxes - Amount of Intere

Income Taxes - Amount of Interest and Penalties Included in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Interest and penalties included in the liability for uncertain tax positions	$ 2,048	$ 427

Stock Award Plan - Stock-Based

Stock Award Plan - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 38,890	$ 42,690	$ 39,331
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	6,061	6,142	6,181
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,640	2,075	2,184
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	4,421	4,067	3,997
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	25,002	27,348	24,213
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 7,827	$ 9,200	$ 8,937

Stock Award Plan - Additional I

Stock Award Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 23, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense included in provision for income taxes	$ 4,800,000
Capitalized stock-based compensation costs	0	$ 0	$ 0
Unrecognized compensation cost	$ 51,300,000
Unrecognized compensation expense expected to recognized over weighted-average period, in years	2 years 3 months 18 days
Shares settled for tax withholding	808,000	705,000	695,000
Stock options, contractual terms	7 years
Aggregate intrinsic value of stock options outstanding	$ 0
Aggregate intrinsic value of stock options exercisable	0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual fair value limit on shares purchased	25,000
Service-based share awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 42,600,000
Unrecognized compensation expense expected to recognized over weighted-average period, in years	2 years 4 months 24 days
Share based compensation award vesting period	4 years
Deferred share units awarded to directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	1 year
Awards Granted Under Financial Performance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	3 years
Performance-Based Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 2,400,000
Unrecognized compensation expense expected to recognized over weighted-average period, in years	2 years 2 months 12 days
Market-Based Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 6,300,000
Unrecognized compensation expense expected to recognized over weighted-average period, in years	1 year 8 months 12 days
Share based compensation award vesting period	3 years
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for awards				5,500,000
Common stock shares reserved for issuance under future share-based awards	8,200,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payroll deductions	20.00%
Offering price percentage	15.00%
Shares purchased under the ESPP	2,000,000	2,000,000

Stock Award Plan - Activity for

Stock Award Plan - Activity for Restricted Stock Units (Detail) - Restricted Stock Unit [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shares
Shares, Unvested restricted stock units, beginning balance	8,914	7,950	7,259
Shares, Awarded	5,607	4,777	4,024
Shares, Vested	(2,756)	(2,360)	(2,222)
Shares, Forfeited	(2,097)	(1,453)	(1,111)
Shares, Unvested restricted stock units, ending balance	9,668	8,914	7,950
Weighted-Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value, Unvested restricted stock units, beginning balance	$ 11.53	$ 12.81	$ 12.57
Weighted-Average Grant Date Fair Value, Awarded	6.88	10.15	13.25
Weighted-Average Grant Date Fair Value, Vested	11.69	12.62	13.03
Weighted-Average Grant Date Fair Value, Forfeited	10.79	12.20	12.43
Weighted-Average Grant Date Fair Value, Unvested restricted stock units, ending balance	$ 8.95	$ 11.53	$ 12.81

Stock Award Plan - Stock Option

Stock Award Plan - Stock Options Outstanding (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Options Outstanding
Options Outstanding, Beginning balance	1,234	1,332	1,635
Options Outstanding, Options granted	0	0	0
Options Outstanding, Options exercised	0	0	(92)
Options Outstanding, Options forfeited	(1,234)	(98)	(211)
Options Outstanding, Ending balance	0	1,234	1,332
Weighted-Average Exercise Price
Weighted-Average Exercise Price, Beginning balance	$ 13.67	$ 13.69	$ 13.85
Weighted-Average Exercise Price, Options granted	0	0	0
Weighted-Average Exercise Price, Options exercised	0	0	14.01
Weighted-Average Exercise Price, Options forfeited	13.67	14.01	14.74
Weighted-Average Exercise Price, Ending balance	$ 0	$ 13.67	$ 13.69
Options Exercisable
Options Exercisable	0	1,234	1,332	1,635
Weighted-Average Exercise Price, Exercisable	$ 0	$ 13.67	$ 13.69	$ 13.85

Stock Award Plan - Stock Opti_2

Stock Award Plan - Stock Option Activity (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total intrinsic value of stock options exercised	$ 0	$ 0	$ 69
Total fair value of share awards vested	$ 32,218	$ 29,793	$ 28,954

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Dec. 30, 2020$ / sharesshares	Dec. 02, 2020USD ($)	Nov. 30, 2020USD ($)	Nov. 18, 2020USD ($)	Dec. 09, 2019USD ($)	Jun. 30, 2016USD ($)Installment$ / sharesshares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)Installment$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Jun. 30, 2020	Aug. 02, 2018USD ($)	Jun. 30, 2013$ / sharesshares
Class Of Stock [Line Items]
Common stock repurchased, amount									$ 134,863,000	$ 111,460,000	$ 138,928,000
Common stock, par value | $ / shares							$ 0.01	$ 0.01	$ 0.01	$ 0.01
Maturity date									Jul. 1, 2020
0.875% Convertible Senior Notes [Member]
Class Of Stock [Line Items]
Interest rate					0.875%		0.875%	0.875%	0.875%	0.875%		0.875%
Debt instrument convertible, principal amount					$ 1,000			$ 16,100,000	$ 16,100,000
Maturity date					Jan. 1, 2027		Jan. 1, 2027
0.875% Convertible Senior Notes [Member] | Additional Paid-In Capital [Member]
Class Of Stock [Line Items]
Debt instrument convertible, principal amount							$ 40,058,000	$ 40,058,000	$ 40,058,000	$ 40,058,000
Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares								1,500,000	1,500,000
Initial exercise price of warrant per share | $ / shares								$ 9.82	$ 9.82
Number of installments | Installment									4
Number of warrants vesting annually | shares									375,000
Warrant expiration period									2026-12
Warrants value								$ 12,400,000	$ 12,400,000
Warrants vesting period									3 years
Warrant Issued to Commercial Partner [Member] | Customary Anti-Dilution Adjustments [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares	900,000,000
Initial exercise price of warrant per share | $ / shares	$ 14.18
Number of installments | Installment						4
Number of warrants vesting annually | shares	108,000					750,000
Warrant expiration period						2026-06
Warrants value						$ 11,000,000
Warrants vesting period						4 years
Additional warrants issued | shares								0	0
Warrant Issued to Commercial Partner [Member] | Case 1 [Member] | Customary Anti-Dilution Adjustments [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares						900,000
Common stock, par value | $ / shares						$ 0.01
Sale of common stock, price per share | $ / shares						$ 12.47
Warrant Issued to Commercial Partner [Member] | Case 2 [Member] | Customary Anti-Dilution Adjustments [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares						1,000,000
Sale of common stock, price per share | $ / shares						$ 14.34
Warrant Issued to Commercial Partner [Member] | Case 3 [Member] | Customary Anti-Dilution Adjustments [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares						1,100,000
Sale of common stock, price per share | $ / shares						$ 15.59
1.25% Warrants [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares								0	0					20,100,000
Initial exercise price of warrant per share | $ / shares														$ 23.135
Warrants value							$ 51,200,000	$ 51,200,000	$ 51,200,000	$ 51,200,000
Warrant expiration term									The 1.25% Warrants began to expire as of October 1, 2020, with expiration continuing to expire over the next 70 trading days. The 1.25% Warrants are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap.
Warrant expiration beginning period									Oct. 1, 2020
Warrant expiration period									70 days
August 2018 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, shares | shares									10,600,000	10,500,000
Common stock repurchased, amount									$ 102,000,000	$ 111,500,000
Stock repurchase program, authorized amount													$ 250,000,000
November 2020 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, shares | shares								14,100,000
Common stock repurchased, amount				$ 300,000,000
Accelerated Share Repurchase Agreement [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount			$ 200,000,000
Initial delivery received		$ 11,700,000
Percentage of expected shares repurchased			80.00%
Reduction to shareholders equity			$ 165,700,000
Reduction to shareholders equity as an unsettled forward contract			$ 34,300,000
Shares of common stock yet to be repurchased, amount								$ 67,200,000	$ 67,200,000

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basic income (loss) per Common Share:
Loss from continuing operations, net of tax	$ (64,699)	$ (13,956)	$ (21,579)	$ (32,385)	$ (33,864)	$ (19,744)	$ (163,534)	$ (21,269)	$ (132,619)	$ (238,411)	$ (43,216)
Net loss attributable to non-controlling interests					0	0	0	424	0	424	4,527
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders									(132,619)	(237,987)	(38,689)
Income from discontinued operations, net of tax	792,523	14,498	13,974	12,031	14,894	14,019	13,604	13,292	833,026	55,809	451,023
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations									0	0	(48,594)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders									833,026	55,809	402,429
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 727,824	$ 542	$ (7,605)	$ (20,354)	$ (18,970)	$ (5,725)	$ (149,930)	$ (7,553)	$ 700,407	$ (182,178)	$ 363,740
Weighted-average common shares outstanding									159,281	166,306	176,038
Basic loss from continuing operations per Common Share	$ (0.43)	$ (0.09)	$ (0.13)	$ (0.20)	$ (0.21)	$ (0.11)	$ (0.98)	$ (0.12)	$ (0.83)	$ (1.43)	$ (0.22)
Basic income from discontinued operations per Common Share	5.25	0.09	0.08	0.07	0.09	0.08	0.08	0.08	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ 4.82	$ 0	$ (0.05)	$ (0.13)	$ (0.12)	$ (0.03)	$ (0.90)	$ (0.04)	$ 4.40	$ (1.10)	$ 2.07
Diluted income (loss) per Common Share:
Loss from continuing operations, net of tax	$ (64,699)	$ (13,956)	$ (21,579)	$ (32,385)	$ (33,864)	$ (19,744)	$ (163,534)	$ (21,269)	$ (132,619)	$ (238,411)	$ (43,216)
Net loss attributable to non-controlling interests					0	0	0	424	0	424	4,527
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders									(132,619)	(237,987)	(38,689)
Income from discontinued operations, net of tax	$ 792,523	$ 14,498	$ 13,974	$ 12,031	$ 14,894	$ 14,019	$ 13,604	$ 13,292	833,026	55,809	451,023
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations									0	0	(48,594)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders									833,026	55,809	402,429
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders									$ 700,407	$ (182,178)	$ 363,740
Weighted-average common shares outstanding									159,281	166,306	176,038
Dilutive effect of stock options, restricted stock unit awards and warrants									0	0	0
Weighted-average common shares outstanding assuming dilution									159,281	166,306	176,038
Diluted (loss) income from continuing operations per Common Share	$ (0.43)	$ (0.09)	$ (0.13)	$ (0.20)	$ (0.21)	$ (0.11)	$ (0.98)	$ (0.12)	$ (0.83)	$ (1.43)	$ (0.22)
Diluted income from discontinued operations per Common Share	5.25	0.09	0.08	0.07	0.09	0.08	0.08	0.08	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ 4.82	$ 0	$ (0.05)	$ (0.13)	$ (0.12)	$ (0.03)	$ (0.90)	$ (0.04)	$ 4.40	$ (1.10)	$ 2.07

Earnings (Loss) Per Share - Ant

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	42,845	27,945	26,175

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,285,188
Other comprehensive (loss) income before reclassifications	3,022	$ 1,253	$ (3,172)
Net (gains) losses reclassified from accumulated other comprehensive loss	(468)	(256)	(232)
Total other comprehensive income (loss)	2,554	997	(3,404)
Balance at the end of the period	1,666,243	1,285,188
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(4,392)	(5,584)	(2,676)
Other comprehensive (loss) income before reclassifications	1,435	1,192	(2,908)
Net (gains) losses reclassified from accumulated other comprehensive loss	0	0	0
Total other comprehensive income (loss)	1,435	1,192	(2,908)
Balance at the end of the period	(2,957)	(4,392)	(5,584)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	0	195	691
Other comprehensive (loss) income before reclassifications	1,587	61	(264)
Net (gains) losses reclassified from accumulated other comprehensive loss	(468)	(256)	(232)
Total other comprehensive income (loss)	1,119	(195)	(496)
Balance at the end of the period	1,119	0	195
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(4,392)	(5,389)	(1,985)
Balance at the end of the period	$ (1,838)	$ (4,392)	$ (5,389)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2017
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)		$ 68	$ 390
Revaluation of tax effects	$ 149	$ 149
Unrealized Net Gains (Losses) on Marketable Securities and Foreign Exchange Contracts [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)				$ 445

Accumulated Other Comprehensi_5

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 1,435	$ 1,192	$ (2,908)
Derivatives qualifying as cash flow hedges, net gains (losses), Before-Tax Amount	1,509	(262)	(873)
Other comprehensive (loss) income, Before-Tax Amount	2,944	930	(3,781)
Foreign currency translation adjustments, Tax Effect	0	0	0
Other comprehensive (loss) income, Tax Effect	(390)	67	377
Foreign currency translation adjustments, Net	1,435	1,192	(2,908)
Other comprehensive income (loss), Net	2,554	997	(3,404)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	2,139	82	(357)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(630)	(344)	(516)
Derivatives qualifying as cash flow hedges, net gains (losses), Before-Tax Amount	1,509	(262)	(873)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	(552)	(21)	93
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	162	88	284
Derivatives qualifying as cash flow hedges, net (losses) gains, Tax Effect	(390)	67	377
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	1,587	61	(264)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(468)	(256)	(232)
Derivatives qualifying as cash flow hedges, net gains (losses), Net	1,119	(195)	(496)
Other comprehensive income (loss), Net	$ 1,119	$ (195)	$ (496)

Accumulated Other Comprehensi_6

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2018
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 390	$ 68

Derivative Financial Instrume_3

Derivative Financial Instruments - Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 1,509	$ 84
Derivative liability, fair value	0	185
1.25% Call Option [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	84
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	1,509	0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	84
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 0	$ 185

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Detail)	Jul. 01, 2020	Jun. 30, 2013USD ($)	Dec. 31, 2020USD ($)Derivative$ / shares	Dec. 31, 2013USD ($)	Dec. 31, 2020INR (₨)Derivative	Dec. 31, 2019	Jun. 18, 2013USD ($)$ / shares
Derivative [Line Items]
Maturity date			Jul. 1, 2020
Purchase of call option related to 1.25% senior cash convertible notes		$ 82,800,000
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate			1.25%		1.25%	1.25%
1.25% Cash Convertible Senior Notes [Member]
Derivative [Line Items]
Maturity date	Jul. 1, 2020		Jul. 1, 2020
Debt instrument interest rate	1.25%		1.25%		1.25%	1.25%	1.25%
Purchase of call option related to 1.25% senior cash convertible notes				$ 82,800,000
Conversion price per common stock | $ / shares			$ 17.19				$ 17.19
Fair value liability of embedded cash conversion option							$ 82,800,000
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative			6		6
Derivative notional amount outstanding			$ 3,100,000		₨ 225,000,000
Unrealized derivatives gains included in accumulated other comprehensive (loss) income reclassified into income			$ 1,500,000
Estimated period of unrealized losses included in AOCI reclassified into income			6 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature			Jan. 31, 2021
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature			Jun. 30, 2021
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate			1.25%		1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option							$ 82,800,000

Derivative Financial Instrume_5

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ 2,139	$ 82	$ (357)
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	249	124	165
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	122	83	138
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ 259	$ 137	$ 214

Derivative Financial Instrume_6

Derivative Financial Instruments - Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments Gain Loss [Line Items]
Net income included in Other income, net	$ 101	$ 769	$ 329
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net income included in Other income, net	(84)	(9,020)	(37,474)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net income included in Other income, net	$ 185	$ 9,789	$ 37,803

Commitments - Additional Inform

Commitments - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
Base annual payment obligation for data center and hosting services	$ 35
Base annual payment obligation for data center and hosting services before renegotiation	$ 30

Commitments - Summary of Expens

Commitments - Summary of Expense Incurred under Atos Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Long Term Purchase Commitment [Line Items]
Expenses incurred under Atos agreements	$ 225,391	$ 230,480	$ 231,706	$ 249,428	$ 261,711	$ 259,767	$ 251,680	$ 249,166	$ 937,005	$ 1,022,324	$ 996,450
Atos [Member]
Long Term Purchase Commitment [Line Items]
Expenses incurred under Atos agreements									$ 102,730	$ 100,089	$ 55,903

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail)	Oct. 15, 2020USD ($)Segment	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2018USD ($)Offering	Dec. 31, 2020USD ($)BusinessSegment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of reportable segments | Segment	2						2
Gain (Loss) on disposal of discontinued solutions before tax		$ 1,156,504,000	$ 0	$ 0	$ 0		$ 1,156,504,000	$ 0	$ 500,471,000
EPSi and CarePort [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of businesses sold | Business							2
Gain (Loss) on disposal of discontinued solutions before tax							$ 1,156,504,000	0	0
Disposal group including discontinued operation accrued liabilities current		6,669,000					6,669,000	$ 381,000
EPSi [Member] | EPSi Purchase Agreement [Member] | Strata Decision Technology LLC [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sale price	$ 365,000,000
CarePort [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sale price		$ 1,350,000,000					$ 1,350,000,000
Netsmart [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain (Loss) on disposal of discontinued solutions before tax									500,471,000
Netsmart [Member] | Class A Common Units [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sale price						$ 566,600,000			566,600,000
Horizon Clinicals and Series2000 [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of product offerings acquired | Offering						2
Gain (Loss) on disposal of discontinued solutions before tax									0
Disposal group including discontinued operation accrued liabilities current						$ 900,000			$ 900,000

Discontinued Operations - Summa

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Carrying amounts of major classes of assets associated with EPSi and CarePort included as part of discontinued operations:
Total current assets attributable to discontinued operations	$ 0	$ 41,871
Total long-term assets attributable to discontinued operations	0	428,021
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Total current liabilities attributable to discontinued operations	322,811	49,392
Total long-term liabilities attributable to discontinued operations	0	2,843
EPSi and CarePort [Member]
Carrying amounts of major classes of assets associated with EPSi and CarePort included as part of discontinued operations:
Accounts receivable, net of allowance of $1,874 as of December 31, 2019	0	35,336
Contract assets, net of allowance of $0 as of December 31, 2019	0	2,690
Prepaid expenses and other current assets	0	3,845
Total current assets attributable to discontinued operations	0	41,871
Fixed assets, net	0	386
Software development costs, net	0	21,237
Intangible assets, net	0	7,014
Goodwill	0	387,907
Contract assets - long-term, net of allowance of $0 as of December 31, 2019	0	4,034
Right-of-use assets - operating leases	0	2,263
Other assets	0	5,180
Total long-term assets attributable to discontinued operations	0	428,021
Carrying amounts of major classes of liabilities associated with EPSi and CarePort included as part of discontinued operations:
Accounts payable	0	1,190
Accrued expenses	6,669	381
Income tax payable	316,142	0
Accrued compensation and benefits	0	2,788
Deferred revenue	0	44,224
Current operating lease liabilities	0	809
Total current liabilities attributable to discontinued operations	322,811	49,392
Deferred revenue long-term	0	1,269
Long-term operating lease liabilities	0	1,574
Total long-term liabilities attributable to discontinued operations	$ 0	$ 2,843

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Parenthetical) (Detail) - EPSi and CarePort [Member] $ in Thousands	Dec. 31, 2019USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal group including discontinued operation accounts receivable, allowance	$ 1,874
Disposal group including discontinued operation contract asset, allowance current	0
Disposal group including discontinued operation contract asset, allowance noncurrent	$ 0

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Major Classes of Line Items Constituting Income (Loss) of Discontinued Operations (Detail) - USD ($)		3 Months Ended								12 Months Ended
		Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cost of revenue:
Gain on sale of discontinued operations		$ 1,156,504,000	$ 0	$ 0	$ 0					$ 1,156,504,000	$ 0	$ 500,471,000
Income from discontinued operations before income taxes		16,847,000	19,545,000	18,838,000	16,218,000	$ 20,078,000	$ 18,899,000	$ 18,339,000	$ 17,919,000	71,448,000	75,235,000	2,501,000
Income tax benefit (provision)		(380,828,000)	(5,047,000)	(4,864,000)	(4,187,000)	(5,184,000)	(4,880,000)	(4,735,000)	(4,627,000)	(394,926,000)	(19,426,000)	(51,949,000)
Income from discontinued operations, net of tax		$ 792,523,000	$ 14,498,000	$ 13,974,000	$ 12,031,000	$ 14,894,000	$ 14,019,000	$ 13,604,000	$ 13,292,000	833,026,000	55,809,000	451,023,000
EPSi and CarePort [Member]
Revenue:
Total revenue										136,821,000	139,031,000	132,121,000
Cost of revenue:
Total cost of revenue										36,062,000	35,772,000	28,969,000
Amortization of software development and acquisition-related assets										9,053,000	8,166,000	6,194,000
Gross profit										100,759,000	103,259,000	103,152,000
Selling, general and administrative expenses										15,539,000	18,964,000	18,118,000
Research and development										8,269,000	9,065,000	9,673,000
Amortization of intangible assets										29,000	29,000	29,000
Income (loss) from discontinued operations										76,922,000	75,201,000	75,332,000
Interest expense										(5,241,000)	0	0
Other (expense) income, net										(192,000)	2,000	5,000
Gain on sale of discontinued operations										1,156,504,000	0	0
Income from discontinued operations before income taxes										1,227,993,000	75,203,000	75,337,000
Income tax benefit (provision)	[1]									(394,926,000)	(19,417,000)	(19,452,000)
Income from discontinued operations, net of tax	[2]									833,067,000	55,786,000	55,885,000
EPSi and CarePort [Member] | Software delivery, Support and Maintenance [Member]
Revenue:
Total revenue										122,791,000	122,268,000	116,639,000
Cost of revenue:
Total cost of revenue										11,424,000	12,482,000	10,737,000
EPSi and CarePort [Member] | Client services [Member]
Revenue:
Total revenue										14,030,000	16,763,000	15,482,000
Cost of revenue:
Total cost of revenue										$ 15,585,000	$ 15,124,000	12,038,000
Horizon Clinicals and Series2000 [Member]
Revenue:
Total revenue												9,845,000
Cost of revenue:
Total cost of revenue												3,152,000
Gross profit												6,693,000
Research and development												1,651,000
Gain on sale of discontinued operations												0
Income from discontinued operations before income taxes												5,042,000
Income tax benefit (provision)												(1,311,000)
Income from discontinued operations, net of tax												3,731,000
Horizon Clinicals and Series2000 [Member] | Software delivery, Support and Maintenance [Member]
Revenue:
Total revenue												9,441,000
Cost of revenue:
Total cost of revenue												2,322,000
Horizon Clinicals and Series2000 [Member] | Client services [Member]
Revenue:
Total revenue												404,000
Cost of revenue:
Total cost of revenue												$ 830,000
[1]	Income tax provision does not agree to the consolidated statement of operations for the year ended December 31, 2019 due to residual amounts related to Netsmart.
[2]	Income from discontinued operations, net of tax for EPSi and CarePort does not agree to the consolidated statement of operations for the years ended December 31, 2020 and 2019 due to residual amounts related to Netsmart.

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Major Income and Expense Line Items Reported in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cost of revenue:
Gain on sale of discontinued operations	$ 1,156,504	$ 0	$ 0	$ 0					$ 1,156,504	$ 0	$ 500,471
Income from discontinued operations before income taxes	16,847	19,545	18,838	16,218	$ 20,078	$ 18,899	$ 18,339	$ 17,919	71,448	75,235	2,501
Income tax benefit (provision)	(380,828)	(5,047)	(4,864)	(4,187)	(5,184)	(4,880)	(4,735)	(4,627)	(394,926)	(19,426)	(51,949)
Income from discontinued operations, net of tax	$ 792,523	$ 14,498	$ 13,974	$ 12,031	$ 14,894	$ 14,019	$ 13,604	$ 13,292	$ 833,026	$ 55,809	451,023
Netsmart [Member]
Revenue:
Total revenue											345,231
Cost of revenue:
Total cost of revenue											188,518
Amortization of software development and acquisition-related assets											34,357
Gross profit											156,713
Selling, general and administrative expenses											125,807
Research and development											25,315
Amortization of intangible and acquisition-related assets											24,029
Income (loss) from discontinued operations											(18,438)
Interest expense											(59,541)
Other income											101
Gain on sale of discontinued operations											500,471
Income from discontinued operations before income taxes											422,593
Income tax benefit (provision)											(31,186)
Income from discontinued operations, net of tax											391,407
Software delivery, Support and Maintenance [Member] | Netsmart [Member]
Revenue:
Total revenue											214,065
Cost of revenue:
Total cost of revenue											60,100
Client services [Member] | Netsmart [Member]
Revenue:
Total revenue											131,166
Cost of revenue:
Total cost of revenue											$ 94,061

Business Segments - Additional

Business Segments - Additional Information (Detail) - Segment	Oct. 15, 2020	Dec. 31, 2020
Segment Reporting [Abstract]
Number of operating segments		3
Number of reportable segments	2	2

Business Segments - Revenues an

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 386,414	$ 365,618	$ 369,304	$ 381,364	$ 414,330	$ 408,280	$ 410,883	$ 399,118	$ 1,502,700	$ 1,632,611	$ 1,617,841
Gross profit	161,023	135,138	137,598	131,936	152,619	148,513	159,203	149,952	565,695	610,287	621,391
Loss from operations	$ (68,078)	$ (11,161)	$ (24,665)	$ (26,976)	$ (55,102)	$ (15,717)	$ (13,596)	$ (15,274)	(130,880)	(99,689)	(168,384)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue									(12,870)	(7,200)	(8,376)
Gross profit									0	0	0
Loss from operations									0	0	0
Core Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue									1,254,249	1,377,147	1,379,499
Gross profit									434,288	473,033	491,421
Loss from operations									(116,139)	(80,465)	(158,440)
Data Analytics and Care Coordination [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue									261,321	262,664	246,718
Gross profit									131,407	137,254	129,970
Loss from operations									$ (14,741)	$ (19,224)	$ (9,944)

Supplemental Disclosures - Supp

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 531,104	$ 129,668
Restricted cash	6,361	7,871
Total cash, cash equivalents and restricted cash	537,465	137,539
Interest, including convertible senior notes	24,616	23,917	$ 33,200
Income taxes paid, net of tax refunds	76,595	42,972	10,108
Non-cash transactions:
Obligations incurred to purchase capitalized software or enter into finance leases	0	0	1,501
Contributions of assets in exchange for equity interest	0	0	4,000
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0	0	48,594
Issuance of treasury stock	$ 752	$ 701	$ 1,121

Supplemental Disclosures - Accr

Supplemental Disclosures - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Supplemental Disclosures [Line Items]
Royalties, certain third-party product costs and licenses	$ 37,841	$ 35,064
Other	62,421	90,217
Total Accrued expenses	100,262	270,281
Practice Fusion [Member]
Schedule Of Supplemental Disclosures [Line Items]
Practice Fusion settlement	$ 0	$ 145,000

Supplemental Disclosures - Addi

Supplemental Disclosures - Additional Information (Detail)	Dec. 31, 2020
Supplemental Disclosures [Abstract]
Maximum percentage accounted by individual expenses of total current liabilities	5.00%

Supplemental Disclosures - Prep

Supplemental Disclosures - Prepaid and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Supplemental Disclosures [Abstract]
Prepaid assets	$ 132,944	$ 142,191
Other current assets	3,320	1,954
Total Prepaid and other current assets	$ 136,264	$ 144,145

Supplemental Disclosures - Othe

Supplemental Disclosures - Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Other Assets Noncurrent [Line Items]
Derivative asset, fair value	$ 1,509	$ 84
Long-term deferred hosting fees	11,025	36,002
Long-term prepaid commissions	27,882	28,876
Investments in non-marketable securities	35,805	43,806
Long-term deposits and other assets	16,916	10,819
Total Other assets	91,628	119,587
1.25% Call Option [Member]
Other Assets Noncurrent [Line Items]
Derivative asset, fair value	$ 0	$ 84

Supplemental Disclosures - Ot_2

Supplemental Disclosures - Other Assets (Parenthetical) (Detail)	Dec. 31, 2020	Dec. 31, 2019
1.25% Call Option [Member]
Other Assets Noncurrent [Line Items]
Debt instrument interest rate	1.25%	1.25%

Geographic Information - Revenu

Geographic Information - Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Revenues From External Customers [Line Items]
Total revenue	$ 386,414	$ 365,618	$ 369,304	$ 381,364	$ 414,330	$ 408,280	$ 410,883	$ 399,118	$ 1,502,700	$ 1,632,611	$ 1,617,841
United States [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									1,439,737	1,562,107	1,565,057
Canada [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									15,624	16,495	15,377
Other International [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									$ 47,339	$ 54,009	$ 37,407

Geographic Information - Long-L

Geographic Information - Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	$ 72,162	$ 87,953
United States [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	62,016	77,736
India [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	5,876	5,321
Israel [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	2,611	3,240
Canada [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	187	51
Other International [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	$ 1,472	$ 1,605

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - US Department of Justice and US Attorney [Member]	12 Months Ended
	Dec. 31, 2020USD ($)
Criminal Fine [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 25,300,000
Forfeiture Payment [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	959,700
Civil Settlements [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	118,600,000
State Medicaid Program Expenditures [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 5,200,000

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) - Quarterly Financial Information (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Revenue from contract with customers	$ 386,414	$ 365,618	$ 369,304	$ 381,364	$ 414,330	$ 408,280	$ 410,883	$ 399,118	$ 1,502,700	$ 1,632,611	$ 1,617,841
Cost of revenue	225,391	230,480	231,706	249,428	261,711	259,767	251,680	249,166	937,005	1,022,324	996,450
Gross profit	161,023	135,138	137,598	131,936	152,619	148,513	159,203	149,952	565,695	610,287	621,391
Selling, general and administrative expenses	93,777	93,442	109,897	92,825	108,275	96,080	100,462	95,991	389,941	400,808	432,849
Research and development	54,287	46,352	46,045	59,377	60,112	61,062	61,922	62,347	206,061	245,443	258,736
Asset impairment charges	74,759	210	0	0	6,800	248	3,691	98	74,969	10,837	58,166
Goodwill impairment charge					25,700	0	0	0	0	25,700	13,466
Amortization of intangible and acquisition-related assets	6,278	6,295	6,321	6,710	6,834	6,840	6,724	6,790	25,604	27,188	26,558
Loss from operations	(68,078)	(11,161)	(24,665)	(26,976)	(55,102)	(15,717)	(13,596)	(15,274)	(130,880)	(99,689)	(168,384)
Interest expense	(6,458)	(6,667)	(10,314)	(10,665)	(11,725)	(10,839)	(10,424)	(10,184)	(34,104)	(43,172)	(50,914)
Other income (loss), net	9	398	(875)	522	4,796	781	(144,994)	513	54	(138,904)	69
(Impairment) recovery of long-term investments	0	(1,025)	(550)	0	(1,696)	0	0	1,045
Equity in net income of unconsolidated investments	(223)	383	16,834	200	125	386	218	(64)	17,194	665	259
Loss before income taxes	(74,750)	(18,072)	(19,570)	(36,919)	(63,602)	(25,389)	(168,796)	(23,964)	(149,311)	(281,751)	(62,199)
Income tax benefit	10,051	4,116	(2,009)	4,534	29,738	5,645	5,262	2,695	16,692	43,340	18,983
Loss from continuing operations, net of tax	(64,699)	(13,956)	(21,579)	(32,385)	(33,864)	(19,744)	(163,534)	(21,269)	(132,619)	(238,411)	(43,216)
Income from discontinued operations	16,847	19,545	18,838	16,218	20,078	18,899	18,339	17,919	71,448	75,235	2,501
Gain on sale of discontinued operations	1,156,504	0	0	0					1,156,504	0	500,471
Income tax effect on discontinued operations	(380,828)	(5,047)	(4,864)	(4,187)	(5,184)	(4,880)	(4,735)	(4,627)	(394,926)	(19,426)	(51,949)
Income from discontinued operations, net of tax	792,523	14,498	13,974	12,031	14,894	14,019	13,604	13,292	833,026	55,809	451,023
Net income (loss)	727,824	542	(7,605)	(20,354)	(18,970)	(5,725)	(149,930)	(7,977)	700,407	(182,602)	407,807
Net loss attributable to non-controlling interests					0	0	0	(424)	0	(424)	(4,527)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations									0	0	48,594
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 727,824	$ 542	$ (7,605)	$ (20,354)	$ (18,970)	$ (5,725)	$ (149,930)	$ (7,553)	$ 700,407	$ (182,178)	$ 363,740
Basic
Continuing operations	$ (0.43)	$ (0.09)	$ (0.13)	$ (0.20)	$ (0.21)	$ (0.11)	$ (0.98)	$ (0.12)	$ (0.83)	$ (1.43)	$ (0.22)
Discontinued operations	5.25	0.09	0.08	0.07	0.09	0.08	0.08	0.08	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	4.82	0	(0.05)	(0.13)	(0.12)	(0.03)	(0.90)	(0.04)	4.40	(1.10)	2.07
Diluted
Continuing operations	(0.43)	(0.09)	(0.13)	(0.20)	(0.21)	(0.11)	(0.98)	(0.12)	(0.83)	(1.43)	(0.22)
Discontinued operations	5.25	0.09	0.08	0.07	0.09	0.08	0.08	0.08	5.23	0.33	2.29
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ 4.82	$ 0	$ (0.05)	$ (0.13)	$ (0.12)	$ (0.03)	$ (0.90)	$ (0.04)	$ 4.40	$ (1.10)	$ 2.07
Net income (loss)	$ 727,824	$ 542	$ (7,605)	$ (20,354)	$ (18,970)	$ (5,725)	$ (149,930)	$ (7,977)	$ 700,407	$ (182,602)	$ 407,807
Net loss attributable to non-controlling interests					0	0	0	424	0	424	4,527
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ 727,824	$ 542	$ (7,605)	$ (20,354)	$ (18,970)	$ (5,725)	$ (149,930)	$ (7,553)	$ 700,407	$ (182,178)	$ 363,740

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Valuation And Qualifying Accounts [Abstract]
Beginning Balance	$ 25,826	$ 12,317
Charged to Expenses/Against Revenue	3,467	21,081
Write-Offs, Net of Recoveries	(7,288)	(7,572)
Ending Balance	$ 22,005	$ 25,826